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Abstract 
Adiponectin is an adipocyte-derived pro-inflammatory adipokine that 
regulates metabolic homeostasis, although it has been reported to 
modulate platelet function and thrombosis. In this study the effects of 
globular adiponectin (gAd), a novel platelet agonist that stimulates platelet 
aggregation was characterised. While it had been previously noted that 
gAd stimulated platelet aggregation through a tyrosine kinase-dependent 
mechanism, in this thesis we further elaborated the mechanisms 
underlying gAd-induced platelet aggregation by investigating the role of 
platelet secondary mediators, granule secretion and intracellular signalling 
events using a series of receptor antagonists and inhibitors.  
The experimental data demonstrated that gAd-stimulated aggregation 
required adenosine diphosphate (ADP) and thromboxane A2 (TxA2) to 
achieve the maximal response. Consistent with this, threshold 
concentrations of gAd could synergise with ADP. However, using receptor 
antagonists this synergy was found to occur via the Gi-coupled P2Y12 
receptor and not Gq-coupled P2Y1. Since the secretion of ADP from platelet 
dense-granules is driven by protein kinase C (PKC), we examined the role of 
PKC in gAd-mediated platelet aggregation. Ablation of PKC using a general 
inhibitor reduced platelet aggregation and abolished dense-granule 
secretion stimulated by gAd. Importantly, the aggregation response and 
dense-granule secretion under conditions of PKC inhibition could be 
partially restored by ADP acting through the P2Y12 coupled Gi receptor and 
by adrenaline acting through the Gz-linked α2A-adrenoceptor. Further 
examination of this pathway revealed that the activation of phosphatidyl-
inositol-3-kinase (PI3K) was required to restore secretion. To clarify the 
role of PI3K in this process we measured Akt phosphorylation as a marker 
of PI3K activity. We found that ADP and adrenaline potentiated gAd-
induced Akt phosphorylation which could be inhibited with a selective 
PI3Kβ isoform inhibitor and to a lesser degree α isoform inhibitor. These 
data demonstrate that gAd requires the release of platelet secondary 
mediators to induce full platelet aggregation and the potentiation of initial 
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aggregation occurs through G-protein coupled receptors linked to Gi-
coupled G-proteins. Furthermore, the stimulation of Gi/Gz-coupled G-
proteins can potentiate platelet aggregation by stimulating secretion 
through a PKC-independent manner.  
Since adiponectin accumulates at sites of vascular lesions, the ability of 
immobilised gAd to support platelet adhesion was examined. GAd 
supported the adhesion of platelets under static and flow conditions. 
Adhesion under static conditions was inhibited by the glycoprotein VI 
(GPVI) blocking antibody, 10B12, but not ethylene glycol-bis (β-aminoethyl 
ether)-N,N,N’,N’,-tetraacetic acid (EGTA), suggesting a GPVI-dependent and 
integrin-independent mechanism. 
Together these data significantly improve our understanding of the 
mechanisms by which gAd may promote unwanted platelet aggregation 
and adhesion at sites of vascular injury. 
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Chapter 1: General Introduction 
Platelets are specialised blood cells that play a central role in supporting 
haemostasis. However, improper platelet activation can lead to thrombosis 
and the development of pathological diseases such as acute coronary 
syndrome that includes myocardial infarction (Ruggeri, 2002, Davi and 
Patrono, 2007). Platelets circulate in the blood in a quiescent state and can 
undergo rapid activation at sites of vascular injury to form a platelet plug. 
Platelet activation involves a complex association between exposed 
components of the extracellular matrix proteins and platelet surface 
receptors. This association is dependent on the complex interplay of 
adhesion and signalling molecules that regulate platelet function. The 
critical role of platelets in both health and disease has led to an intensive 
search for new factors that may influence platelet function. In this thesis, 
one such protein called adiponectin was investigated as a novel regulator 
of platelet activity. Adiponectin is an adipokine produced exclusively by 
adipose tissue (Kadowaki et al., 2006). The biological function of 
adiponectin is complex and varied. Its primary function is as an insulin-
sensitising hormone and therefore plays a role in carbohydrate and lipid 
metabolism, although anti-diabetic, anti-inflammatory and vascular 
protective actions have also been described (Okamoto et al., 2002, Ouchi 
and Walsh, 2007, Zhu et al., 2008).  This chapter will review the literature 
regarding platelet function, in particular focusing on molecular pathways 
involved in platelet activation and any possible platelet-adiponectin 
interaction will be explored.   
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1.1 Blood platelets 
1.1.1 Platelet formation  
Platelets are small non-nucleated cells that were first described by Osler in 
1874 (Osler, 1874). At that time some individuals prescribed to the view 
that platelets could be parasitic organisms found in the blood. Almost ten 
years after platelets were first described, Bizzozero (1882) correctly 
characterised platelets anatomically and their role in haemostasis and 
thrombosis (Bizzozero, 1882). Wright (1906) discovered that platelets were 
produced from progenitor cells called megakaryocytes (Wright, 1906). Like 
other blood cells, megakaryocytes are derived from hematopoietic stem 
cells in the bone marrow. Mature megakaryocytes rapidly fill with platelet-
specific proteins, organelles  and membrane systems that will ultimately be 
subdivided and packaged into platelets (Kaushansky, 1995). Small 
fragments termed pro-platelets containing these platelet proteins and 
organelles are released into circulation through mechanisms requiring 
thrombopoieitin (Kaushansky et al., 1994). Each of these pro-platelet 
processes can give rise to 2000-5000 new platelets, which helps to 
maintain a normal human blood platelet concentration of 150x109 to 
450x109 platelets/L. Platelets have a relatively short half-life of 8 to 10 days 
in the blood and are removed from the circulation by the spleen (Weiss, 
1975).   
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1.1.2 Platelet structure 
Much of platelet structure has been defined by electron microscopy. 
Human platelets are characterised by their disc like shape and are 
approximately 2-5 µm in diameter (White, 1979) [Figure 1.1]. Platelets are 
surrounded by a plasma membrane which is composed of phospholipid 
bilayer, proteins and sugars (White, 1979). The membrane forms multiple 
invaginations into the cytoplasm to form the open canalicular system 
(OCS), which facilitates platelet spreading and granule release (White, 
1979, White and Clawson, 1980). Platelets in addition to the OCS have 
separate membrane network called the dense tubular system (DTS). These 
are believed to be remnants of smooth endoplasmic reticulum from the 
parent megakaryocyte that enables the storage of calcium (Gerrard et al., 
1978). The release of calcium ions (Ca2+) from the DTS is proposed to drive 
platelet activation pathways (Varga-Szabo et al., 2009). An enzyme 
involved in TxA2 synthesis, cyclo-oxygenase-1 (COX-1) is also found in the 
DTS (Gerrard et al., 1978). 
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1.1.3 Platelet organelles 
In addition to the tubular systems, platelets contain three main types of 
storage granules; alpha-granules, dense-granules and lysosomes (Holmsen 
and Day, 1968, White, 1979, Harrison and Cramer, 1993). There are 
approximately 40-80 alpha-granules found per platelet with a diameter of 
0.4 µm (Harrison and Cramer, 1993). In contrast, 4-5 dense-granules are 
found per platelet and are much smaller than alpha-granules, with a 
diameter of 0.10-0.15 µm (White, 1968). Alpha-granules mainly contain 
adhesive proteins which include von Willebrand factor (vWF), P-selectin 
and fibrinogen [Table 1.1] and are released during platelet activation. The 
release of these contents has multiple effects on the haemostatic process 
by enhancing the coagulation response (fibrinogen, Factor VII), endothelial 
repair (PDGF) and the inflammatory response (P-selectin) (Abrams, 2008). 
The contents of dense-granules are also released during platelet activation, 
which includes ADP, adenosine triphosphate (ATP), serotonin and Ca2+. 
These agents are all thought to enhance the platelet aggregation response 
(Charo et al., 1977). Platelet secretion and shape change are both energy-
dependent processes, and consequently platelets contain mitochondria 
and glycogen granules to provide required ATP (Weiss, 1975). 
 21 
 
 
Figure 1.1: Ultrastructure of platelet. The platelet is composed of an outer 
plasma membrane which forms invaginations to form the open canalicular 
system. The platelet also contains alpha and dense-granules whose 
contents are released upon platelet activation. Adapted from 
www.platelet.net/platelets/platelets.html (Platelets.net, 2011). 
 
Alpha granules Dense granules 
vWF ADP 
Factor V ATP 
Fibrinogen Serotonin 
P-selectin Ca2+ 
Thrombospondin  
PDGF  
Platelet factor IV  
Table 1.1: Summary of important platelet granule contents.   
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1.1.4 Platelet receptors 
Platelets have a range of important plasma membrane receptors that 
recognise various activating factors and are responsible for platelet 
activation. Platelet surface receptors can be divided into several groups; 
integrins, G-protein coupled receptors, tyrosine kinase-linked receptors 
and leucine rich-repeat family receptors. Important receptors that are 
involved in platelet activation include the collagen receptors GPVI and the 
integrin α2β1, vWF receptor complex GPIb-V-IX and the fibrinogen receptor 
αIIbβ3 (Clemetson, 2003, Gibbins, 2004, Watson et al., 2005). A summary of 
important platelet surface receptors is shown in Table 1.2.  
Many platelet surface receptors are coupled to heterotrimeric G-proteins 
that are involved in platelet activation and inhibition. These include the 
ADP receptors, P2Y1 and P2Y12 and thrombin receptors, protease activated 
receptors (PAR) 1 and 4 (Offermanns, 2006). G-proteins consist of an α-
subunit and an undissociable β and γ-subunit complex (Gilman, 1987, 
Kleuss et al., 1993). The α-subunit contains a guanine nucleotide binding 
site that is occupied by guanosine diphosphate (GDP) and is exchanged by 
guanosine triphosphate (GTP) once receptor activation has taken place 
(Gilman, 1987). Binding of GTP to the α-subunit induces a conformational 
change resulting in the dissociation of the α-subunit and the βγ-subunit 
complex. The dissociated α-subunit and the βγ complex interact with 
downstream effectors such as phospholipase C (PLC). The α-subunit 
contains intrinsic GTPase activity which hydrolyses GTP back to GDP and 
results in the re-dissociation of the GDP bound α-subunit to the βγ 
complex, thereby restoring the G-protein back to its resting state (Sprang, 
1997). G-proteins are identified on their α-subunits, Gαs, Gαq, Gαi, Gα12 and 
Gα13 are all present in human platelets (Simon et al., 1991). Studies on 
gene deletions in mice have shown Gαq, Gαi and Gα12 family members are 
involved in platelet activation (Offermanns, 2000, Offermanns, 2006). 
Platelets also contain Gαz, a G-protein coupled to α2A receptor of 
adrenaline involved in the inhibition of adenylyl cyclase (Hayes et al., 
1999). Gαs-proteins are coupled to prostacyclin receptor, IP and act to 
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increase cyclic adenosine monophosphate (cAMP) formation via adenylyl 
cyclase activation and promote platelet inhibition (Gorman et al., 1977, 
Tang and Gilman, 1991, Yang et al., 2002). G-protein receptors coupled to 
Gαi subtype, mainly Gαi2 and Gαi3 have an inhibitory effect on adenylyl 
cyclase (Murayama, 1996). 
 
Agonist Receptor Receptor 
type 
Signalling 
pathway 
Copy 
number 
ADP P2Y1 GPCR Gq/G12 150 
 P2Y12 GPCR Gi 600 
Thromboxane TPα/β GPCR Gq/G12/G13 1000 
Adrenaline α2A-receptor GPCR Gz 300 
Thrombin PAR1 GPCR Gq/G12/G13 2500 
 PAR4 GPCR Gq/G12/G13 2000-3000 
Prostacyclin IP GPCR Gs - 
Collagen GPVI Ig Tyrosine kinase 5000* 
 α2β1 Integrin Tyrosine kinase 2000-4000 
vWF GPIb-V-IX Leucine-
rich 
Tyrosine kinase 50,000 
Fibrinogen αIIbβ3 Integrin Tyrosine kinase 60,000-
80,000 
Table 1.2: Summary of important platelet surface receptors. Platelets 
express surface receptors which are involved in platelet inhibition and 
activation pathways. *(Best et al., 2003) 
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1.2 Platelet function 
Platelets circulate in the blood in an inactive state and can undergo rapid 
activation at sites of vascular injury. Platelets are normally separated from 
the underlying thrombogenic extracellular matrix proteins by endothelial 
cells. This lining of endothelial cells provides a non-thrombogenic surface, 
which helps to preserve platelets in their quiescent state. Platelets are 
forced towards the endothelium due to the haemodynamic forces exerted 
upon them (Malone and Morris, 1978, Zhao et al., 2007). This process of 
margination allows platelets to be in the perfect position to detect any 
damage or changes in the lining of endothelial cells. Upon injury, the 
endothelial barrier is damaged and extracellular matrix proteins such as 
vWF and collagen are exposed. Platelets have a range of important plasma 
membrane receptors that recognise these activating factors and are 
responsible for platelet activation (section 1.1.4). Platelet activation has 
been divided into three stages; initiation, extension and perpetuation 
[Figure 1.2]. These stages are further broken down into platelet adhesion, 
secretion and aggregation.  
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Figure 1.2: Stages of platelet plug formation. (A)  The platelet plug 
formation is initiated by the exposure of vWF and collagen at the site of 
injury which allows circulating platelets to adhere and spread and form a 
platelet monolayer. (B) The local secretion of ADP and TxA2 by the adhered 
platelet monolayer in conjunction with thrombin generation reinforces 
platelet activation allowing the recruitment of additional platelets. (C) The 
final stage of platelet plug formation is associated with the stabilisation 
and growth of the platelet plug. Figure adapted from Platelets, Second 
Edition, 2007 (Michelson, 2007).   
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1.2.1 Platelet adhesion 
The initial step in the haemostatic process is platelet adhesion with 
exposed elements of extracellular matrix proteins such as collagen or vWF 
at the site of vascular injury. At very high shear rates found in small arteries 
and arterioles, platelet adhesion requires the interaction of vWF with 
platelet GPIb-IX-V receptor complex (Ikeda et al., 1991). vWF is a large 
multimeric plasma protein primarily found in the endothelium, sub-
endothelial tissue and platelet alpha-granules (Sadler, 1998). vWF is able to 
interact with  a number of proteins including coagulation factor VIII and 
collagen (Ruggeri and Zimmerman, 1981, Rand et al., 1991). Factor VIII is 
found in circulation bound to vWF and is rapidly degraded when not bound 
(Morton et al., 1983). Plasma vWF is able to bind to exposed collagen fibres 
through a conformation change with the interaction of vWF A3 domain 
with collagen (Lankhof et al., 1996, Tsai, 1996).  
This interaction between vWF and GPIb-IX-V receptor complex is reversible 
and insufficient for stable adhesion (Ikeda et al., 1991). It is thought that 
the high shear stress causes vWF, GPIb-V-IX or both to change their 
conformation to allow the platelet to adhere. This reversible process is 
called tethering and slows the platelet down sufficiently to allow stable 
adhesion to take place. Firm platelet adhesion requires the interaction of 
platelet integrins and collagen [Figure 1.3].  Integrins are a group of 
ubiquitously expressed heterodimeric receptors that play a key role in cell-
cell contact, cell-ligand contact and cell spreading (Shattil and Newman, 
2004). Under normal circumstances integrins are found in a low affinity 
state unable to bind their ligands. However, upon cell activation a 
conformational change ensues that allows binding to extracellular proteins. 
In platelets, integrins α2β1 or αIIbβ3 play major roles, although there is 
evidence that integrins α5β1, α6β1 and αvβ3 can also participate (Varga-
Szabo et al., 2008). Collagen can bind directly to α2β1 or indirectly to αIIbβ3 
via vWF to facilitate stable adhesion. In both cases inside-out signalling 
events from other receptors are required to convert these integrins from a 
low affinity state to a high affinity state (Clemetson and Clemetson, 2001). 
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For firm platelet adhesion to occur under high shear requires intracellular 
signals from GPVI and outside-in signalling resulting in the transformation 
of the platelet from a discoid to a more spherical shape with the extrusion 
of filipodia (Inoue et al., 2003, Nieswandt and Watson, 2003). At low shear 
rates, collagen itself can support platelet adhesion in the absence of vWF 
through α2β1 (Saelman et al., 1994). Thus, regardless of the shear rate the 
platelet-collagen interaction is critical to the haemostatic response. 
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Figure 1.3: Proposed model of platelet adhesion in high shear. Circulating 
platelets are slowed down by the association of vWF to GPIb-V-IX receptor 
complex which enables the platelet to roll along the surface. Firm platelet 
adhesion is mediated through the interaction of collagen between GPVI 
and integrin α2β1. Integrin activation in combination with the release of 
soluble platelet agonists such as ADP and TxA2 reinforce platelet activation 
by outside-in signalling resulting in the transformation of the platelet from 
a discoid shape to spherical with the extrusion of filipodia (Varga-Szabo et 
al., 2008). 
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1.2.2 Platelet-collagen interaction 
Platelets are activated at the site of vascular injury when exposed to 
activating factors, such as collagen. There are at least 9 types of collagen 
found in the vascular system; namely types I, III, IV, V. VI, VII, XII, XIII and 
XIV with collagen I, III and IV forming a major component of the blood 
vessels (Barnes and Farndale, 1999, Nieswandt and Watson, 2003). 
Typically, collagen is composed of a triple helix structure that contains a 
repeat motif glycine-proline-X (GPX), where X can be any amino acid but 
frequently hydroxyproline (O) (Knight et al., 1999, Smethurst et al., 2007). 
The GPO repeat motif is found abundantly in collagen and makes up 
approximately 10% of collagen type I and III (Farndale et al., 2004). 
Furthermore, synthetic peptides have been developed such as cross linked-
collagen related peptide (CRP-XL) which are composed of the GPO motifs 
and shown to mimic collagen-stimulated platelet activation (Knight et al., 
1999). Platelets express surface receptors that can bind to collagen such as 
GPVI and integrin α2β1. Platelets can also bind indirectly to collagen via its 
interaction with vWF to GPIb and αIIbβ3 (Nieswandt and Watson, 2003).  
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1.2.2.1 Structure of glycoprotein VI 
GPVI is a 58 kDa platelet membrane immunoglobulin (Ig) family receptor 
that has been described as the central receptor in platelet-collagen 
interactions (Nieswandt and Watson, 2003). GPVI is composed of two Ig 
domains, a mucin rich stalk and a cytosolic tail that is 51 amino acids long 
[Figure 1.4] (Clemetson and Clemetson, 2001). The cytosolic tail of GPVI 
contains motifs that can bind to calmodulin and Src-kinases (Watson et al., 
2005). GPVI is constitutively associated to a disulfide-linked Fc receptor 
(FcR) γ-chain homodimer in the membrane via a salt bridge between 
charged arginine amino acid within the transmembrane and cytosolic tail 
(Tsuji et al., 1997, Ezumi et al., 2002). Importantly, this association is 
required for GPVI surface expression (Nieswandt et al., 2000). Each copy of 
the FcR-γ homodimer contains an immunoreceptor tyrosine activation 
motif (ITAM) which provides a docking site (YxxL) for Src homology (SH) 3 
containing Src tyrosine kinase family such as Lyn and Fyn  and is essential 
for GPVI activation (Suzuki-Inoue et al., 2002).   
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Figure 1.4: Structure of collagen receptor glycoprotein VI. GPVI is 
composed of two Ig domains, a mucin rich stalk and a cytosolic tail. GPVI is 
coupled to a disulfide linked FcRγ-chain homodimer in the membrane via a 
salt bridge between charged arginine amino acid within the 
transmembrane and cytosolic tail (Nieswandt and Watson, 2003). 
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1.2.2.2 Platelet activation through ligation of glycoprotein VI  
The present model for GPVI activation is based on the ability of distinct 
transmembrane regions of GPVI and the attached FcRγ-chain complex to 
associate with other proteins that enable inside-out signalling which 
support the activation of αIIbβ3 from a low to high affinity state (Kamiguti et 
al., 2000). Binding of collagen to GPVI results in the dimerisation of GPVI 
receptors with its associated FcRγ-chain [Figure 1.5] (Tsuji et al., 1997, 
Arthur et al., 2007). The GPVI cytosolic tail contains recognised sequence 
motifs for binding with SH3 domain Fyn and Lyn (Ezumi et al., 1998, Bori-
Sanz et al., 2003). These Src-family tyrosine kinases phosphorylate tyrosine 
residues in the associated FcRγ-chain ITAM that allow the binding and 
activation of tyrosine kinase, spleen tyrosine kinase (Syk) (Gibbins et al., 
1997, Quek et al., 2000). Recently, the protein tyrosine phosphatase CD148 
has shown to a play a role in regulating Fyn and Lyn downstream of GPVI 
by dephosphorylating an inhibitory tyrosine residue and returning the 
protein back into an inactive conformation (Senis et al., 2009). 
Syk contains a SH2 domain which can recognise the phosphorylated 
tyrosine residues within the ITAM (Yanaga et al., 1995). Mouse platelets 
which are deficient in Syk are found to be unresponsive to collagen and 
therefore confirming the critical role of Syk in collagen-stimulated platelet 
activation (Poole et al., 1997). GPVI-mediated activation of Syk has been 
shown to mediate phosphorylation of a number of downstream adaptor 
proteins such as linker for activation of T-cells (LAT) (Gibbins et al., 1996, 
Asazuma et al., 2000). The activation of LAT is an important stage in 
platelet GPVI activation that allows the recruitment of SH2 domain 
containing proteins and formation of a signalosome [Figure 1.5] (Asazuma 
et al., 2000). The recruitment of Grb2 (growth factor receptor bound 
protein 2), Gads (Grb2 related protein downstream of Shc) and SLP76 (SH2 
domain containing leukocyte proteins of 76 kDa) are critical for the 
activation of PLCγ2 isoform (Gross et al., 1999, Liu et al., 1999, Yablonski et 
al., 2001). LAT also binds to PI3K and brings PLCγ2 in closer proximity to 
PI3K  derived phosphoinositide products which bind to the pleckstrin 
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homology (PH) domain of PLCγ2 and therefore support its localisation to 
the membrane [Figure 1.5] (Gibbins et al., 1998).  Activated PLCγ2 results in 
the formation of secondary messengers, inositol 1,4,5 trisphosphate (IP3) 
and diacylglycerol (DAG). IP3 acts as a ligand to open ligand gated Ca
2+ 
channels in the platelet plasma membrane and Ca2+ channels in the 
platelet DTS (Kaibuchi et al., 1983). This increase in cytosolic Ca2+ 
concentration in combination with DAG leads to the activation of PKC 
isoforms that drive ADP and TxA2 secretion (Tyers et al., 1988, Quinton et 
al., 2002). The release of ADP and TxA2 bind to their own receptors and 
generate signals that support the activation of the platelet (Nieswandt and 
Watson, 2003, Watson et al., 2005).  
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Figure 1.5: Glycoprotein VI signalling. The activation of GPVI-FcRγ complex 
leads to Syk dependent formation of LAT signalosome which include Gads, 
SLP76 and PLCγ2 isoform that enables the mobilisation of secondary 
messengers involved in platelet activation (Watson et al., 2005). 
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1.2.2.3 The role of glycoprotein VI in haemostasis 
The major functional role for GPVI in haemostasis is to prevent excessive 
blood loss after injury. Recently, two patients have been reported with a 
mild bleeding phenotype due to mutations of GPVI (Dumont et al., 2009, 
Hermans et al., 2009). Both patients had compound heterozygous 
mutations preventing the expression of the receptor or causing impaired 
function. 
Much of our understanding about the role of GPVI in haemostasis is from 
GPVI or FcR-γ deficient mice. These genetically engineered mice fail to 
undergo aggregation to collagen and exhibit defects to both adhesion and 
aggregation under flow (Poole et al., 1997, Best et al., 2003, Kato et al., 
2003). Furthermore, FcR-γ deficient mice only show delayed and decreased 
thrombosis formation in vivo following only mild injury (Kalia et al., 2008, 
Senis et al., 2009). Interestingly, mice deficient in either GPVI or FcR-γ only 
have a mild increase in tail bleeding time and therefore may demonstrate 
that other mechanisms can compensate for loss of GPVI and prevent 
excess blood loss (Kato et al., 2003, Kalia et al., 2008). 
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1.2.3 Platelet secretion 
During the extension phase platelets release soluble agonists such as ADP 
and TxA2 that reinforce platelet activation and thrombus formation. The 
success of anti-thrombotic agents such as aspirin and clopidgrel to target 
TxA2 synthesis and ADP signalling respectively has shown the importance of 
these secondary mediators in thrombus formation.  The release of ADP 
from platelet dense-granules is a complex process that involves soluble 
NEM-sensitive attachment protein receptors (SNARE) and associated 
proteins (Chung et al., 2000, Feng et al., 2002, Barclay et al., 2003, Polgar et 
al., 2003). The activation of PKC and intracellular Ca2+ mobilisation 
signalling pathways are essential for granule secretion (Harper and Poole, 
2007). PKC is a serine-threonine kinase which plays an important role in 
platelet activation, adhesion and thrombus formation (Harper and Poole, 
2010). This kinase is composed of a catalytic domain attached to a 
regulatory domain via a hinge (Murugappan et al., 2004, Buensuceso et al., 
2005, Cohen et al., 2009). Conventional PKC isoform (α and β) are 
expressed in human platelets and are sensitive to both the secondary 
messengers, Ca2+ and DAG. These PKC isoforms contain the Ca2+ sensitive 
domain, C2 and the DAG sensitive domain, C1 in the regulatory domain 
(Heemskerk et al., 2011). In contrast, the novel PKC isoforms (δ and θ) 
which are also expressed in human platelets can only bind to DAG and are 
insensitive to Ca2+ (Yoshioka et al., 2001). Due to lack of specific PKC 
isoform inhibitors, the role of these isoforms in granule secretion has been 
extensively investigated in genetically engineered mice. PKCα isoform-
deficient mice show almost complete loss of alpha and dense-granule 
secretion in platelets induced by thrombin or CRP-XL stimulation 
(Konopatskaya et al., 2009). However, platelets from PKC δ isoform-
deficient mice show enhanced GPVI-dependent secretion and decreased 
granule secretion in PAR-stimulated platelets (Chari et al., 2009). 
Therefore, PKC δ isoform can positively or negatively regulate granule 
secretion in an agonist dependent manner.  Experiments with PKC θ 
isoform-deficient mice have shown that this isoform can negatively 
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regulate GPVI-dependent granule secretion, especially at low 
concentrations (Hall et al., 2008, Harper and Poole, 2009). However, 
reduced granule secretion has been reported at higher CRP-XL 
concentrations and therefore suggesting a negative and positive feedback 
mechanism dependent on the agonist concentration (Nagy et al., 2009).  
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1.2.3.1 Mechanism of platelet activation by ADP 
ADP is stored in platelet dense-granules and is released upon platelet 
activation. Studies have shown that platelet stimulation by ADP promotes 
TxA2 synthesis, shape change and aggregation (Hechler et al., 1998, Daniel 
et al., 1999, Kim and Kunapuli, 2011). ADP acts through two G-protein 
coupled receptors, P2Y1 and P2Y12 (Hollopeter et al., 2001, Kunapuli et al., 
2003). The P2Y1 receptor is coupled to Gq and P2Y12 receptors are coupled 
to Gi α-subunits (Daniel et al., 1999, Kunapuli et al., 2003). Activation of 
P2Y1 induces the pertussis-toxin resistant Gq to activate PLCβ isoform. Gq 
mediated activation of PLCβ isoforms increase IP3 and DAG formation that 
enables the mobilisation of intracellular Ca2+, activation of PKC and 
supports αIIbβ3 activation (Jin et al., 1998, Daniel et al., 1999). Pathways 
that involve the small G-protein RhoA and Src-kinases have been reported 
to be activated downstream of P2Y1 that support TxA2 formation and shape 
change (Dorsam and Kunapuli, 2004, Kahner et al., 2006).  Studies on P2Y1- 
deficient mice have shown that these platelets failed to aggregate or 
change shape in response to ADP-stimulation (Fabre et al., 1999). These 
platelets also show severely impaired aggregation in response to collagen 
(Fabre et al., 1999).    
ADP activation of P2Y12 induces G-protein Gi to dissociate into Giα and Gβγ 
subunits that activate different pathways. Giα subunit is able to inhibit 
adenylyl cyclase and therefore decreases intracellular cAMP levels 
(Kunapuli et al., 2003). It is well established that high cytosolic cAMP levels 
inhibit platelet responsiveness to platelet activating factors (Eigenthaler et 
al., 1992). The dissociated Gβγ subunit can activate PI3K isoforms that 
enhance granule secretion and αIIbβ3 activation through the pathways 
involving Akt and RapIb (Woulfe et al., 2002, Kim et al., 2004). These 
pathways are able to synergise with low doses of other agonists such as 
collagen to enhance platelet aggregation (Atkinson et al., 2001, 
Dangelmaier et al., 2001).  Platelets from P2Y12-deficient mice show a 
significant reduction in ADP-induced aggregation, with no effect on P2Y1 
receptor induced shape change (Foster et al., 2001). These mice also 
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exhibit an increase in tail bleeding time and therefore demonstrate the 
importance of this receptor in haemostasis and thrombus formation (André 
et al., 2003). 
The release of ADP at the site of vascular injury must be regulated. The 
release of ADP from platelet dense-granules along with damaged red blood 
cells are broken down by ectonucleotidases (CD39) found in the 
endothelium (Boeynaems et al., 2005). This will limit ADP-mediated 
platelet activation and thrombus formation.  
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1.2.3.2 The role of thromboxane A2 in platelet function 
TxA2 is synthesised from the hydrolysis of arachadonic acid released from 
phospholipids by phospholipase A2 (PLA2). Newly liberated arachadonic 
acid is converted to TxA2 by sequential steps involving cyclo-oxygenase and 
TxA2-synthase (Henriksen et al., 1997). Once formed it can easily diffuse 
across the plasma membrane and activate other platelets that are in close 
proximity. TxA2 has a very short half-life of 30 seconds and this limits the 
spread of platelet activation. TxA2 acts through two G-protein coupled 
receptors, TPα/β that are coupled to Gq and G12/G13 families (Shenker et 
al., 1991). Similar to ADP signalling, TxA2 signalling involves the activation 
of PLCβ isoforms by Gq to increase the formation of IP3 and DAG and 
therefore enabling Ca2+ mobilisation and PKC activation (Berridge, 1993). It 
is now well established that TxA2 signalling initially drives a first wave of 
ADP release which promotes integrin activation and aggregation (Li et al., 
2003). Studies have shown TxA2 is important in the platelet response to 
collagen (Nieswandt and Watson, 2003). Collagen-induced platelet 
aggregation is both TxA2 and ADP-dependent, especially at lower 
concentrations (Atkinson et al., 2001). In contrast, thrombin-induced 
aggregation does not require secondary mediators (Macfarlane et al., 
1975).  
The TP receptor isoforms are also coupled to G12/G13 which has been linked 
to platelet shape change (Klages et al., 1999, Dorsam et al., 2002, 
Nieswandt et al., 2002). Platelet shape change has been shown to involve 
the interaction between myosin and actin through the phosphorylation of 
myosin light chain (MLC) (Daniel et al., 1984). The phosphorylation of MLC 
is regulated by MLC kinase and myosin phosphatase. Platelet stimulation 
by TxA2 results in the phosphorylation of the MLC and inactivation of 
myosin phosphatase in a Rho-kinase dependent manner (Dorsam et al., 
2002, Nieswandt et al., 2002, Paul et al., 2003). 
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1.2.4 Thrombin 
Thrombin is a potent platelet activator and can activate platelets at a very 
low concentration. Thrombin, a serine protease is formed locally at the site 
of vascular damage from the inactive precursor prothrombin (Esmon et al., 
1974). The prothrombinase complex is confined to the platelet surface by 
the expression of negatively charged phosphatidylserine, and in this way 
thrombin is generated in the immediate vicinity of its site of action. 
Thrombin binds to G-protein coupled receptors belonging to the protease-
activating receptor family, namely PAR1 and PAR4 , which are coupled to 
Gq and G12/G13 (Kahn et al., 1999). Thrombin cleaves the N-terminus of 
these receptors which can act as a tethered ligand. In the cleaved state, 
part of the receptor itself acts as the agonist, causing a physiological 
response (Macfarlane et al., 2001). Once activated, this leads to the 
activation of PLCβ and the subsequent mobilisation of intracellular Ca2+ and 
PKC activation, similar to ADP and TxA2 platelet activation mechanism 
described earlier. Initially thrombin signals through PAR1 and then PAR4, 
prolonging the duration of the thrombin response (Covic et al., 2000). 
Activation of G12/G13 leads to the rearrangement of the actin cytoskeleton 
and shape change in a Rho and Rac dependent mechanism (McCarty et al., 
2005).   
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1.2.5 Platelet aggregation 
Platelet aggregation is essential in the formation of the haemostatic plug. 
The importance of platelet aggregation was first recognised in the late 19th 
century by Bizzozero (1882) who correctly described platelet clumping at 
sites of vascular injury (Bizzozero, 1882). However, it was not until the 
discovery of the aggregometer in 1962 by Born (Born, 1962) which allowed 
us to study platelet aggregation in vitro. This relatively simple assay was 
designed to assess the ability of activated platelets to clump together in 
suspension and the changes in light transmission could accurately measure 
platelet aggregation (see section 2.3.1). 
Integrin αIIbβ3 is a highly expressed platelet surface receptor that plays a 
critical role in platelet aggregation and haemostasis. There are 
approximately 80,000-100,000 copies of αIIbβ3 per platelet, which accounts 
for 3% of total cell protein (Phillips et al., 1988). Platelet alpha-granules 
also contain αIIbβ3 and become available upon platelet activation (Cramer 
et al., 1990). Integrin αIIbβ3 is composed of two heterodimeric subunits, αIIb 
and β3 which are associated with each other through non-covalent 
interactions (Fujimura and Phillips, 1983). Successful formation of the 
haemostatic plug requires the activation of integrin αIIbβ3 from a low to 
high affinity state. This transition from a low to high affinity state alters the 
conformation of the integrin to allow the binding of extracellular ligands 
which include fibrinogen, vWF, fibronectin, vitronectin and 
thrombospondin-1 (Jackson, 2007). However, only fibrinogen and vWF 
directly support platelet aggregation via the interaction of αIIbβ3 with the 
arginine-glycine-serine (RGD) motif (Jackson, 2007). Initial platelet 
activation and signalling by G-protein coupled receptors, GPVI, GPIb-IX-V 
and other receptors enable the activation of αIIbβ3 by a process known as 
inside-out signalling (Shattil, 1999, Shattil and Newman, 2004). Activated 
integrin αIIbβ3 can bind to fibrinogen allowing platelets to cross-link with 
each other and form a stable haemostatic plug. In addition, activated 
integrin αIIbβ3 can signal once bound to a ligand in a process called outside- 
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in signalling (Shattil, 1999, Phillips et al., 2001). This process reinforces 
platelet activation and causes irreversible aggregation (Phillips et al., 2001).  
Fibrinogen is a 340 kDa soluble plasma protein synthesised by the liver that 
plays a critical role in platelet aggregation and haemostasis (Bennett, 2001, 
Mosesson, 2005). Fibrinogen is composed of two sets of polypeptide chains 
called α, β and γ (Mosesson, 2005). Fibrinogen contains two RGD motifs in 
the α-chain and a non-RGD sequence in the γ-chain (Kloczewiak et al., 
1984, Bennett, 2001). This Lysine-Glutamate-Aspartate-Valine sequence 
rather than the two RGD motifs is the most important in integrin αIIbβ3 
binding (Springer et al., 2008). Fibrinogen has two main roles in 
haemostasis, (i) ligand for αIIbβ3 (ii) and the precursor for fibrin formation. 
Fibrinogen is cleaved to form fibrin by the protease action of thrombin in 
the coagulation cascade (Mosesson, 2005). Fibrin formation is essential for 
the anchoring of thrombi to the injured vessel wall. Furthermore, 
fibrinogen plays an essential role in the stability of the thrombus by 
bridging αIIbβ3 between neighbouring platelets (Holmback et al., 1996).  
Studies with vWF or fibrinogen-deficient mice have demonstrated that vWF 
plays an important role in platelet aggregation under high shear (Denis et 
al., 1998, Ni et al., 2000). Kulkami and colleagues showed platelet 
aggregation under flow is a multi-step process involving the exposure of 
vWF (Kulkarni et al., 2000). The first step of this process is the interaction 
of vWF with GPIb to cause reversible aggregation. The second step was the 
irreversible aggregation dependent on integrin αIIbβ3 interaction with a 
ligand which was associated with platelet shape change and granule 
release. However, platelet aggregation and thrombus formation was 
observed in mice deficient in both fibrinogen and vWF, although the 
thrombi were very unstable (Ni et al., 2000). Recently a third mechanism 
initiating platelet aggregation was proposed at very high shear rate 
(>10,000 s-1). This mechanism of platelet aggregation does not require 
platelet activation or integrin αIIbβ3 ligand binding (Ruggeri et al., 2006). In 
this case platelet aggregates were formed via GPIb-vWF adhesive bonds. 
However, it is important to remember that the platelet aggregometer can 
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only test the traditional mechanism of platelet aggregation involving 
integrin αIIbβ3 and fibrinogen binding. 
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1.3 Regulation of platelet function by cyclic nucleotides 
Platelets circulate in an inactive state and are activated once they are 
exposed to sub-endothelial proteins which lead to the formation of a 
haemostatic plug. The balance between haemostasis and thrombus 
formation must be tightly regulated. Platelets are regulated by platelet 
inhibitors released from the endothelium, such as nitric oxide (NO) and 
prostacyclin (PGI2). These inhibitors induce the production of platelet cyclic 
nucleotides which activate downstream kinases that reduce platelet 
activity by inhibiting key enzymes involved in platelet adhesion, shape 
change, degranulation and aggregation (Nishikawa et al., 1984, Halbrügge 
et al., 1990, Giesberts et al., 1995, Jin et al., 2005). 
NO is a free radical synthesised in vivo from L-arginine by endothelial nitric 
oxide synthase (eNOS) (Alderton et al., 2001). NO is able to freely diffuse 
across the platelet membrane and enter the cytosol where it activates 
soluble guanylyl cyclase (sGC) and it converts GTP to cyclic guanosine 
monophosphate (cGMP) resulting in the activation of protein kinase G 
(PKG). PKG is a serine-threonine kinase which phosphorylates target 
proteins leading to inhibition of most platelet activatory pathways 
(Schwarz et al., 2001). PKG-deficient mice show increased platelet adhesion 
and aggregation in vivo (Massberg et al., 1999). Platelet activation by many 
platelet agonists depends on the mobilisation of intracellular calcium via 
PLC activation. It is widely accepted that NO can reduce platelet activation 
by inhibiting intracellular calcium mobilisation. For example, the 
mobilisation of intracellular calcium is restricted through the inhibition of 
IP3 receptors and activation of sarcoendoplasmic reticulum calcium ATPase 
(Enouf et al., 1997). Furthermore, PKG has been shown to directly 
phosphorylate PLCβ1 and β2 isoforms and thereby reducing its activity by 
70% (Xia et al., 2001). The inhibition of PLC isoforms by NO signalling 
pathway also limits the activation of PKC through the decreased DAG 
production (Jin et al., 2005). NO has also been shown to inhibit platelets via 
calcium independent actions. These include inhibition of PI3K, PKC, ADP 
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receptor P2Y12 and MLC kinase (Nishikawa et al., 1984, Gopalakrishna et 
al., 1993, Pigazzi et al., 1999, Aktas et al., 2002).  
The endothelium releases another potent platelet inhibitor, PGI2 which 
helps to limit unwanted platelet activation. PGI2 is able to elevate cytosolic 
cAMP levels through the activation of adenylyl cyclase via the Gs-coupled IP 
receptors (Gorman et al., 1977). Elevated cAMP levels activate protein 
kinase A (PKA), a serine-threonine kinase which also targets calcium 
mobilisation and PLC activation pathways as previously described for NO. 
The release of platelet derived TxA2 is an important event in platelet 
activation and thrombus formation. Activation of PGI2/PKA pathway has 
been demonstrated to inhibit TxA2 secretion and signalling by the 
phosphorylation of serine329 within the carboxyl terminal of the TPα 
receptor (Walsh and Kinsella, 2000). This phosphorylation disrupts the 
coupling of the receptor to Gq and thereby limiting its activation (Walsh 
and Kinsella, 2000). PGI2 has also been shown to limit integrin αIIbβ3 
dependent aggregation by returning the integrin to its low affinity state 
and therefore preventing fibrinogen binding (Giesberts et al., 1995). The 
action of NO and PGI2 normally work synergistically to regulate platelet 
function. 
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1.4 Adipokines 
Cardiovascular disease is a major cause of death in the western world 
(Naseem, 2005). Obesity is a major risk factor in developing cardiovascular 
disease along with metabolic abnormalities such as hyperglycaemia and 
hyperlipidaemia (Grundy, 2004, Aggoun, 2007). It is widely known that 
obesity is often the cause of the insulin resistance that leads to these 
metabolic abnormalities (Ferrannini et al., 1997). Adipose tissue has been 
widely recognised as a complex endocrine organ that plays a central role in 
energy and vascular homeostasis (Kershaw and Flier, 2004). In addition to 
its role as an energy reserve, adipose tissue also secretes metabolic 
hormones, enzymes, anti-fibrinolytic proteins and inflammatory cytokines 
(Ahima and Flier, 2000, Kershaw and Flier, 2004). These secretory proteins 
are called adipokines which include leptin, tumour necrosis factor-alpha 
(TNF-α), plasminogen activator inhibitor type 1 (PAI-1), resistin and 
adiponectin [Table 1.3]. Adiponectin and leptin are the major adipokines 
released from adipose tissue which participate in the regulation of energy 
homeostasis and are the major insulin-sensitising hormones (Combs et al., 
2003). Leptin stimulates fatty acid oxidation, glucose uptake and prevents 
lipid accumulation in adipose and non-adipose tissues (Kamohara et al., 
1997). In contrast, a pro-inflammatory adipokine, resistin has the opposite 
effect to that of leptin and adiponectin. Circulating levels of resistin are 
elevated in obesity and can cause insulin resistance (Degawa-Yamauchi et 
al., 2003). In fact, many pro-inflammatory adipokines such as retinol 
binding protein 4 (RBP4) in circulation are elevated in obesity and type II 
diabetes which contributes to the development of cardiovascular disease 
(Yang et al., 2005). These pro-inflammatory adipokines induce the 
expression of cell adhesion molecules such as intracellular adhesion 
molecule (ICAM-1), vascular cellular adhesion molecule-1 (VCAM-1) and E-
selectin which promote vascular inflammation and the development of 
atherosclerosis (Ahima and Flier, 2000). However, some adipokines such as 
adiponectin have been described to have anti-inflammatory and anti-
artherogenic properties (Okamoto et al., 2002, Ouchi and Walsh, 2007, Zhu 
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et al., 2008). In this section we will discuss the function of adiponectin in 
metabolism and the vascular system and in particular explore possible 
platelet-adiponectin interaction. 
 
Adipokine Concentration in 
circulation 
Primary function 
Leptin 2-10 ng/ml Metabolic homeostasis 
TNF-α 5-10 pg/ml Inflammation 
PAI-1 10-20 ng/ml Haemostasis 
Resistin 5-15 ng/ml Metabolic homeostasis 
RBP4  5-20 µg/ml Retinol binding protein/ 
metabolic homeostasis 
Adiponectin 5-30 µg/ml Metabolic homeostasis 
Table 1.3: Summary of adipokines derived from adipose tissue. A wide 
range of adipokines are released from adipose tissue that plays an 
important role in metabolic and vascular homeostasis. 
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1.5 Adiponectin 
Adiponectin was originally discovered by four research groups (Scherer et 
al., 1995, Hu et al., 1996, Maeda et al., 1996, Nakano et al., 1996). In 1995, 
Scherer and colleagues identified a protein by cDNA cloning from the 
mouse adipocyte cell line 3T3-L1 and named it adipose complement 
related protein (Acrp30) (Scherer et al., 1995). Hu and colleagues (1996) 
using the same cell line isolated the same protein and called it AdipoQ (Hu 
et al., 1996). Nakano and colleagues isolated the protein by high affinity 
chromatography and called it gelatine binding protein 28 kDa (GBP-28) 
(Nakano et al., 1996). The name adiponectin was proposed by Arita and 
colleagues, in 1998 but all four names are used (Kihara et al., 1998).  In this 
thesis the most common name of the protein, adiponectin will be used. 
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1.5.1 Synthesis and structure of adiponectin 
Adiponectin is a 244 amino acid protein synthesised by adipocytes, most 
abundant gene transcript (ApM1) found on chromosome 3 locus 3q27 in 
adipose tissue (Hu et al., 1996). This locus is of special interest since it is 
associated with increased susceptibility to type II diabetes and 
cardiovascular disease (Kankova et al., 2007). ApM1 consists of three exons 
and two introns which shares similarity with leptin encoding gene (Saito et 
al., 1999). Adiponectin synthesis is regulated by several mechanisms and 
studies have shown that insulin-like growth factor-1 (IGF-1) stimulates 
adiponectin gene expression in adipose tissue (Berg et al., 2002). Members 
of the nuclear hormone family, peroxisome proliferator activated receptors 
(PPAR) are also involved in the regulation of adiponectin synthesis (Maeda 
et al., 2001). Recently, some studies have shown that other tissues may 
express adiponectin such as bone (Berner et al., 2004), mammary glands 
(Weyermann et al., 2006), salivary glands (Katsiougiannis et al., 2006) and 
cardiac tissue (Pineiro et al., 2005) albeit in very limited quantities. 
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1.5.1.1 Structure of adiponectin 
Adiponectin, a single monomer is composed of four structurally distinct 
domains, an amino terminal sequence, a variable region, a collagen-like 
domain and an amino terminal globular domain [Figure 1.7] (Kadowaki and 
Yamauchi, 2005); this is termed as full-length adiponectin (fAd). 
Adiponectin is structurally similar to complement C1q protein (Scherer et 
al., 1995) and the globular fragment is structurally similar to TNF-α (Berg et 
al., 2002). C1q and TNF-α both play an important role in inflammation and 
the immune response. Circulating adiponectin is found primarily as 
disulfide-linked oligomers, composed of trimers, hexamers and a high 
molecular mass multimers (HMW), containing up to 18 monomers [Figure 
1.8]. Adiponectin trimers are generated when a triple helix is formed by 
non-covalent interactions between the collagenous domains and 
hydrophobic interactions between the globular head groups (Scherer et al., 
1995, Shapiro and Scherer, 1998). Oligomer formation of adiponectin is 
dependent on the disulfide bond formation mediated by cysteine 39 
(Pajvani et al., 2003). Furthermore, biochemical analysis of purified 
complexes and in vivo studies have revealed that different forms of 
adiponectin complexes do not interconvert after secretion (Simpson and 
Whitehead, 2010).  
Several years after the initial discovery of adiponectin, a globular form of 
protein was identified in the circulation of mice (Kishida et al., 2003) and 
humans (Fruebis et al., 2001). This form contains the globular head but is 
deficient in the collagen-like domain. Without the collagen-like domain, the 
globular domain of adiponectin still trimerises, but does not associate into 
HMW isoforms (Waki et al., 2005). It is thought that both the globular and 
the collagenous domains are important for ensuring the stability and 
activity of the multimeric forms. Nearly all circulating plasma adiponectin 
exists as full-length multimeric forms of adiponectin. The source of gAd is 
unknown, it has been demonstrated in vitro that leukocyte elastase 
secreted from activated human monocytes and neutrophils was 
responsible for the proteolytic cleavage of recombinant murine fAd to form 
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the globular fragment (Waki et al., 2005). However, the physiological 
importance of this remains unclear.  
 
 
Figure 1.7: Structure of different isoforms of adiponectin. FAd consists of 
three main domains; a variable domain, collagen-like domain and globular 
domain. The globular domain can be cleaved to form the gAd isoform. 
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Figure 1.8: Multiple forms of adiponectin in circulation. FAd monomers 
consist of a globular head and a collagen triple helix which can trimerise 
through the formation of disulfide bonds. Adiponectin trimers can further 
combine to form hexamers and high molecular weight isoforms. However, 
the globular head can be cleaved by neutrophil elastase to form gAd.  
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1.5.1.2 Synthesis of adiponectin 
The molecular details of adiponectin synthesis pathway remains poorly 
defined. Recent studies with murine derived fAd have shown that 
chaperone proteins such as BiP, ERp44, Ero1-Lα and Dslb aid the assembly 
of adiponectin multimers and secretion in vitro (Qiang et al., 2007, Wang et 
al., 2007, Liu et al., 2008, Simpson and Whitehead, 2010). Furthermore, 
high levels of expression of these chaperones result in efficient adiponectin 
secretion and are associated with high circulating adiponectin levels. The 
secretion of adiponectin is regulated by the binding of adiponectin in the 
endoplasmic reticulum (ER) to the protein ERp44 through a thiol bond with 
cysteine 39, therefore adiponectin is retained in the ER (Wang and Scherer, 
2008). It is secreted when ERp44 forms a new thiol bond with a second 
protein Ero1-Lα, thus releasing the previous thiol-bound adiponectin 
(Anelli et al., 2003). The treatment of cells with β-mercaptoethanol breaks 
this bond to increase the secretion of these isoforms into the culture 
medium in vitro (Anelli et al., 2003). Once synthesised, adiponectin 
undergoes extensive post-translational hydroxylation and glycosylation 
modifications to produce eight isoforms. Six of the adiponectin isoforms 
are glycosylated at four lysine residues, 68, 71, 80 and 104. A proline 
residue 94 located within the collagenous domain is also glycosylated 
(Wang et al., 2008). The secretion of adiponectin is dependent on Gamma-
ear adaptor 1 coated vesicles (Xie et al., 2006). This field of work has 
attracted a lot of interest lately since adiponectin synthesis is down 
regulated in disease and therefore, understanding the molecular 
mechanism of adiponectin synthesis can have a potential therapeutic 
value.  
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1.5.2 Adiponectin in circulation 
Adiponectin circulates in the plasma at approximately 5-30 µg/ml, 
accounting for 0.01% of the total plasma protein (Arita et al., 1999). This 
concentration is higher than that of most hormones found in the 
circulation, for example leptin and cortisol circulate in ng/ml, while TNF-α 
or interleukin-6 are measured in pg/ml. Furthermore, eight human serum 
proteins have been identified that were co-purified with adiponectin. Many 
of these proteins include thrombospondin-1, histidine-rich glycoprotein, 
kinogen1 and alpha 2 macroglobulins. These proteins might bind directly or 
indirectly to adiponectin in the circulation and may modulate adiponectins 
anti-inflammatory and anti-artherogenic activities (Wang et al., 2006). 
Furthermore, albumin has been found to be associated with the low 
molecular weight isoforms of adiponectin through the formation of a 
disulfide bond (Hada et al., 2007). 
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1.5.3 Adiponectin receptors 
There are two distinct adiponectin receptors identified, called AdipoR1 and 
AdipoR2, which are thought to facilitate the biological actions of 
adiponectin (Yamauchi et al., 2003). Northern blot analysis of human and 
murine tissue found mRNA from AdipoR1 was abundantly expressed in 
skeletal muscle and to a lesser extent in the heart and spleen. In contrast, 
AdipoR2 expression was mostly restricted to the liver (Yamauchi et al., 
2003). The expression of these adiponectin receptors have been identified 
in monocytes (mRNA and protein) and are thought to play an important 
role in the immune system (Weigert et al., 2008).  The existence of these 
adiponectin receptors in platelets is not clear. Kato and colleagues have 
found AdipoR1 and AdipoR2 (mRNA) expressed in murine platelets (Kato et 
al., 2006). Furthermore, AdipoR1 (mRNA) was detected in human platelets, 
whereas both AdipoR1 and AdipoR2 were found in megakaryocyte cell 
lines (Kato et al., 2006). Analysis of AdipoR1 and AdipoR2 has shown that 
AdipoR1 has a very strong affinity for gAd and AdipoR2 is the preferred 
receptor for fAd (Kadowaki and Yamauchi, 2005). 
AdipoR1 and AdipoR2 are composed of seven transmembrane domains 
similar to that of G-protein coupled receptors. However, AdipoR1 and 
AdipoR2 do not transduce G-protein coupled signalling [Figure 1.9] 
(Yamauchi et al., 2003). The N-terminus of AdipoR1 and AdipoR2 are found 
in the cytoplasmic region of the cell and the C terminus is found externally 
which is opposite to that of G-protein coupled receptors. Once activated 
AdipoR1 and AdipoR2 can form both homo and heterodimeric complexes, 
however, the physiological significance is unknown. In 2004, a third 
receptor for adiponectin was proposed, T-cadherin, a member of the 
cadherin superfamily which are involved in cell adhesion and signalling. T-
cadherin is thought to bind to hexamers and HMW adiponectin oligomers 
(Hug et al., 2004). The existence of these adiponectin receptors can be 
explained by different isoforms of adiponectin which require different 
receptor conformations to ensure a high binding affinity, and by the wide 
biological actions of adiponectin in different tissues.   
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Figure 1.9: Adiponectin receptors. Adiponectin signals through two G-
protein like receptors, AdipoR1 and AdipoR2 which consist of seven 
transmembrane domains (Kadowaki and Yamauchi, 2005). 
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1.5.4 Insulin-sensitising actions of adiponectin 
The insulin-sensitising effect of adiponectin was first identified by 3 
independent groups (Berg et al., 2001, Fruebis et al., 2001, Yamauchi et al., 
2001). Berg and colleagues showed in vivo that fAd decreased basal 
glucose levels by inhibiting the expression of hepatic gluconeogenic 
enzymes, such as phosphoenolpyruvate carboxylase and glucose-6-
phosphatase (Berg et al., 2001). Similar data was obtained by Yamauchi 
and colleagues and suggested a link between adiponectin and insulin 
resistance (Yablonski et al., 2001). Fruebis and colleagues showed that gAd 
was involved in lipid metabolism (Fruebis et al., 2001) and therefore these 
studies indicate that both forms of adiponectin are involved in metabolic 
homeostasis.  
It has become clear that adiponectin can exert its metabolic effect through 
several pathways in different tissues. For example, in skeletal muscle 
adiponectin increases expression of CD36 which is involved in fatty acid 
transport and increases enzymes involved in fatty acid oxidation such as 
acyl coenzyme A oxidase (Tomas et al., 2002). The combined effect of 
increased fatty acid transport and oxidation results in a lower tissue 
triglyceride content. Reduced tissue triglyceride content has been shown to 
improve insulin signal transduction pathways since high tissue triglyceride 
content interferes with insulin-stimulated PI3K activation, glucose 
transporter-4 translocation and glucose uptake which can lead to insulin 
resistance (Maeda et al., 2002). Furthermore, gAd can indirectly increase 
fatty-acid oxidation by PPARα activation, which can decrease triglyceride 
content in the liver and skeletal muscle (Yamauchi et al., 2003). 
Adiponectin knock-out mice fed on a high fat diet developed severe insulin 
resistance, compared to wild-type controls (Maeda et al., 2002) and 
therefore clearly placing this adipokine as a central factor in metabolic 
health. 
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The metabolic effects of adiponectin are mainly dependent on its ability to 
activate 5' adenosine monophosphate-activated protein kinase (AMPK) 
enzyme which is involved in energy homeostasis. AMPK is a heterotrimeric 
complex composed of a catalytic α-subunit and the regulatory β and γ-
subunits  (Dugan et al., 1982). Both gAd and fAd can stimulate AMPK 
activation in skeletal muscle, whereas only fAd activates AMPK in the liver 
(Combs et al., 2003). Experimentally, gAd has been shown to activate 
AMPK in primary rat adipocytes to increase glucose uptake (Wu et al., 
2003). Therefore, both gAd and fAd exerts their metabolic effects through 
different pathways as shown in Figure 1.10.  
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Figure 1.10: Metabolic effects of adiponectin. AdipoR1 and AdipoR2-
mediated activation by different adiponectin isoforms stimulate glucose 
uptake and fatty acid oxidation through the activation of AMPK and p38 
mitogen-activated protein kinase (MAPK), which results in increased insulin 
sensitivity (Kadowaki et al., 2006).  
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1.5.5 Role of adiponectin beyond vascular biology 
A number of recent studies in humans and animals have demonstrated 
that a decrease in plasma concentrations of adiponectin increases the risk 
of developing type II diabetes, hypertension and cardiovascular disease 
(Weyer et al., 2001, Pischon et al., 2004, Kadowaki et al., 2006). 
Furthermore, adiponectin appears to play an important role in vascular 
biology. Adiponectin knock-out mice develop increased neointimal 
thickening and increased proliferation of smooth muscle cells compared to 
control mice (Matsuda et al., 2002). Importantly, adiponectin treatment 
reversed many of these vascular changes (Kihara et al., 1998, Ouchi and 
Walsh, 2007). Thus, there is clear evidence that adiponectin exerts much 
broader biochemical and cellular effects than simply regulating 
metabolism.  
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1.5.5.1 Atherosclerosis  
Atherosclerosis is characterised by chronic systemic inflammation and the 
narrowing of the lumen of the blood vessel through the deposition of lipids 
(Ross, 1993). Studies have shown that adiponectin has many anti-
atherosclerotic and cardio-protective properties. It is proposed that the 
anti-atherosclerotic properties of adiponectin are due to its anti-
inflammatory properties. Circulating plasma adiponectin can bind to 
exposed extracellular matrix proteins such as collagen fibres in the 
damaged intima of blood vessels and subsequently can inhibit the 
expression of adhesion molecules, including ICAM-1, VCAM-1, E-selectin 
and macrophage induced TNF-α production (Okamoto et al., 2000). The 
inhibition of TNF-α mediated signalling and synthesis by adiponectin, 
through the inhibition of NF-ⱪB pathway in endothelial cells, prevents the 
expression of cell surface adhesion proteins (Ouchi and Walsh, 2007). It is 
known that adiponectin promotes cAMP/PKA signalling in endothelial cells, 
which inhibits the NF-ⱪB pathway (Ajuwon and Spurlock, 2005). Therefore, 
the activation of cAMP/PKA signalling is an important mechanism by which 
adiponectin protects endothelial cells from activation (Ouchi et al., 2000).  
As previously described in section 1.3 the endothelium release platelet 
inhibitors such as NO and PGI2 to regulate platelet function. However, the 
release of these inhibitors has much more broader implications in vascular 
disease beyond their effect on platelets (Naseem, 2005). The decreased 
synthesis and bioavailability of NO has been implicated in the development 
of atherosclerosis (Cooke and Dzau, 1997). NO can reduce leukocyte 
recruitment to sites of vascular inflammation and limit smooth muscle 
proliferation (Naseem, 2005). NO is a free radical synthesised in vivo from 
L-arginine by eNOS (Alderton et al., 2001). The production of NO can be up-
regulated by adiponectin through the phosphorylation of eNOS at 
serine1777 by pathways requiring AMPK activation (Chen et al., 2003). 
Adiponectin can also increase the formation of eNOS and heat shock 
protein 90 complex which is necessary for NO synthesis (Xi et al., 2005).  
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 The accumulation of lipid-laden foam cells and macrophage related 
inflammation is an important stage in the development of atherosclerosis. 
Adiponectin inhibits the expression of macrophage scavenger receptor 
class A-1, resulting in the decreased uptake of oxidised low density 
lipoproteins by macrophages and thus inhibiting the formation of foam 
cells (Ouchi et al., 2001). Decrease in plasma adiponectin has been 
demonstrated to increase platelet-monocyte interaction and thereby 
promoting the formation of the atherosclerotic plaque (Ouchi and Walsh, 
2007). Taken together, adiponectin reduces atherosclerosis by reducing 
vascular inflammation, increasing NO synthesis and inhibiting macrophage 
to foam cell transformation and lipid uptake.  
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1.5.5.2 Pro-inflammatory properties of globular adiponectin  
Anti-inflammatory properties of adiponectin are well characterised but the 
role of gAd in inflammation is less clear. There is emerging evidence that 
suggests that gAd has pro-inflammatory properties. Studies have shown 
that gAd induces the production of pro-inflammatory cytokines from 
macrophages such as IL-1β, IL-6, IL-8 and TNF-α which act to increase the 
expression of cell adhesion molecules and thereby promoting inflammation 
(Tsatsanis et al., 2005, Tsatsanis et al., 2006). Consistent with these pro-
inflammatory properties, gAd has been shown to increase angiotensin-II 
induced proliferation of cardiac fibroblasts (Hattori et al., 2006, Hattori et 
al., 2007) and stimulate THP-1 production by monocytes (Neumeier et al., 
2006).  Thus emerging evidence suggests that gAd may possess pro-
inflammatory properties in addition to its insulin-sensitising effects (Hattori 
et al., 2006, Hattori et al., 2007). However, the importance of these pro-
inflammatory properties in disease needs further investigation.  
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1.5.5.3 Adiponectin and platelet function 
The data linking hypoadiponectinaemia and increased platelet-monocyte 
interactions (Shoji et al., 2006) points to a potential effect on platelet 
function, although it is unclear if this is a direct effect on platelet function. 
Elbatarny and colleagues showed that fAd had no effect on platelet 
aggregation or adhesion in vitro (Elbatarny et al., 2007). However, it is 
important to note that a very low concentration of fAd was used, 0-500 
ng/ml compared to 5-30 µg/ml found at physiological levels. 
 The major evidence for the effect of adiponectin on platelet function 
comes from an important study by Kato and colleagues (Kato et al., 2006). 
This study used a He-Ne laser–induced injury model to assess thrombus 
formation in adiponectin-deficient mice and proposed adiponectin as an 
endogenous anti-thrombotic factor. These mice displayed enhanced 
thrombus formation in response to injury to the carotid artery, which could 
be delayed by the addition of exogenous adiponectin. Analysis of platelets 
in vitro from the same adiponectin-deficient mice displayed enhanced 
aggregation and thrombus formation under flow conditions. However, it 
was unclear if the increased thrombus formation in adiponectin-deficient 
mice was due to the direct effect of adiponectin on platelets or the indirect 
effect via the vascular system. Furthermore, circulating levels of 
adiponectin are decreased in individuals with coronary artery disease and 
may promote increased risk of thrombosis (Shibata et al., 2005).  
Interestingly, the direct effect of gAd on platelet function has not been 
investigated and the effect of adiponectin on platelets may provide a 
tangible link between metabolic syndrome and cardiovascular disease. 
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1.6 Aims of thesis 
In the present study the effects of adiponectin on platelet function in vitro 
was investigated. We wished to  
i. Examine if different forms of adiponectin had differential effects 
on platelet function 
ii. Determine the signalling events underlying any observed effects 
on aggregation 
iii. Identify the receptor(s) responsible for the effects of 
adiponectin on platelet function 
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Chapter 2: Materials and methods 
2.1 Materials 
Recombinant human globular and full-length adiponectin was purchased 
from BioVision Research Products (CA, USA). Horm collagen type I (equine) 
was from Nycomed (Munich, Germany). Ro 31-8220, wortmannin, U46619, 
SQ29548, PP1 and PP3 were from Calbiochem (Darmstadt, Germany). 
Adrenaline, ADP, thrombin, fibrinogen, indomethacin, apyrase, MRS2395 
and A3P5P were from Sigma (Poole, UK). TGX-221, PIK75 and AS242525 
were from Cayman chemicals (Michigan, USA). Anti-phosphotyrosine 
monoclonal antibody (mAb) 4G10 antibody and anti-β-tubulin mAb were 
from Upstate Biotechnology (Milton Keynes, UK). Anti-PKC substrate mAb 
recognising the sequence (R/K)X(S*)(Hyd)(R/K) and anti-Akt serine473 mAb 
were from New England Biolabs (Hertfordshire, UK). CRP-XL and GPVI 
blocking antibody were from Prof. Richard Farndale, University of 
Cambridge (UK). The integrin α2β1 blocking antibody 6F1 was a kind gift 
from Prof. Barry Coller, The Rockefeller University (USA). The chrono-lume 
reagent was from Labmedics (Manchester, UK).   
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2.2 Methodology for the study of platelets 
2.2.1 Isolation of human platelets 
Human blood was collected from volunteers by a trained phlebotomist and 
written consent was obtained from each volunteer. The consent form was 
used in conjunction with a short health questionnaire used to collect 
information about the volunteers health status, i.e. the presence of any 
transmitted infections and the use of prescribed and over the counter 
medication. In particular, the volunteers were asked about the use of 
aspirin or any other drugs that could interfere with platelet function.  
Human blood was collected into pre-warmed acid citrate dextrose (ACD; 
29.9 mM sodium citrate, 113.8 mM glucose, 72.6 mM sodium chloride and 
2.9 mM citric acid, pH 6.4) at a ratio 1:6. ACD chelates calcium from the 
blood and thus preventing the coagulation cascade, and lowers the pH of 
the blood to 6.5 and subsequently inhibiting platelet aggregation (Mustard 
et al., 1972, Cazenave et al., 2004).  The first 5 ml of venous blood collected 
from the volunteer was discarded as the platelets possibly could be 
partially activated due to the procedure. The citrated blood was gently 
inverted to ensure equal mixing with the ACD and was centrifuged at 120g, 
20°C for 20 minutes. Centrifugation separated the blood into three layers; 
a well-defined bottom layer containing white and red blood cells, an 
intermediate layer called the buffy coat which contains substances derived 
from red blood cells such as ADP and the upper most layer called platelet 
rich plasma (PRP). Washed platelets were prepared by carefully 
transferring the PRP into a clean falcon tube, ensuring no contamination 
with the buffy coat and was further centrifuged at 800g, 20°C for 12 
minutes in the presence of prostaglandin E1 (50 ng/ml). Prostaglandin 
inhibits platelet activation during centrifugation and re-suspension steps by 
elevating cAMP levels and therefore preventing calcium mobilisation and 
platelet activation (Vargas et al., 1982). The platelet pellet was re-
suspended at a concentration of 2.5x108 platelets/ml in modified Tyrode 
buffer (150 mM NaCl, 5 mM HEPES, 0.55 mM anhydrous NaH2PO4, 7 mM 
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anhydrous NaHCO3, 2.7 mM KCl, 0.5 mM MgCl2 and 5.6 mM anhydrous 
glucose, pH 7.4) unless otherwise stated. The platelets were left to recover 
from the prostaglandin effect for one hour before use. 
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2.2.2 Platelet count 
The platelet concentration was calculated after re-suspending the platelet 
pellet in modified Tyrodes buffer. Washed platelets (5 μl) were diluted 
1:100 in ammonium oxalate (1% w/v) to fix the platelets and was then 
mixed and applied to a double chamber haemocytometer with a coverslip.  
The haemocytometer was left to rest for 10 minutes to allow the platelets 
to settle and an inverted light microscope 40x objective lens was used to 
count the number of platelets in the ten small squares on each side of the 
haemocytometer [Figure 2.1]. These ten squares have a total volume of 
0.04 μl and from this the platelet count could be calculated in platelets/ml.  
The total number of platelets counted was multiplied by 25,000 
(1000/0.04) and followed by 100 to account for the dilution with 
ammonium oxalate. The washed platelets volume was adjusted with 
modified Tyrode buffer to give the platelet count required for those 
experiments.   
 
 
Figure 2.1: A schematic diagram of Nebauer counting chamber. Platelets 
were counted in the squares labelled “x”. 
  
Counted 
square 
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2.3 Platelet aggregation and luminescence studies 
2.3.1 Platelet aggregation  
Measurement of platelet aggregation is based on a turbidimetric assay first 
described by Born (Born, 1962) in which changes of light transmission 
through a platelet suspension is detected by a photocell. In unstimulated 
platelet suspension light transmission is low and upon addition of platelet 
agonist such as collagen, the platelets undergo shape change and 
aggregate, thus increasing light transmission. Therefore the increase in 
platelet aggregation is directly proportional to increase in light 
transmission. These changes in light transmission can be expressed as a 
digital image as shown in Figure 2.2. The aggregation response can be 
separated into three distinct phases; platelet shape change, reversible 
primary aggregation where platelets can disaggregate and return back to 
resting state, and if a strong agonist is used, an irreversible secondary 
aggregation response is seen which is driven by platelet secretion.   
Aggregation tubes containing 250 μl of washed platelets (2.5x108 
platelets/ml) were incubated for 5 minutes at 37°C in a multi-channel 
Chronolog aggregometer (Pennsylvania, USA) prior to stimulation to allow 
for temperature equilibration. The platelet suspension were then 
stimulated with platelet agonists under stirring conditions and platelet 
aggregation was recorded for 4 minutes and expressed as percentage 
increase in light transmission.  The platelet aggregometer was recalibrated 
for every individual platelet sample used. The aggregometer was calibrated 
using washed platelets as 0% aggregation and modified Tyrode buffer as 
100% aggregation. Data was expressed as mean %aggregation ± standard 
error of mean (SEM) and statistical analysis was performed using the 
students t test. 
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Figure 2.2: Aggregation assay. (A) Reversible primary aggregation 
characterised by shape change (B) Primary aggregation with some granule 
secretion (C) Full secondary aggregation response induced by granule 
secretion.  
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For some experiments platelets were incubated with pharmaceutical 
agents that targeted particular receptors and signalling enzymes. The 
incubation times used for inhibitors added prior to stimulation of platelets 
are given in Table 2.1. 
 
Inhibitor Target Concentration Incubation time 
(min) 
A3P5P P2Y1 300 µM 1 
MRS2395 P2Y12 10 µM 1 
Indomethacin COX-1 10 µM 5 
SQ29548 TPα/β 10 µM 5 
Ro 31-8220 Pan PKC isoform 
inhibitor 
10 µM 5 
PP1 Pan Src-kinase 
inhibitor 
10 µM 5 
PP3 Structural inactive 
analogue of PP1 
10 µM 5 
Wortmannin Pan PI3K inhibitor 100 nM 20 
PIK75 PI3Kα 100 nM 20 
TGX-221 PI3Kβ 500 nM 20 
AS242525 PI3Kγ 100 nM 20 
Table 2.1: Summary of inhibitors used in this study.   
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2.3.2 Measurement of ATP secretion  
As highlighted in section 1.1.3, platelets release a number of factors that 
can enhance the aggregation response. Several methodologies have been 
developed to assess granule release including the measurement of P-
selectin expression as a marker of alpha-granule release and ATP secretion 
as a marker of dense-granule release (Feinman et al., 1977, Stenberg et al., 
1985). In the present study we examined aggregation simultaneously with 
ATP release. For these luminescence studies, platelet aggregation was 
performed in the presence of a luciferin-luciferase reagent and the 
subsequent change in luminescence was monitored in a single-channel 
Chrono-log lumi-aggregometer (Pennsylvania, USA) (Feinman et al., 1977). 
ATP released from platelet dense-granules is hydrolysed when magnesium 
dependent-luciferase catalyses the oxidation of luciferin into adenyl-
luciferin (Reaction 1) and light is emitted with the oxidation of adenyl-
luciferin into oxyluciferin (Reaction 2) [Figure 2.3]. When ATP is the limiting 
reagent, the light emitted is proportional to the ATP released from platelet 
dense-granules.  
 
Reaction 1: Luciferin + ATP          `Adenyl-luciferin + PPi 
Reaction 2: Adenyl-luciferin + O2      Oxyluciferin+ H2O + CO2 
Figure 2.3: Chemical basis of luminescence reaction. 
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Aggregation tubes containing 225 μl of washed platelets (3x108 
platelets/ml) were incubated for 5 minutes at 37°C in the lumi-
aggregometer prior to stimulation. 25 μl of luciferin-luciferase reagent was 
added into the washed platelets under stirring conditions for 1 minute and 
then the platelet suspension was stimulated with various platelet agonists 
and the ATP secretion was recorded for 4 minutes and data was expressed 
as mean ATP nM ± SEM. Statistical analysis was performed using the 
student t test. The lumi-aggregometer was calibrated with 1 nM ATP 
standard.  
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2.4 Platelet adhesion methodologies 
The exposure of components of the extracellular matrix is an important 
event in the formation of the haemostatic plug. Initial experiments were 
designed to assess platelet adhesion to immobilised gAd under static and 
flow conditions since plasma adiponectin has been found immobilised to 
collagen fibres (Okamoto et al., 2002).  
2.4.1 Visualisation of platelet actin cytoskeleton 
Platelet adhesion to immobilised gAd under static conditions was used to 
assess platelet adhesion and spreading. This method relies on staining of 
the actin cytoskeleton with a fluorescent dye and fluorescence microscopy 
to visualise the platelets after they have been immobilised. Microscope 
slides were coated with either collagen 10 µg/ml diluted in 0.9% NaCl, CRP-
XL 10 µg/ml, diluted in acetic acid (0.01M) and gAd 50 µg/ml, diluted in 
0.9% NaCl or human serum (HS) (100%) overnight at 4°C. HS was obtained 
from the Blood Transfusion Unit (Sheffield) and prepared by heating at 
80°C for 1 hour and was filtered, aliquoted and stored at -20°C. Slides were 
washed with modified phosphate buffered saline (PBS; 2.7 mM KCl, 1.2 
mM, KH2PO4, 0.2 mM MgCl2, 15 mM NaCl, 7.4 mM NaH2PO4, pH 7.4) and 
blocked with 5% HS diluted in 0.9% NaCl for 30 minutes at room 
temperature. Slides were then washed 3 times with PBS to remove any 
unbound protein.  
Washed platelets (5x107 platelets/ml) were pre-incubated with tirofoban (2 
ng/ml) for 20 minutes, an integrin αIIbβ3 blocking antibody to stimulate 
non-aggregatory conditions and with various inhibitors before adhesion to 
the slides for 1 hour at 37°C. Slides were then washed with PBS to ensure 
any unbound platelets were washed off. The adherent platelets were fixed 
in 4% formaldehyde for 30 minutes and washed extensively before 
permeabilised with 0.1% Triton X for 7 minutes. Adherent platelets were 
stained with TRITC-phalloidin (10 µg/ml) for 1 hour which binds specifically 
to the actin filaments of the adherent platelets cytoskeleton 
(Vandekerckhove et al., 1985). The slides were washed extensively to 
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ensure removal of any excess stain and histomount with a coverslip was 
added. The slides were visualised at x100 magnification with a fluorescent 
microscope (Olympus). Adherent platelets were counted from 8 random 
fields, an area equivalent to 0.1 mm2 and expressed as mean number of 
adhered platelets ± SEM. Statistical analysis was performed using the 
student t test.   
2.4.2 Visualisation of platelet P-selectin expression on immobilised 
platelets 
Microscope slides were prepared and platelets adhered and fixed as 
outlined in the previous section. However, the slides were blocked with 
PBS containing 2% BSA (bovine serum albumin) for 30 minutes to block any 
non-specific binding sites. Anti-FITC conjugated P-selectin antibody (1:100) 
diluted in PBS containing 1% BSA was added after extensive washing steps 
with PBS for 1 hour and left in the dark. The slides were washed with PBS 
to ensure any unbound antibody was washed off and histomount with a 
coverslip was added. 
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2.4.3 Platelet adhesion under conditions of flow 
Preliminary data performed with immobilised gAd under flow was 
performed in collaboration with Prof. R. Farndale and Dr N. Pugh at 
University of Cambridge. This adhesion assay was adapted from Siljander 
and colleagues (Siljander et al., 2004). In this adhesion assay labelled whole 
blood is flowed over immobilised protein such as collagen and platelet 
adhesion and thrombus formation can be observed under a confocal 
microscope.  This assay will help us to understand if immobilised gAd can 
support platelet adhesion and thrombus formation under physiological 
conditions found in the veins and arteries. Blood from healthy donors was 
collected in 40 µM D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone 
(PPACK) to inhibit prothrombin to thrombin cleavage and supplemented 
with 1 µM 3,3’ dihexyloxacarbocyanine iodine (DiOC6), a lipophilic 
fluorescent dye which binds to all cells and can be visualised under a 
microscope. Glass coverslips were coated with CRP-XL (10 µg/ml) or gAd 
(40 µg/ml) overnight at 4°C and then blocked by 1% BSA in HEPES buffer 
(36 mM NaCl, 2.7 mM KCl, 10 mM glucose, 2 mM MgCl2, 2 mM CaCl2 and 5 
mM N-2-hydroxyethylpiperazine-N’ -2-ethanesulfonic acid). The coverslip 
in a 125 µm deep flow chamber was mounted on to a FV300 laser-scanning 
confocal microscope (Olympus) and washed for 1 minute with HEPES 
buffer containing heparin 100 U/ml. Blood was drawn down to the 
chamber for 5 minutes using a syringe pump at 100, 300 and 1000s-1. 
Platelet surface coverage and thrombus height was calculated using Image 
J software (NIH) as described by Pugh and colleagues (Pugh et al., 2010). 
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2.5 Methodologies for analysing proteins and signalling pathways in 
platelets 
2.5.1 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis   
Electrophoresis allows the separation of charged macromolecules in an 
electric field. When applied to a porous matrix such as a gel it can be used 
to separate molecules based on their size and charge. Sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), uses a 
combination of sodium dodecyl sulphate (SDS) and the polyacrylamide gels 
to separate proteins according to their molecular weight by electrophoretic 
migration. SDS-PAGE under denaturing conditions is a widely used method 
to separate proteins according to their size and not their charge (Towbin et 
al., 1979). Mercaptoethanol is used as a reducing agent to break disulfide 
bonds, returning the protein to its primary structure. SDS then gives the 
protein an overall negative charge [Figure 2.4].  
SDS-PAGE is performed using a stacking gel which sits on top of the 
resolving gel and are composed of polyacrylamide. Polymerization of 
acrylamide is initiated by adding tetramethylethylenediamine (TEMED) and 
ammonium persulfate (APS). The TEMED acts as an electron carrier to 
activate the acrylamide monomer, providing an unpaired electron to 
convert the acrylamide monomer to a free radical.  The activated monomer 
then reacts with an inactivated monomer to start the polymer chain 
reaction.  The elongating polymer chains are randomly cross-linked by 
bisacrylamide, resulting in polymerization. When a current is applied, the 
negatively charged proteins will move towards the anode but due to the 
unique properties of the polyacrylamide gel i.e. pore size, smaller proteins 
will move faster compared to the larger proteins. As the stacking gel has a 
lower pH of 6.8 compared to the pH 8 of the resolving gel it allows the 
proteins to stack up and enter the resolving gel at the same time, thereby 
improving resolution. This is a discontinuous pH gel system that was 
originally described by Laemmli (Laemmli, 1970). 
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Figure 2.4: Overview of sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis. (i) SDS binds to amino acid residues and gives uniform 
negative charge to the protein sample which is then further subjected to a 
cycle of heat induced denaturisation. (ii) Protein sample is loaded onto the 
SDS-PAGE gel. (iii) An electric current is applied to separate proteins 
according to size.  
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2.5.1.1 Preparation of platelet proteins for sodium dodecyl sulphate-
polyacrylamide gel electrophoresis 
Washed platelets were prepared as described in section 2.2.1 and were 
pre-incubated with EGTA (1 mM) to promote non-aggregatory conditions 
by inhibiting integrin function (Gogstad et al., 1982). In some experiments, 
apyrase (2 U/ml) and indomethacin (10 µM) was added to eliminate 
platelet secondary mediated signalling by removing the β phosphate from 
ADP and inhibiting COX-1 and therefore TxA2 synthesis respectively (Smith, 
1971, Mustard et al., 1972). Platelets were incubated with various 
inhibitors under stirring conditions for 1 minute at 37°C and for longer 
incubation times, the platelets were initially stirred for 1 minute and left at 
37°C under non-stirring conditions. The washed platelets were then 
stimulated under stirring conditions with an agonist for 90 seconds, unless 
otherwise stated. The reaction was stopped by the addition of an equal 
volume of 2x Laemmli buffer (0.5 M Tris HCL, 4% SDS, 20% glycerol and 
10% mercaptoethanol) and stored at -20°C until required. The samples 
were boiled for 5 minutes before use to ensure denaturation of the 
proteins.  
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2.5.1.2 Measurement of protein concentrations 
Protein concentration was measured using the Bio Rad DC Protein Assay 
Kit. The assay is a colorimetric reaction based on the Lowry method (Lowry 
et al., 1951), in which the reaction between the protein and an alkaline 
copper tartate solution leads to the reduction of the folin reagent and 
results in the development of a blue colour with maximal absorbance at 
750 nm. BSA was used as a standard protein to compare protein 
concentration against the platelet protein sample. The BSA standards were 
prepared in the same buffer as the samples.  
2.5.1.3 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
method 
Protein lysates were separated by SDS-PAGE under denaturing conditions 
using a mini protean III gel kit (Bio Rad). A 3% stacking gel was used to 
allow all the proteins to stack up and enter the resolving gel at the same 
time.  A 10% or 10-18% gradient gel was used as a resolving gel and placed 
in the electrophoresis tank containing running buffer (25 mM Tris base, 192 
mM glycine, 0.1% (w/v) SDS, pH 8.3). A total protein concentration of 20 µg 
unless otherwise stated was loaded into each well in the stacking gel and 
sample buffer was added to any free wells and was electrophoresed for 2.5 
hours at 120 volts to ensure the proteins were fully distributed across the 
resolving gel. 
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 2.5.2 Immunochemical techniques 
2.5.2.1 Immunoblotting  
Immunoblottting or western blotting is a sensitive and powerful method 
used to detect proteins of interest by using protein specific monoclonal 
and polyclonal antibodies. Once proteins have been separated by SDS-
PAGE, they are transferred to an adhesive matrix or membrane such as 
nitrocellulose or polyvinylidene fluoride (PVDF) by application of an 
electrical current. The immobilised proteins on the membrane are allowed 
to interact with specific primary antibodies forming an antibody-antigen 
complex that can be identified by using different detection systems. The 
method of detection used in this study was an enhanced chemiluminescent 
(ECL) system. This method uses a species-specific secondary antibody, 
which is conjugated to an enzyme called horseradish peroxidase (HRP). 
Numerous secondary antibodies bind specifically to the primary antibody-
antigen complex, acting to amplify the complex. The HRP catalyses the 
oxidation of chemiluminescent reagent, luminol, by hydrogen peroxide 
resulting in a luminescent signal which is detected by a photographic film.  
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2.5.2.2 Immunoblotting method 
PVDF membranes were activated by pre-wetting with 10 ml of methanol 
for 1 minute, washed with 10 ml of water for 1 minute and left in 10 ml of 
transfer buffer until use (25 mM Tris base, 192 mM glycine, 20% (w/v) 
methanol, pH 8.3). Platelet protein samples were separated by SDS-PAGE 
as described in section 2.5.1.3 and the resolving gels was assembled into a 
transfer cassette [Figure 2.5]. The proteins were transferred into the 
activated PVDF membranes by applying 100 volts for 2.5 hours. After 
transfer membranes were blocked for 30 minutes with 10% BSA dissolved 
in Tris buffered saline-tween (TBS-T; 20 mM Tris, 137 mM NaCl, 0.1% 
tween-20; pH 7.6) or 5% milk protein dissolved in TBS-T to block any non-
specific binding sites. Immunoblotting studies were performed using anti-
phosphotyrosine 4G10 (1:1000), anti-Akt serine473 (1:2000), anti-β-tubulin 
(1:1000) and anti-PKC substrate (1:1000) dissolved in TBS-T containing 2% 
BSA and were left overnight at 4°C with gentle agitation. Membranes were 
then washed two times for 5 minutes with TBS-T to remove any unbound 
primary antibody and incubated either with a secondary antibody HRP-
conjugated anti-mouse IgG (1:10000) or HRP-conjugated anti-rabbit 
(1:10000) as appropriate and HRP-conjugated anti-biotin (1:2000) for 
detection of biotinylated protein ladders for 1 hour at room temperature 
with gentle agitation. Membranes were subsequently washed five to six 
times for 15 minutes with TBS-T to remove any excess secondary antibody 
and membranes were developed with enhanced chemiluminescence 
solutions.  
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Figure 2.5: Assembly of western blotting cassette. The western blot 
cassette was assembled to allow proteins in the gel to be transferred to the 
PVDF membrane under an electric current.  
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2.5.2.3 Stripping and reprobing of membranes 
Membranes can be stripped of antibodies and subsequently reprobed with 
different primary antibodies. In most cases this is performed to check for 
equal loading of proteins. Membranes were washed in stripping buffer 
composed of TBS-T, 5% mercaptoethanol and 2% SDS at 80°C for 20 
minutes. Membranes were then washed three times with TBS-T for 10 
minutes and the immunobloting procedure was repeated with the new 
primary antibody. 
2.5.2.4 Densitometric measurement 
Densitometric measurement of immunoblots was calculated using Image J 
software (NIH) and data was expressed as relative density to basal ± SEM 
or relative density/total ± SEM where appropriate. Statistical analysis was 
performed using the student t test. Briefly, a standard template box was 
drawn around the first band and was then cut and pasted onto the next 
band to maintain accuracy.  
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Chapter 3: The effects of adiponectin on platelet function  
Adiponectin has been described as an endogenous anti-thrombotic factor 
but its direct effect on platelet function is not clear. Elbatarney and 
colleagues showed that fAd had no effect on platelet aggregation 
(Elbatarny et al., 2007). In contrast, Restituto and colleagues suggested 
that fAd can inhibit ADP and adrenaline-stimulated aggregation (Restituto 
et al., 2010). However, the effect of gAd on platelet aggregation remains to 
be determined. In this chapter we aim to investigate the effect of globular 
and full-length forms of adiponectin on platelet aggregation. In particular, 
look at the signalling events underlying any observed effects on 
aggregation. These experiments will allow us to determine the direct effect 
of adiponectin on platelet aggregation in vitro. 
3.1 Aggregation and tyrosine phosphorylation studies with adiponectin 
Initial experiments were designed to determine the effect of recombinant 
forms of adiponectin on platelet aggregation, since a recombinant form of 
the protein has been shown to stimulate platelet aggregation (Riba et al., 
2008). Recombinant gAd (5-20 µg/ml) expressed from E. Coli was added to 
platelets and the effects on aggregation were monitored. Under these 
conditions, gAd stimulated platelet aggregation in a concentration-
dependent manner, with a threshold response at 5 µg/ml and induced 
maximal aggregation at 20 µg/ml [Figure 3.1A]. In contrast, both collagen 
and CRP-XL induced maximal platelet aggregation at 10 µg/ml [Figure 3.1C 
and D]. Furthermore, we found platelet stimulation by gAd (20 µg/ml) also 
induced platelet dense-granule secretion as exemplified by the release of 
0.38±0.07 nM ATP [Figure 3.1E]. However, this was significantly less when 
compared to other strong agonists such a GPVI specific agonist; CRP-XL or 
thrombin [Figure 3.1E]. These data suggest that only the globular form of 
adiponectin is able to stimulate full irreversible aggregation through 
platelet dense-granule secretion. In contrast, addition of fAd (20 µg/ml) to 
the platelet preparations failed to stimulate aggregation [Figure 3.1B]. 
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These data suggested that different forms of adiponectin induced distinct 
effects on platelet aggregation with only gAd being pro-aggregatory. 
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Figure 3.1: Globular adiponectin stimulates platelet aggregation. (A) 
Washed platelets (2.5x108 platelets/ml) were stimulated with a range of 
gAd concentrations (5-20 µg/ml) and the aggregation response was 
monitored for 4 minutes under constant stirring. (B) As in (A) except 
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platelets were stimulated with fAd (20 µg/ml). All representative 
aggregation traces are taken from three independent experiments 
performed with distinct blood donors.  (C) and (D) Platelets were 
stimulated with gAd (20 µg/ml), collagen (10 µg/ml), CRP-XL (10 µg/ml) and 
thrombin (0.5 U/ml). The aggregation response was monitored for 4 
minutes and expressed as %aggregation ± SEM of three independent 
experiments. (E) Washed platelets (3x108 platelets/ml) were stimulated 
with gAd (20 µg/ml), collagen (10 µg/ml), CRP-XL (10 µg/ml) and thrombin 
(0.5 U/ml).  The luminescence response was monitored for 4 minutes 
under constant stirring and results were expressed as ATP nM secretion ± 
SEM of three independent experiments. 
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3.1.1 Characterisation of globular adiponectin-stimulated aggregation 
Platelets are activated through surface receptors that enable the activation 
of integrin αIIbβ3 by inside-out signalling and thus allowing plasma 
fibrinogen to bind (Du et al., 1991). The fibrinogen acts as an inter-platelet 
bridge that facilitates platelet aggregation and forming the haemostatic 
plug. It was important to establish that responses observed with the 
platelet aggregometer were integrin-mediated aggregation and not 
platelet agglutination. To achieve this we used a number of 
pharmacological agents including Arginine-Glycine-Aspartate-Serine 
(RGDS), a peptide antagonist of the integrin αIIbβ3, and the extracellular 
Ca2+ chelator EGTA which prevents integrin function through removal of 
critical Ca2+ ions.  GAd induced platelet aggregation was completely 
inhibited in the presence of RGDS (1 mM) (p<0.05), although platelet shape 
change still occurred as this is independent of integrin αIIbβ3 outside-in 
signalling [Figure 3.2A(i) and B]. Furthermore, incubation of washed 
platelets with EGTA (1 mM) totally ablated gAd-induced aggregation 
(p<0.05), thereby indicating that gAd-stimulated aggregation is integrin 
dependent [Figure 3.2A(ii) and B].  
Platelet integrin αIIbβ3 activation requires signalling pathways that involve 
intracellular Ca2+ mobilisation, and numerous enzymes such as  PLC, PKC 
and PI3K activation (Carpenter and Cantley, 1990, Atkinson et al., 2003, 
Lian et al., 2005, Harper and Poole, 2007). However, individual platelet 
agonists activate platelets by distinct mechanisms and therefore it was 
important to establish the importance of these key signalling events to 
platelet aggregation stimulated by gAd. Platelet aggregation was abolished 
by the intracellular Ca2+ chelator, 2-bis (2-aminophenoxy) ethane-
N,N,N,N’,N’-tetraacetic acid tetra(acetoxymethyl) ester (BAPTA-AM; 20 
µM), consistent with the key role of Ca2+ in platelet aggregation [Figure 
3.1A(iii) and B]. It is widely recognised that platelet activation can proceed 
through pathways that involve Src-kinases in response to both collagen and 
vWF (Nieswandt and Watson, 2003). A pan Src-kinase inhibitor, PP1 (20 
µM) was able to fully ablate gAd-stimulated aggregation (p<0.05) [Figure 
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3.2A(iv) and B]. Similarly wortmannin (100 nM), a pan PI3K inhibitor, also 
completely abolished aggregation (p<0.05) [Figure 3.2A(v) and B]. In 
contrast, Ro 31-8220 (10 µM), a pan PKC inhibitor, only partially inhibited 
gAd-stimulated (20 µg/ml) aggregation from 73±3.28% to 37±5.45% 
(p<0.05), therefore indicating that platelet aggregation can proceed 
through pathways independent of PKC [Figure 3.2A(vi) and B]. Taken 
together, these data suggest that gAd-stimulated aggregation is tyrosine 
kinase-dependent mechanism that requires PI3K and to a lesser degree an 
isoform of PKC.  
  
 93 
 
 
Figure 3.2: Characterisation of globular adiponectin-stimulated 
aggregation. (A) Washed platelets (2.5x108 platelets/ml) were stimulated 
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with gAd (20 µg/ml) in the absence and presence of RGDS (1 mM), EGTA (1 
mM), BAPTA-AM (10 µM), PP1 (20 µM), wortmannin (100 nM) and Ro 31-
8220 (10 µM) and the aggregation response was monitored for 4 minutes 
under constant stirring. All representative aggregation traces are taken 
from four independent experiments performed with distinct blood donors. 
(B) Representative of data in (A) and results are shown as the mean ± SEM 
of four independent experiments, where ** indicates p<0.005 compared to 
gAd alone with the inhibitors.  
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3.1.2 Globular adiponectin stimulates tyrosine phosphorylation  
These initial platelet aggregation experiments with gAd revealed an 
absolute requirement of Src-kinase isoforms in gAd-stimulated aggregation 
[Figure 3.2]. Since activation of Src-kinase isoforms leads to the 
phosphorylation of platelet proteins on tyrosine residues (Thomas and 
Brugge, 1997, Ezumi et al., 1998), the role of Src-kinases in gAd-stimulated 
platelets was investigated. In the first instance the ability of gAd to induce 
tyrosine phosphorylation was investigated. GAd (20 µg/ml) induced a 
robust increase in tyrosine phosphorylation of platelet proteins in whole 
cell lysates, with prominent bands at 38, 45, 70 and 140 kDa [Figure 3.3]. 
However, proteins at 60 kDa region were found to be basally 
phosphorylated and maintained their phosphorylation state after 
stimulation with gAd. Platelets stimulated with gAd in the presence of PP1 
(20 µM), the pan Src family kinase inhibitor, completely inhibited tyrosine 
phosphorylation of these platelet proteins, including proteins at 70 and 
140 kDa, previously seen to be stimulated by gAd [Figure 3.3B]. 
Importantly, PP3 (20 µM), the inactive structural analogue of PP1, had no 
effect on tyrosine phosphorylation [Figure 3.3]. Taken together, these data 
suggest that gAd activate platelets through a tyrosine kinase-dependent 
mechanism mediated at least in part by Src-kinases. Importantly, these 
tyrosine phosphorylation experiments were performed in the presence of 
EGTA, indomethacin and apyrase which remove the positive feedback of 
soluble platelet agonists such as TxA2 and ADP respectively.  
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Figure 3.3: Globular adiponectin stimulates tyrosine phosphorylation of 
platelet proteins. (A) Washed platelets (5x108 platelets/ml) were 
incubated with apyrase (2 U/ml), indomethacin (10 µM) and EGTA (1 mM) 
for 20 minutes and then stimulated with gAd (20 µg/ml) in the presence of 
either PP1 (20 µM) or PP3 (20 µM) for 90 seconds. Proteins were resolved 
on 10-18% gradient polyacylamide gel SDS-PAGE and immunoblotted using 
anti-phosphotyrosine antibody. (B) Densitometric measurement of 
phosphotyrosine at band labelled “x” and expressed as relative density to 
basal. (This confirms previous data from Riba et al., 2007) 
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3.2 The role of secondary mediators in globular adiponectin-stimulated 
aggregation 
Platelets release secondary mediators such as ADP and TxA2 that reinforce 
platelet activation and thrombus formation. Since early platelet 
aggregation experiments with gAd [Figure 3.1] had established that the 
release of dense-granules was required for maximal aggregation, the role 
of ADP and TxA2 was investigated in this process. To achieve this platelet 
aggregation was monitored in the presence of ADP receptor antagonists, 
A3P5P and MRS2395 to inhibit the potential effects of ADP signalling 
through P2Y1 and P2Y12 receptors respectively (Atkinson et al., 2001, 
Kunapuli et al., 2003), or indomethacin to prevent TxA2 formation (Vane, 
1971, Charo et al., 1977). It was important to ensure that the concentration 
of these inhibitors was able to inhibit these pathways.  
In the first instance the effectiveness of the ADP receptor antagonists were 
tested against ADP-induced aggregation to confirm their effectiveness. The 
addition of A3P5P (300 µM) and MRS2395 (10 µM) (Atkinson et al., 2001) 
was sufficient to ablate ADP-mediated aggregation when combined, 
suggesting the concentration of these antagonists was sufficient to prevent 
ADP receptor signalling [Figure 3.4]. Studies have shown that indomethacin 
can irreversibly inhibit TxA2 synthesis at 10 µM through the inhibition of 
COX-1 (Maderna et al., 1985).  
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Figure 3.4: ADP receptor antagonists inhibit ADP-mediated aggregation. 
Washed platelets (2.5x108 platelets/ml) supplemented with fibrinogen (20 
µg/ml) were stimulated with ADP (50 µM) and the aggregation response 
was monitored for 4 minutes under constant stirring in the presence or 
absence of ADP receptor antagonists; A3P5P (300 µM) and MRS2395 (10 
µM). 
 
  
 99 
 
3.2.1 Globular adiponectin-stimulated aggregation requires secondary 
platelet agonists 
In the first instance the role of ADP and TxA2 on gAd-stimulated 
aggregation was investigated. Since gAd stimulates platelets through a 
tyrosine kinase-dependent mechanism [Figure 3.3], the effects of gAd was 
compared with collagen. Stimulation of platelets with gAd (20 μg/ml) 
induced full irreversible aggregation of 68±0.60% (EC50 17.26 μg/ml), which 
was reduced to 58±1.5% (p<0.05) by the presence of A3P5P/MRS2395 
(EC50 29.61 μg/ml), to 47±0.90% (p<0.05) by indomethacin (EC50 29.03 
μg/ml) and then further reduced to 33±1.90% (p<0.05) when all three 
inhibitors were combined (EC50 27.83 μg/ml) [Figure 3.5A and C].  
In contrast, at threshold concentrations of gAd (10 µg/ml) the inhibitors 
had potent inhibitory effect on aggregation [Figure 3.5B]. The ADP 
receptors antagonists alone reduced aggregation from 25±3.93% to 
7±3.17%, and indomethacin reduced aggregation to 6±1.20%, while in 
combination the inhibitors ablated aggregation. As can be seen in Figure 
3.5C, the presence of the inhibitors led to a rightward shift in the 
concentration response curve for gAd.  
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Figure 3.5: Globular adiponectin-stimulated aggregation is dependent on 
secondary platelet mediators. (A) Washed platelets (2.5x108 platelets/ml) 
were stimulated with gAd (20 µg/ml) in the presence or absence of ADP 
receptor antagonists; A3P5P (300 µM), MRS2395 (10 µM) or cyclo-
oxygenase inhibitor indomethacin (10 µM). (B) As in (A) except platelets 
were stimulated with gAd (10 µg/ml). All representative aggregation traces 
are taken from four independent experiments performed with distinct 
blood donors. 
 
 101 
 
 
Figure 3.5: Globular adiponectin-stimulated aggregation is dependent on 
secondary platelet mediators. (C) Washed platelets were stimulated with 
gAd dose response (1-50 µg/ml) alone ( ), in the presence of A3P5P 
(300 µM) and MRS2395 (10 µM) ( ), in the presence of cyclo-oxygenase 
inhibitor indomethacin (10 µM) ( ) or in the presence of A3P5P, 
MRS2395 and indomethacin combined ( ). Results are shown as the 
mean ± SEM of four independent experiments, where * indicates p<0.05 
compared with gAd alone to the inhibitors. 
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Under these identical experimental conditions, the role of ADP and TxA2 on 
collagen-stimulated aggregation was also investigated. Stimulation of 
platelets with collagen (10 µg/ml) induced full irreversible aggregation of 
80±3.97% (EC50 3.43 μg/ml). This was reduced to 72±2.83% by the 
presence of the ADP receptor antagonists (EC50 4.04 μg/ml), to 36±4.88% 
by the presence of indomethacin (EC50 10.18 μg/ml) and then further 
reduced to 22±2.01% (p<0.05) when all three inhibitors were combined 
(EC50 17.88 μg/ml) [Figure 3.6A and C]. In contrast, platelets stimulated 
with threshold concentration of collagen (0.25 µg/ml) also showed a strong 
dependency on secondary mediators as evidenced by the rightward shift in 
the concentration response curve for collagen [Figure 3.6B and C]. Thus, 
gAd stimulates platelet aggregation through pathways that are both 
dependent and independent of secondary mediators. These data also 
demonstrate that gAd behaves in a manner similar to collagen in that 
secondary mediators are required to induce a maximal aggregation 
response (Dawood et al., 2007).  
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Figure 3.6: Collagen-stimulated aggregation is dependent on secondary 
platelet mediators. (A) Washed platelets (2.5x108 platelets/ml) were 
stimulated with collagen (10 µg/ml) in the presence or absence of ADP 
receptor antagonists; A3P5P (300 µM), MRS2395 (10 µM) or cyclo-
oxygenase inhibitor indomethacin (10 µM). (B) As in (A) except platelets 
were stimulated with collagen (1 µg/ml). All representative aggregation 
traces are taken from four independent experiments performed with 
distinct blood donors. 
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Figure 3.6: Collagen-stimulated aggregation is dependent on secondary 
platelet mediators. (C) Platelets were stimulated with collagen dose 
response (0.25-50 µg/ml) alone ( ), in the presence of A3P5P (300 µM) 
and MRS2395 (10 µM) ( ), in the presence of cyclo-oxygenase inhibitor 
indomethacin (10 µM) ( ) or in the presence of A3P5P, MRS2395 and 
indomethacin combined ( ). Results are shown as the mean ± SEM of 
four independent experiments, where * indicates p<0.05 compared with 
collagen alone to the inhibitors. 
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3.2.2 Globular adiponectin can synergise with Gi-coupled platelet agonists 
Since gAd-induced platelet aggregation required secondary mediators to 
induce a maximal response, this led to the possibility that these agonists 
could synergise with the adipokine to increase aggregation. Platelets were 
stimulated with gAd (5 µg/ml) which induced an aggregation response of 
16±2.1%. The presence of ADP (1 µM) potentiated gAd (5 µg/ml)-
stimulated aggregation from 12±4.3% to 63±2.7% (p<0.05) [Figure 3.7A]. 
Having established that synergism could take place, the identification of 
the ADP receptor responsible was investigated. This synergistic response 
was maintained in the presence of A3P5P, but reduced in the presence of 
MRS2395 [Figure 3.7B].  
 We next examined the potential for adrenaline and TxA2 to synergise with 
gAd. Similar to ADP, adrenaline (10 µM) synergised with gAd to increase 
threshold platelet aggregation response from 18±0.7% to 32±2.7% (p<0.05) 
[Figure 3.8A], without inducing aggregation itself.  In contrast, the TxA2 
mimetic U46619 failed to synergise with gAd at any concentration tested 
whilst inducing full aggregation by itself at 10 µM [Figure 3.83]. These data 
suggest a role of P2Y12 Gi and Gz-coupled G-proteins in the potentiation of 
gAd-stimulated aggregation.  
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Figure 3.7: Globular adiponectin synergies with Gi-coupled agonists to 
promote platelet aggregation. (A) Washed platelets (2.5x108 platelets/ml) 
were stimulated with sub-threshold concentrations of gAd (5 µg/ml) alone, 
ADP (1 µM) alone or gAd and ADP combined and the aggregation response 
was monitored for 4 minutes under constant stirring. (B) Platelets were 
stimulated with both gAd (5 μg/ml) and ADP (1 µM) in the presence or 
absence of ADP receptor antagonists A3P5P (300 µM) or MRS2395 (10 
µM). All traces are representative of data obtained from four independent 
experiments. 
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Figure 3.8: Globular adiponectin synergies with Gi-coupled agonists to 
promote platelet aggregation. (A) Washed platelets (2.5x108 platelets/ml) 
were stimulated with sub-threshold concentrations of gAd (5 µg/ml) alone 
or adrenaline (10 µM) or combined. (B) As in (A) except platelets were 
stimulated with gAd (5 µg/ml) and the TxA2 mimetic U46619 (0.5 µM).  All 
traces are representative of data obtained from four independent 
experiments. (C) Quantified data of (A) and (B), where * indicates p<0.05 
compared with gAd in the presence and absence of adrenaline. 
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3.2.3 The influence of thromboxane signalling on platelet dense-granule 
secretion in globular adiponectin-stimulated aggregation 
To further clarify the role of TxA2 and ADP on gAd-stimulated aggregation, 
platelet dense-granule secretion was examined with lumi-aggregation in 
the presence and absence of indomethacin and ADP receptor antagonists. 
Stimulation of platelets with gAd (20 µg/ml) induced dense-granule 
secretion as exemplified by the release of 0.44±0.08 nM ATP [Figure 3.9]. 
However, ATP secretion stimulated by gAd was unaffected by the presence 
of the ADP receptor antagonists (0.42±0.06 nM ATP secretion), but was 
abolished under conditions of TxA2 blockade by indomethacin (p<0.05), 
suggesting that secretion was driven by TxA2.  
To explore this further we used the TxA2 mimetic U46619 (Parise et al., 
1982, Zatta et al., 1993). The inhibition of secretion in the presence of 
indomethacin was restored to 0.25±0.065 nM ATP by the addition of 
U46619 (5 µM) (p<0.05) when compared to indomethacin alone while the 
effects of U46619 were abolished by the thromboxane TPα/β receptor 
antagonist SQ29548 (10 µM) (p<0.05) [Figure 3.9] and the pan PKC 
inhibitor Ro 31-8220. Taken together, these data may suggest that gAd 
induced secretion requires the synthesis of TxA2, which drives PKC-
dependent secretion of ADP from dense-granules to further amplify gAd-
stimulated aggregation.      
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Figure 3.9: Thromboxane drives platelet dense-granule secretion in 
response to globular adiponectin. Washed platelets (3x108 platelets/ml) 
were stimulated with gAd (20 µg/ml) in the presence and absence of 
indomethacin (10 µM), SQ29548 (10 µM) A3P5P (300 µM), MRS2395 (10 
µM) and U46619 (5 µM) and the luminescence response was monitored for 
4 minutes under constant stirring. Results were expressed as ATP nM 
secretion ± SEM of four experiments, where #, § and ǿ indicates p<0.05 
compared with gAd stimulation in the presence of the inhibitors and * 
indicates p<0.05 compared with U46619 stimulation in the presence of the 
inhibitors. 
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3.2.4 The influence of platelet derived mediators on tyrosine 
phosphorylation stimulated by globular adiponectin 
Since gAd-mediated aggregation required both Src-family kinases and the 
release of ADP and TxA2, the potential relationship between these two 
events was investigated. Hence, the influence of platelet derived TxA2 and 
ADP on gAd-induced tyrosine phosphorylation was examined. Consistent 
with earlier experiments [Figure 3.3], gAd (20 μg/ml) stimulated a marked 
increase in tyrosine phosphorylation, with the most prominent bands 
observed at 45, 50, 72, and 140 kDa [Figure 3.10]. After 90 seconds, at 
which point gAd induced tyrosine phosphorylation was maximal and 
reproducible (Riba et al., 2008), the inhibitors of P2Y1 and P2Y12 inhibitors 
and indomethacin were tested.  A3P5P and MRS2395, either alone or in 
combination, failed to influence phosphorylation induced by gAd [Figure 
3.10]. Consistent with this data the presence of indomethacin did not 
influence tyrosine phosphorylation induced by the adipokine [Figure 3.10]. 
Thus, tyrosine phosphorylation in response to gAd is independent of 
secondary mediators. 
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Figure 3.10: Secondary mediators do not influence globular adiponectin-
stimulated tyrosine phosphorylation. (A) Washed platelets (5x108 
platelets/ml) were stimulated with gAd (20 µg/ml) in the presence or 
absence of ADP receptor antagonists; A3P5P (300 µM), MRS2395 (10 µM) 
and cyclo-oxygenase inhibitor indomethacin (10 µM). Platelets were lysed, 
separated by SDS-PAGE and blotted for phosphotyrosine containing 
proteins. (B) Densitometric measurement of phosphotyrosine at band 
labelled “x” and expressed as relative density to basal ± SEM of three 
independent experiments. 
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As a comparison the importance of secondary mediators to tyrosine 
phosphorylation in other tyrosine kinase agonists such as collagen was 
tested. Stimulation of washed platelets by collagen (10 µg/ml) induced 
tyrosine phosphorylation of a number of platelet proteins, with prominent 
bands at 28, 45, 72, 100 and 120 kDa [Figure 3.11]. Similar to gAd-induced 
tyrosine phosphorylation, proteins at 60 kDa were found to be basally 
phosphorylated and maintained their phosphorylation state after 
stimulation. Consistent with the previous data obtained from gAd and 
previously published work with collagen (Atkinson et al., 2003), the ADP 
receptor antagonists, indomethacin or in combination had no influence on 
tyrosine phosphorylation [Figure 3.11]. These data are consistent with a 
mechanism whereby tyrosine phosphorylation is independent of platelet 
derived secondary mediators.   
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Figure 3.11: Secondary mediators do not influence collagen-stimulated 
tyrosine phosphorylation. (A) Washed platelets (5x108 platelets/ml) were 
stimulated with collagen (10 µg/ml) in the presence or absence of ADP 
receptor antagonists; A3P5P (300 µM), MRS2395 (10 µM) and cyclo-
oxygenase inhibitor indomethacin (10 µM). Platelets were lysed, separated 
by SDS-PAGE and blotted for phosphotyrosine containing proteins. (B) 
Densitometric measurement of phosphotyrosine at band labelled “x” and 
expressed as relative density to basal ± SEM of three independent 
experiments. 
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3.2.5 The direct effect of secondary mediators on tyrosine 
phosphorylation 
To confirm that platelet derived secondary mediators do not influence 
tyrosine phosphorylation in gAd-stimulated platelets, the ability of ADP and 
TxA2 to induce tyrosine phosphorylation by itself was investigated. Washed 
platelets in non-aggregatory conditions were stimulated for 90 seconds 
with ADP (10 µM) and no increase in tyrosine phosphorylation was 
detected [Figure 3.12]. The Gq-coupled agonist, U46619 (10 µM)-a 
thromboxane mimetic and Gz-coupled agonist adrenaline also did not 
stimulate increase in tyrosine phosphorylation levels [Figure 3.12]. These 
data suggest that platelet derived ADP and TxA2 do not play a significant 
role in gAd-stimulated tyrosine phosphorylation.  
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Figure 3.12: Platelet secondary agonists do not induce tyrosine 
phosphorylation. (A) Washed platelets (5x108 platelets/ml) were 
stimulated for 90 seconds with collagen (10 µg/ml), ADP (10 µM), 
adrenaline (10 µM), thromboxane mimetic U46619 (10 µM) and gAd (20 
µg/ml). Platelets were lysed, separated by SDS-PAGE and blotted for 
phosphotyrosine containing proteins, followed by re-probing for β-tubulin. 
(B) Densitometric measurement of phosphotyrosine at band labelled “x” 
and expressed as relative density to basal ± SEM of three independent 
experiments. 
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3.3 Role of PKC in globular adiponectin-stimulated platelet aggregation 
PKC is a family of serine-threonine kinases that are known to play a key 
role in platelet secretion (Harper and Poole, 2007). Since early data 
indicate that secretion of ADP was required for gAd-stimulated platelet 
aggregation, the role of PKC was examined in this process using the general 
PKC inhibitor, Ro 31-8220 (10 μM). Under these conditions, PKC blockade 
abolished aggregation induced by low concentrations of gAd (1-15 µg/ml) 
[Figure 3.13], whereas gAd-induced (20 µg/ml) platelet aggregation was 
inhibited by 53±3.8% (p<0.05). These data would suggest that PKC is 
required for maximal aggregation induced by gAd.  
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Figure 3.13: Globular adiponectin-stimulated platelet aggregation occurs 
through PKC-dependent and independent pathways. (A) Washed platelets 
(2.5x108 platelets/ml) were stimulated with gAd (1-50 µg/ml) and the 
aggregation response was monitored for 4 minutes under constant stirring 
in the absence ( ) or presence of Ro 31-8220 (10 µM) ( ). Results are 
shown as the mean ± SEM of four independent experiments, where * 
indicates p<0.05 compared to gAd alone with Ro 31-8220.   
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3.3.1 PKC substrate phosphorylation by globular adiponectin 
To confirm the activation of PKC by gAd, and the ability of Ro 31-8220 to 
inhibit PKC activation, an antibody that recognises phosphorylation 
substrate by PKC isoforms (sequence (R/K)X(S*)(Hyd)(R/K)) was used 
(Pearson and Kemp, 1991, Nishikawa et al., 1997). GAd increased 
phosphorylation of a number of PKC substrates with molecular weights of 
60, 80, 100 and 140 kDa in a concentration-dependent manner [Figure 
3.14].  Although the ability to activate PKC was modest in comparison to 
phorbol 12-myristate 13-acetate (PMA) (300 nM) [Figure 3.14 and 3.15], 
densitometric measurements of these bands showed different PKC 
substrate phosphorylation kinetics. For example, PKC substrate 
phosphorylation levels at 140 kDa were found to be maximal between gAd 
5-10 µg/ml stimulation [Figure 3.14B]. In contrast, PKC substrate 
phosphorylation levels at 60 kDa were maximal at gAd 20 µg/ml 
stimulation [Figure 3.14C].  
PMA, a DAG analogue induced a strong increase in phosphorylation of PKC 
substrates with molecular weights of 140, 100, 80, 70, 60, 50, 30 and 25 
kDa [Figure 3.14 and 3.15]. Importantly, the phosphorylation events 
induced by both gAd and PMA were blocked by the PKC inhibitor Ro 31-
8220 [Figure 3.15]. The incubation of washed platelets with Ro 31-8220 (1-
10 µM) reduced PKC substrate phosphorylation in a concentration-
dependent manner [Figure 3.15B and C]. Ro 31-8220 (10 µM) was found to 
be the most effective concentration to inhibit the phosphorylation of PKC 
substrates. Taken together, this data in combination with previous 
aggregation data suggests that gAd activates a PKC isoform that plays a 
critical role in αIIbβ3 dependent aggregation, particularly at low gAd 
concentrations. 
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Figure 3.14: Globular adiponectin stimulates PKC substrate 
phosphorylation in a concentration-dependent manner. (A) Washed 
platelets (5x108 platelets/ml) were stimulated with gAd (2-20 µg/ml) or 
PMA (300 nM) for 90 seconds, in the presence or absence of Ro 31-8220 
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(10 µM). Platelets were lysed, separated by SDS-PAGE and blotted with 
anti-phospho-PKC substrate antibody. (B) Densitometric measurement of 
phospho-PKC substrate at band labelled “x”. (C) As in (B) except band 
labelled “y” was selected and expressed as relative density to basal ± SEM 
of three independent experiments, where * indicates p<0.05 compared 
with PMA in the presence and absence of Ro 31-8220.    
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Figure 3.15: Globular adiponectin stimulates PKC activation. (A) Washed 
platelets (5x108 platelets/ml) were stimulated with gAd (20 µg/ml) or PMA 
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(300 nM) for 90 seconds, in the presence or absence of increasing 
concentration of Ro 31-8220 (1-10 µM). Platelets were lysed, separated by 
SDS-PAGE and blotted with anti-phospho-PKC substrate antibody. The 
arrows indicated gAd-stimulated PKC substrate protein phosphorylation. 
(B) Densitometric measurement of phospho-PKC substrate at band labelled 
“x”. (C) As in (B) except band labelled “y” was selected and expressed as 
relative density to basal ± SEM of three independent experiments, where * 
indicates p<0.05 compared with PMA in the presence and absence of Ro 
31-8220. 
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3.3.2 G-protein coupled receptors can compensate for the loss of PKC 
Having established that gAd stimulated platelet aggregation occurred 
through PKC dependent and independent mechanisms, and that G-protein 
coupled receptors could synergise with gAd to maximise platelet 
aggregation, we investigated the mechanism that link these two 
observations. In the first instance we used aggregation to examine if Gi/Gz-
coupled receptors could synergise with gAd to overcome the loss of PKC 
signalling. Platelet aggregation induced by gAd (20 µg/ml) was reduced 
from 60±5.1% to 28±3.8% in the presence of Ro 31-8220 (p<0.05) [Figure 
3.16A and B]. However, the addition of ADP (5 µM) partially restored 
aggregation to 42±3.6% (p<0.05). This event occurred through the P2Y12 
coupled Gi receptor, since it was maintained in the presence of A3P5P.  
GAd-induced aggregation was also partially reversed by the addition of 
adrenaline acting through Gz-coupled α2A adrenoceptor to 40±4.1% 
(p<0.05). It was possible that the synergism between adrenaline and gAd 
could lead to secretion of ADP, so these latter experiments were 
performed in the presence of apyrase [Figure 3.16A and B]. Since 
potentiation of aggregation still occurred in the presence of ADP 
antagonists the data indicated that the increased aggregation was due to a 
direct effect of adrenaline signalling and not an indirect effect of secreted 
ADP. Finally ADP was added in the presence of A3P5P and adrenaline to 
gAd stimulated platelets and under these conditions the aggregation 
response was fully reversed. These data indicate that Gi/Gz signalling may 
combine with gAd to stimulate aggregation independently of PKC. 
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Figure 3.16: Recovery of platelet aggregation and secretion under 
conditions of PKC inhibition by Gi-coupled agonists. Washed platelets 
(2.5x108 platelets/ml) were pre-incubated with Ro 31-8220 (10 µM) and 
then stimulated with gAd (20 µg/ml) alone or premixed with ADP (5 µM), 
A3P5P (300 µM), adrenaline (10 µM) and apyrase (2 U/ml) and the 
aggregation response was monitored for 4 minutes under constant stirring. 
Stimulation of platelets with gAd in the absence of Ro 31-8220 was used as 
a control for these inhibitors. (A) Representative traces. (B) Collated data of 
three independent experiments expressed as mean ± SEM of aggregation, 
where * indicates p<0.05 compared with gAd in the presence and absence 
of Ro 31-8220 and # indicates p<0.05 compared with gAd/Ro 31-8220 in 
the presence and absence of ADP or adrenaline. 
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3.3.3 The role of dense-granule secretion in aggregation induced by 
globular adiponectin 
While previous experiments indicate synergy between the primary 
pathways stimulated gAd and those by Gi/Gz, it was still unclear whether 
this required secretion. Using lumi-aggregation we found that gAd induced 
dense-granule secretion as exemplified by the release of 0.14±0.01 nM 
ATP, which was taken as 100% ATP secretion was ablated by Ro 31-8220 
(p<0.05) [Figure 3.17], therefore demonstrating a key role for PKC in this 
process. To examine if ADP and adrenaline, which reversed the inhibitory 
effect on aggregation, restored secretion we added these agents to gAd 
stimulated platelets in the presence of Ro 31-8220. The addition of ADP (5 
µM) under conditions of PKC inhibition led to a partially restoration in ATP 
secretion to 44.7±6.7% of the control value (p<0.05). This was not 
influenced by the presence of the P2Y1 antagonist A3P5P [Figure 3.17], but 
was abolished by the P2Y12 inhibitor MRS2395.  
The secretion response was also partially restored by the addition of 
adrenaline to 72.9±3.3% (p<0.05) and fully restored by the combined 
addition of ADP and adrenaline (p<0.05). Importantly, this concentration of 
ADP (5 µM), in the presence of P2Y1 receptor antagonist, and adrenaline 
(10 µM) failed to stimulate ATP secretion when tested independently of 
gAd [Figure 3.17]. Furthermore, the addition of wortmannin, a pan PI3K 
inhibitor was able to block gAd-stimulated secretion under PKC blockade 
and the addition of ADP and adrenaline (p<0.05) [Figure 3.17]. Taken 
together, these data suggest that compensatory pathways may stimulate 
granule secretion independent of PKC. The mechanism responsible for 
these effects is unclear, but may involve PI3K. 
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Figure 3.17: Restoration of dense-granule secretion by globular 
adiponectin by Gi-coupled agonists in platelets treated with PKC inhibitor. 
Washed platelets (3x108 platelets/ml) were pre-incubated with Ro 31-8220 
(10 µM) and then stimulated with gAd (20 µg/ml) alone or in combination 
with ADP (5 µM), or adrenaline (10 µM). In some cases platelets were pre-
treated with A3P5P (300 µM), apyrase (2 U/ml) or wortmannin (100 nM).  
The luminescence response was monitored for 4 minutes under constant 
stirring. Results were expressed as %ATP secretion ± SEM of three 
experiments, where * indicates p<0.05 compared with gAd stimulation in 
the presence of Ro 31-8220, # indicates p<0.05 for gAd/Ro 31-8220 
compared to gAd/Ro 31-8220 in the presence of ADP or adrenaline, and § 
indicates p<0.05 for the presence and absence of wortmannin.   
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3.4 Discussion 
Adiponectin is a major adipokine produced by adipose tissue involved in 
lipid and carbohydrate metabolism, although anti-diabetic and anti-
inflammatory properties have been described (Okamoto et al., 2002, Ouchi 
and Walsh, 2007, Zhu et al., 2008). In addition to these, adiponectin has 
important vascular properties that can indirectly influence platelet function 
such as increasing the bioavailability of NO which is a potent platelet 
inhibitor (Naseem, 2005). However, the direct effect of adiponectin on 
platelet function is not very well understood. In this chapter the aim was to 
understand the role of both gAd and fAd on platelet aggregation and 
explore the mechanisms underpinning any functional effects observed.  
Physiological significant concentrations of recombinant fAd did not 
stimulate platelet aggregation. In contrast, recombinant gAd was able to 
stimulate full irreversible platelet aggregation which was accompanied 
with platelet dense-granule secretion. Since recombinant forms of 
adiponectin expressed from E.Coli were used in these experiments, it was 
important to eliminate the possibility that potential endotoxin 
contamination could stimulate platelet aggregation. Riba et al., (2008) 
showed that similar levels of endotoxin found in the recombinant 
adiponectin (2 ng) do not induce platelet aggregation (Riba et al., 2008). It 
was also important to consider that post-translation modifications differ 
from bacterial to eukaryote systems which can influence its biological 
activity (Wang et al., 2008). The same work by Riba et al., (2008) showed 
that fAd expressed from HEK cells do not stimulate aggregation and 
importantly, gAd stimulated similar levels of platelet aggregation to that of 
the recombinant form of the protein. Taken together, this data suggests 
that only the globular form of adiponectin is able to stimulate platelet 
aggregation. This is surprising since fAd contains the GPVI-specific GPO 
motifs within the collagen-like domain. It could be possible that the 
platelet collagen receptors cannot access the collagen-like domain of the 
fAd monomer due to steric hindrance. In addition to this, fAd also contains 
the globular domain but was unable to stimulate aggregation.  
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Having identified that only globular form of adiponectin can induce 
aggregation, it was important to understand the signalling pathways 
involved. The same study by Riba et al., (2008) suggested that gAd 
activated platelet through a tyrosine kinase-linked mechanism that was 
linked to GPVI. However, the role of other platelet activators and signalling 
enzyme was not studied and required clarification.  
GAd was found to stimulate integrin αIIbβ3 dependent aggregation through 
pathways dependent and independent of PKC activation. It is now widely 
recognised that PKC isoforms are involved in the release of platelet derived 
secondary mediators such as ADP and TxA2 (Harper and Poole, 2010). 
Taking this information in conjunction with previous data indicating that 
gAd-mediated aggregation was tyrosine kinase-dependent, experiments 
were designed to create a more detailed model for aggregation induced by 
gAd.  
Consistent with the study by Riba et al., (2008) using an inhibitor of Src 
family kinases showed that platelet aggregation was tyrosine kinase-
dependent and gAd induced the phosphorylation of numerous proteins. 
Some of these have been identified as Syk, PLCγ2 and LAT (Riba et al., 
2008). Since these data suggest a collagen type mechanism, this was used 
as a model with which to understand gAd-stimulated aggregation. 
Collagen-induced aggregation proceeds via two phases. The first phase is 
the activation of the platelets via a tyrosine kinase dependent mechanism 
which enables integrin αIIbβ3 dependent aggregation by inside-out 
signalling (Calvete, 1995, Shattil, 1999). The second phase involves the 
release of platelet-derived soluble mediators such as ADP and TxA2 through 
pathways linked to PKC activation. In the first instance the effect of 
platelet-derived soluble mediators on gAd-stimulated tyrosine 
phosphorylation was examined. Under non-aggregatory conditions, the 
tyrosine phosphorylation of platelet proteins in whole cell lysates were not 
affected by either inhibition of endogenous ADP and TxA2 signalling or the 
addition of exogenous ADP or U46619. This is consistent with a mechanism 
whereby gAd induces direct receptor mediated tyrosine phosphorylation. 
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In contrast, maximal aggregation induced by higher concentrations of gAd 
showed a critical requirement for the co-secretion of both ADP and TxA2. 
Interestingly, the loss of ADP signalling was found to be less important than 
the loss of TxA2. Aggregation was reduced modestly by the antagonism of 
ADP receptors, but was reduced by approximately 50% due to the loss of 
TxA2 signalling. Interestingly, the combination of the inhibitors caused a 
further reduction in aggregation suggesting that both secondary agonists 
played a role in inducing maximal aggregation. In contrast, at lower 
concentrations the adipokine had an absolute requirement for secondary 
signalling. This led to the possibility that secondary mediators can 
potentiate gAd-stimulated aggregation, particularly at lower 
concentrations. Critically, ADP was able to synergise with threshold 
concentrations of gAd to potentiate aggregation. This may have 
pathophysiological implications since it would suggest that low levels of 
this plasma protein may be able to enhance the effects of physiological 
activators of platelets. 
The presence of A3P5P, a P2Y1 ADP receptor antagonist, had no effect on 
the ability of ADP to enhance gAd-mediated platelet aggregation. 
Conversely, MRS2395, a selective antagonist of the P2Y12 ADP receptor 
coupled to Gi abolished the ability of ADP to influence aggregation 
suggesting strongly that Gi played a critical role in the potentiation of 
aggregation. Furthermore, stimulation of the α2A-adrenoceptor coupled to 
Gz, could overcome the inhibitory effects of
 ADP receptor antagonists. In 
contrast, thromboxane TPα/β receptor coupled to Gq exhibited weak 
synergy with gAd, despite indomethacin exerting a strong inhibitory effect 
on aggregation. These observations indicate that a Gi/Gz-dependent
 
pathway initiated by either ADP or adrenaline participates in gAd-
stimulated platelet aggregation.  However, it was difficult to reconcile why 
indomethacin could block aggregation but U46619 did not potentiate 
submaximal aggregation induced by gAd. One possibility was that TxA2 
signalling was restored by ADP secretion and that the two worked 
concurrently rather than simultaneously. This view was supported by 
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evidence from (Li et al., 2003) who demonstrated that TxA2 may induce 
secretion of ADP in two waves. When dense-granule secretion was 
examined it was found that gAd-induced dense-granule secretion was 
abolished by indomethacin, but remained unaffected by blocking the ADP 
receptors. Critically, the ablation of dense-granule secretion by 
indomethacin is partially reversed by the TxA2 analogue U46619. These 
data suggest that gAd stimulated secretion of ADP was driven at least in 
part by TxA2, which when released was able to synergize with primary 
signalling from gAd.  
Early aggregation experiments determined that secretion of platelet 
granules was required for maximal aggregation. Since PKC isoforms play a 
major role in platelet granule secretion, we examined the role of PKC in 
this process (Gerrard et al., 1989, Murugappan et al., 2004, Harper and 
Poole, 2007). GAd stimulated the phosphorylation of PKC substrates 
suggest that the kinase was activated downstream of the adipokine. The 
use of the cell-permeable inhibitor of PKC, Ro 31-8220, provided an insight 
into the pathways used by gAd to stimulate aggregation. Under conditions 
that block the activity of PKC, we found that platelet aggregation in 
response to gAd was reduced but not abolished, indicating that 
aggregation could proceed through PKC-dependent and independent 
pathways. Indeed that loss of PKC produced an aggregation response 
similar to that found in the absence of ADP or TxA2. GAd-mediated and 
U46619 mediated dense-granule secretion were ablated by PKC inhibitors. 
Taken together this suggested a model whereby gAd may stimulate PKC 
mediated generation of TxA2, which in turn drove dense-granule secretion 
and maximal platelet aggregation.   
Interestingly, diminished platelet aggregation associated with PKC 
inhibition could be overcome by the addition of ADP or adrenaline. Here 
we found that ADP signalling required P2Y12 but not P2Y1, while adrenaline 
could potentiate aggregation directly without the need of ADP. Thus Gi/Gz 
signalling can potentiate platelet aggregation independently of PKC. This 
data suggest that these compensatory pathways may occur through their 
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ability to stimulate secretion independently of PKC. The mechanism 
responsible for these effects is unclear, but may involve either reduced 
activity of PI3K or adenylyl cyclase, since Gi is coupled to both adenylyl 
cyclase and a downstream activation of PI3K (Murugappa and Kunapuli, 
2006). To date Gi has a very limited ability to reduce basal cAMP levels 
(Yang et al., 2002), and is most effective in the presence of agents that 
stimulate the activity of adenylyl cyclase. Thus, it is unlikely that the gAd-
mediated synergism with Gi-coupled receptors occur at the level of 
adenylyl cyclase. We therefore examined how secondary signalling induced 
by gAd influenced PI3K. Platelet dense-granule secretion induced by the 
addition of exogenous ADP, in the absence of PKC activity, was blocked by 
the pan PI3K inhibitor wortmannin. However, it was unclear which isoform 
is responsible since both PI3Kβ and PI3K  are activated downstream of 
ADP Gi-coupled P2Y12 receptor and contribute to integrin αIIbβ3 activation 
and platelet aggregation (Hirsch et al., 2001, Jackson et al., 2005, Lian et 
al., 2005). While more recently, Kim and colleagues (Kim et al., 2009) have 
demonstrated that GPVI mediated secretion, at least in part, requires Gi-
stimulated of PI3Kβ. Thus it is possible that Gi/Gz signalling is required for 
pathways that drive platelet secretion independently of PKC. Taken 
together, these data indicate that gAd-stimulated secondary signalling can 
potentiate platelet activation via the up-regulation of TxA2 formation which 
can further drive ADP release from platelet dense-granules and in 
combination with more established agents can contribute to platelet 
aggregation at sites of vascular injury [Figure 3.18]. 
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Figure 3.18: The proposed role of secondary mediators in globular 
adiponectin-stimulated aggregation. Platelets are stimulated with gAd 
through a tyrosine kinase-dependent mechanism (Step 1) leading to 
increased calcium mobilisation and activation of integrin αIIbβ3 by inside-
out signalling (Step 2). TxA2 formation is up-regulated by PLA2 activation 
(Step 3), which drives ADP release from platelet dense-granules (Step 4) 
and further potentiating platelet aggregation by outside-in signalling (Step 
5). However, signals from Gi/Gz activation (Step 6) can further potentiate 
platelet aggregation (Step 7) through the release of platelet dense-
granules via PKC independent pathways that may include PI3K. 
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Chapter 4: The role of PI3K in globular adiponectin-stimulated 
aggregation 
4.1 Introduction 
In chapter 3 it was established that only the globular form of adiponectin 
stimulates platelet aggregation in a tyrosine kinase-dependent mechanism. 
Furthermore, the release of platelet derived mediators such as ADP and 
TxA2 was required to achieve maximal aggregation. In addition to this we 
found gAd can synergise with Gi/Gz mediated signalling to induce 
aggregation and secretion independent of PKC signalling. The addition of 
the PI3K inhibitor, wortmannin seemed to abolish the ability of gAd to 
induce PKC-independent secretion. These data strongly suggest a 
prominent role for PI3K in this process. In the present chapter the aim was 
to further understand the role of PI3K in gAd-stimulated aggregation and 
secretion.  
The phosphorylation of the D3-hydroxy-group of the inositol ring of 
phosphoinositides was first described in 1988 (Whitman et al., 1988). The 
exploration of these new phosphoinositides products have led to the 
discovery of a new group of enzymes called PI3K (Carpenter et al., 1990, 
Cantley, 2002).  Studies have shown that PI3K plays an important role in 
many different cell types in regulating their function. These include 
haemopoietic cells such as neutrophils, monocytes and B- and T-cells 
(Koyasu, 2003). Three classes of PI3K have been described, which are 
grouped according to their structure and preference of substrate (Fruman 
et al., 1998, Vanhaesebroeck and Waterfield, 1999). Platelets are found to 
express two classes of PI3K including class I, which is further divided to 
class IA (PI3Kα, PI3Kβ and PI3Kδ) and class IB (PI3Kγ), and class II (PI3KC2α) 
(Vanhaesebroeck and Waterfield, 1999). Class IA PI3K isoforms consist of 
p110 catalytic subunit and is associated with p85/p55 regulatory subunit 
that contains SH2 domains (Fruman et al., 1998). These SH2 domains allow 
the binding of tyrosine phosphorylated proteins that can help to activate 
the enzyme (Bibbins et al., 1993). The p85/p55 regulatory subunits also 
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contain a proline rich region that allows the binding of SH3 containing 
proteins such as Fyn and Lyn which can increase PI3K activation by 5 to 7 
fold (Pasquet et al., 1999). Class IB PI3K isoform is also composed of the 
p110 catalytic subunit, but it is associated with a p101 regulatory subunit 
(Fruman et al., 1998). The class IB p110 catalytic subunit can be 
distinguished from class IA by its ability to bind to βγ subunits of 
heterotrimeric G-proteins. Furthermore, class IB PI3K isoform is not 
activated by tyrosine phosphorylated proteins but by βγ subunits in G-
protein coupled receptor signalling (Stephens et al., 1997).  
The activation of PI3K isoforms have been implicated in many platelet 
responses that include platelet shape change and aggregation 
(Rittenhouse, 1996, Pasquet et al., 1999). The type of PI3K isoform 
activated is dependent on the type of receptor activated, indicating that 
different isoforms are linked to distinct receptor mediated pathways. 
Platelet adhesion to exposed sub-endothelial proteins such as vWF is a 
critical step in the formation of a haemostatic plug. The activation of PI3Kα 
and PI3Kβ isoforms downstream of GPIb-V-IX receptor complex activation 
has been reported to play an important role in this process. The inhibition 
of these PI3K isoforms by pharmacological inhibitors can inhibit vWF 
induced integrin αIIbβ3 activation (Yap et al., 2002). Platelet activation by 
soluble platelet agonists such as ADP and thrombin which signal through G-
protein coupled receptors are often coupled to class I PI3K isoforms 
(Jackson et al., 2005, Kim et al., 2009, Kim and Kunapuli, 2011). These PI3K 
isoforms are involved in signalling pathways that enable the activation of 
the integrin αIIbβ3 by inside-out signalling. The activation of Gi-coupled ADP 
P2Y12 receptor is of particular importance since it can potentiate platelet 
aggregation through pathways linked to PI3Kβ and PI3Kγ activation 
(Jackson et al., 2005, Kim et al., 2009, Garcia et al., 2010, Kim and Kunapuli, 
2011). There is compelling evidence that PI3K is involved in outside-in 
signalling downstream of integrin αIIbβ3 activation (Zhang et al., 1998). 
Platelet adhesion to fibrinogen has provided direct evidence of the 
importance of PI3K isoforms in this process. The accumulation of 
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phosphatidylinositol 4,5-bisphosphate (PIP2) downstream of integrin αIIbβ3 
activation via adhesion to fibrinogen is a critical event in Ca2+ mobilisation 
and lamellipodia formation (Gironcel et al., 1996). The PI3K isoforms 
involved in integrin αIIbβ3 activation is less clear but studies have shown 
that the class II PI3KC2α isoform is involved (Banfić et al., 1998, Zhang et 
al., 1998).   
Therefore, the present study set out to define more precisely the role of 
PI3K in gAd-mediated platelet activation and which isoforms were 
responsible. 
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4.2 The role of PI3K in globular adiponectin-stimulated aggregation 
We have established that gAd is a novel platelet agonist and shown that 
aggregation proceeds through pathways that require activation of PKC and 
PI3K [Figure 3.2]. The role of PI3K was further elaborated in gAd-stimulated 
aggregation using a pan PI3K inhibitor, wortmannin. This inhibitor can 
compete with ATP for binding to the PI3K catalytic domain and blocks the 
catalytic site via a covalent interaction with a critical lysine 802 residue and 
therefore inhibiting the kinase (Wymann et al., 1996).  
Aggregation induced by gAd (20 µg/ml) was almost completely abolished 
by treating the platelets with wortmannin (100 nM). Under these 
conditions aggregation was reduced from 61±7.6% to 5±2.8% (p<0.05) 
[Figure 4.1A]. This inhibition of aggregation was accompanied by the 
complete loss of ATP secretion (p<0.05) [Figure 4.2]. To understand the 
contribution of different PI3K isoforms in platelet aggregation in response 
to different platelet agonists, these experiments were repeated with 
collagen, CRP-XL and thrombin. Platelet aggregation and secretion induced 
by collagen (10 µg/ml) was found to be completely abolished in the 
presence of wortmannin (p<0.05) [Figure 4.1C and 4.2]. Similarly, we found 
aggregation induced by CRP-XL (10 µg/ml) in the presence of wortmannin 
was almost completely abolished and this was associated with complete 
inhibition of secretion [Figure 4.1B and 4.2]. In contrast, stimulation of 
platelets with a non-GPVI agonist, thrombin (0.1 U/ml) in the presence of 
wortmannin only had a modest effect on aggregation, reducing it from 
66±7.2% to 43±7.3%, however, we found secretion to be completely 
abolished under these conditions (p<0.05) [Figure 4.1D and 4.2]. 
Interestingly, increasing thrombin concentration to 0.5 U/ml in the 
presence of wortmannin failed to ablate aggregation (86±3.6% to 78±4.3%) 
and only had a modest effect on thrombin-stimulated ATP secretion 
(1.46±0.1 nM to 1.14±0.1 nM) [Figure 4.1E and 4.2], consistent with PI3K 
dependent and independent mechanism of thrombin-induced aggregation 
(Holinstat et al., 2009).  Taken together, these data suggest that PI3K plays 
a critical role in both platelet aggregation and secretion, particularly in 
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response to agonist that stimulates activation through a tyrosine kinase-
dependent mechanism. 
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Figure 4.1: The effect of PI3K inhibition on globular adiponectin-
stimulated aggregation. Washed platelets (3x108 platelets/ml) were 
stimulated with  (A) gAd (20 µg/ml) (B) CRP-XL (5 µg/ml) (C) collagen (10 
µg/ml) (D) thrombin (0.1 U/ml) (E) thrombin (0.5 U/ml) in the absence and 
presence of wortmannin (100 nM) and the aggregation response was 
monitored for 4 minutes under constant stirring. All representative 
aggregation traces are taken from four independent experiments 
performed with distinct blood donors. 
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Figure 4.2: The effect of PI3K inhibition on globular adiponectin-
stimulated secretion. Washed platelets (3x108 platelets/ml) were 
stimulated with gAd (20 µg/ml), CRP-XL (5 µg/ml), collagen (10 µg/ml) and 
thrombin (0.1-0.5 U/ml) in the absence and presence of wortmannin (100 
nM) and the luminescence response was monitored for 4 minutes under 
constant stirring and results were expressed as ATP nM secretion ± SEM of 
four independent experiments, where * indicates p<0.05 compared with 
the agonist alone to wortmannin. 
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4.2.1 Identification of PI3K isoforms in globular adiponectin-stimulated 
aggregation and secretion 
It is established that multiple isoforms of PI3K are expressed in platelets 
and we wished to examine the role of the individual isoforms in platelet 
activation induced by gAd (Vanhaesebroeck and Waterfield, 1999). This 
was achieved by using selective PI3K isoform inhibitors including PI3Kβ 
inhibitor TGX-221, PI3Kα inhibitor PIK75 and PI3Kγ inhibitor AS242525 
(Sadhu et al., 2003, Knight et al., 2006, Kim et al., 2007, Gilio et al., 2009, 
Kim et al., 2009). Here, these same inhibitors were used to identify the 
PI3K isoform activated in response to gAd.  
Treatment of gAd-stimulated (20 µg/ml) platelets with TGX-221 (500 nM) 
(Kim et al., 2009) caused a significant inhibition of aggregation, where 
aggregation was reduced from 65±6.2% to 10±0.7% (p<0.05) [Figure 4.3A]. 
Similarly, the PIK75 (100 nM) (Kim et al., 2009) partially inhibited 
aggregation to 19±5.5% (p<0.05) [Figure 4.3A]. In contrast, platelets 
treated with AS242525 (100 nM) (Kim et al., 2009) showed minor effect on 
gAd-stimulated aggregation that was not significant [Figure 4.3A]. These 
data suggest that the PI3Kα and PI3Kβ isoforms play a significant role in 
gAd-stimulated aggregation.  
To determine if these PI3K isoforms contribute to gAd-stimulated 
secretion, ATP secretion was measured by lumi-aggregation in the 
presence of these selective PI3K isoform inhibitors. Consistent with the 
aggregation data [Figure 4.3A], TGX-221 (500 nM) and PIK75 (100 nM) 
abolished gAd-stimulated dense-granule secretion [Figure 4.3B]. The PI3Kγ 
inhibitor had a minor and non-significant effect on gAd-stimulated 
secretion. Here ATP release was reduced from 0.32±0.1 nM to 0.22±0.1 nM 
[Figure 4.3B]. These data suggest a mechanism whereby PI3K isoforms α 
and β are activated downstream of gAd activation which contribute to 
platelet aggregation and secretion.        
  
 141 
 
 
Figure 4.3: The role of PI3K isoforms on globular adiponectin-stimulated 
aggregation and secretion. (A) Washed platelets (3x108 platelets/ml) were 
stimulated with gAd (20 µg/ml) in the absence and presence of 
wortmannin (100 nM), PIK75 (100 nM), TGX-221 (500 nM), AS242525 (100 
nM) and the aggregation response was monitored for 4 minutes under 
constant stirring and results were expressed as %Aggregation ± SEM of 
three independent experiments. (B) As in (A) but the luminescence 
response was monitored for 4 minutes under constant stirring and results 
were expressed as ATP nM secretion ± SEM of three independent 
experiments, where * indicates p<0.05 compared with gAd alone to the 
inhibitors.
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To determine if these same PI3K isoforms are involved in other agonist 
induced platelet aggregation, which signal via a tyrosine kinase mechanism, 
the previous experiment were repeated with a GPVI selective agonist, CRP-
XL and collagen. Here we found that TGX-221 exerted a strong inhibitory 
response on CRP-XL (10 µg/ml)-stimulated platelets, reducing aggregation 
from 76±3.1% to 13±3.7% (p<0.05) [Figure 4.4A]. In contrast, PIK75 exerted 
a modest effect in comparison, reducing aggregation to 53±5.4% (p<0.05) 
[Figure 4.4A]. This was accompanied with the complete loss of ATP 
secretion with TGX-221 stimulation (p<0.05). Similarly, PIK75 significantly 
reduced ATP secretion from 1.05±0.1 nM to 0.35±0.2 nM (p<0.05) [Figure 
4.4B]. The PI3Kγ isoform inhibitor had only a minor effect on CRP-XL-
stimulated aggregation or secretion [Figure 4.4B]. A similar dependency of 
PI3Kβ and α was observed in collagen-stimulated (10 µg/ml) platelets. Here 
aggregation was reduced from 63±6.1% to 23±9.6% by PIK75 (p<0.05) and 
almost completely abolished with TGX-221 (p<0.05) [Figure 4.5A]. Once 
again inhibition of PI3Kγ only had a minor effect on aggregation and 
secretion [Figure 4.5]. In contrast, inhibition of PI3Kβ and α completely 
abolished collagen-stimulated secretion at 10 µg/ml [Figure 4.5B]. Taken 
together, these data highlight the important roles of PI3K isoforms α and β 
in GPVI-stimulated aggregation and secretion.  
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Figure 4.4: The role of PI3K isoforms in CRP-XL-stimulated aggregation 
and secretion. (A) Washed platelets (3x108 platelets/ml) were stimulated 
with CRP-XL (10 µg/ml) in the absence and presence of wortmannin (100 
nM), PIK75 (100 nM), TGX-221 (500 nM), AS242525 (100 nM) and the 
aggregation response was monitored for 4 minutes under constant stirring 
and results were expressed as %Aggregation ± SEM of three independent 
experiments. (B) As in (A) but the luminescence response was monitored 
for 4 minutes under constant stirring and results were expressed as ATP 
nM secretion ± SEM of three independent experiments, where * indicates 
p<0.05 compared with CRP-XL alone to the inhibitors. 
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Figure 4.5: The role of PI3K isoforms in collagen-stimulated aggregation 
and secretion. (A) Washed platelets (3x108 platelets/ml) were stimulated 
with collagen (10 µg/ml) in the absence and presence of wortmannin (100 
nM), PIK75 (100 nM), TGX-221 (500 nM), AS242525 (100 nM) and the 
aggregation response was monitored for 4 minutes under constant stirring 
and results were expressed as %Aggregation ± SEM of three independent 
experiments. (B) As in (A) but the luminescence response was monitored 
for 4 minutes under constant stirring and results were expressed as ATP 
nM secretion ± SEM of three independent experiments, where * indicates 
p<0.05 compared with collagen alone to the inhibitors. 
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4.3 The effect of PI3K inhibition on globular adiponectin-stimulated 
tyrosine phosphorylation 
Since our previous data suggests that gAd stimulates platelets through a 
tyrosine kinase-dependent manner, we examined the role of PI3K on 
tyrosine phosphorylation. Consistent with our previous data [Figure 3.3], 
gAd (20 µg/ml) induced a robust increase in tyrosine phosphorylation of a 
number of proteins with prominent bands at 45, 50, 70, 125 and 145 kDa 
[Figure 4.6]. The presence of the PI3K inhibitor, wortmannin had no effect 
on tyrosine phosphorylation levels [Figure 4.6], suggesting that PI3K plays a 
critical role in both platelet aggregation and secretion through pathways 
independent of tyrosine phosphorylation. 
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Figure 4.6: The effect of PI3K inhibition on globular adiponectin-
stimulated tyrosine phosphorylation. (A) Washed platelets (5x108 
platelets/ml) were incubated with apyrase (2 U/ml), indomethacin (10 µM) 
and EGTA (1 mM) for 20 minutes and then stimulated with gAd (20 µg/ml) 
in the presence and absence of wortmannin (100 nM) for 90 seconds. 
Proteins were resolved on 10-18% gradient polyacylamide gel SDS-PAGE 
and immunoblotted using anti-phosphotyrosine antibody. (B) 
Densitometric measurement of phosphotyrosine at band labelled “x” , 
expressed as phosphotyrosine/total ± SEM of three independent 
experiments. 
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4.4 The role of PI3K and Akt signalling pathway in globular adiponectin-
stimulated platelets 
4.4.1 Optimisation of Akt phosphorylation antibody 
To understand the signalling events underlying PI3K activation in gAd-
stimulated aggregation and secretion, Akt a downstream marker of PI3K 
activity was chosen. Akt is a 60 kDa serine–threonine kinase that is 
phosphorylated at two different residues, threonine308 and serine473 by 
phosphoinositide-dependent kinase (PDK) 1 and PDK2 respectively, and 
contributes to platelet activation (Wick et al., 2000, Cantley, 2002, Hresko 
and Mueckler, 2005). However, Akt phosphorylation also depends upon 
the upstream activation of PI3K and the synthesis of phosphatidylinositol, 
therefore the changes in Akt phosphorylation can be used to investigate 
PI3K mediated signalling.  
An anti-Akt serine473 antibody was used to investigate the role of Akt in 
gAd-stimulated platelet activation. In the first instance, the optimum 
conditions for the antibody were determined. Washed platelets were 
stimulated with collagen (80 µg/ml) and an equal volume of 2xLaemelli 
buffer was added. The proteins were resolved on a 10% resolving gel, 
transferred to a PVDF membrane, blocked with 10% BSA and subjected to 
immunoblotting. As shown in figure 4.7A, the anti-Akt serine473 antibody 
bound to several proteins at 50, 80 kDa, including Akt at 60 kDa. To reduce 
the non-specific binding to these proteins, the blocking conditions were 
varied. The reduction of blocking buffer from 10% BSA to 5% BSA increased 
some of the non-specific binding at 70, 100 and 140 kDa [Figure 4.7C]. To 
further optimise the blocking conditions of the antibody, the membrane 
was blocked with milk protein. Interestingly, blocking with 10% milk 
protein reduced most of the non-specific binding compared to BSA, 
however, a small band was observed at 50 kDa [Figure 4.7B]. Further 
reduction of milk protein to 5% completely abolished all non-specific 
binding and a prominent Akt serine473 phosphorylation band was observed 
at 60 kDa [Figure 4.7D].      
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Figure 4.7: Optimisation of Akt serine473 phosphorylation antibody 
conditions. Washed platelets (5x108 platelets/ml) were stimulated with 
collagen (80 µg/ml) and proteins were lysed and resolved on 10% 
polyacrylamide gel SDS-PAGE and blotted using phosphoAkt-serine473 
antibody. Blocking conditions were varied to optimise antibody conditions 
(A) 10% BSA (B) 10% milk protein (C) 5% BSA (D) 5% milk protein. 
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4.4.2 Globular adiponectin stimulates Akt phosphorylation in a time and 
dose-dependent manner  
It has been demonstrated by several groups that Akt undergoes 
phosphorylation in response to platelet activation (Kim et al., 2004, Gilio et 
al., 2009, Kim et al., 2009); therefore the ability of gAd to induce Akt 
phosphorylation was investigated. Under non-aggregatory conditions, gAd 
induced Akt serine473 phosphorylation in a time and concentration-
dependent manner [Figure 4.8]. Phosphorylation of Akt was observed with 
a concentration of 20 µg/ml, but was maximal at 100 µg/ml. The 
phosphorylation response was rapid with changes detected within 60 
seconds of gAd (100 µg/ml) stimulation. Maximal Akt phosphorylation 
levels were observed at 90 seconds stimulation before declining back 
towards basal levels after 300 seconds which was the longest time tested 
[Figure 4.8].  
We next looked at the phosphorylation kinetics involved in CRP-XL and 
collagen-stimulated Akt phosphorylation. Both CRP-XL and collagen 
induced Akt serine473 phosphorylation in a time and concentration-
dependent manner. Akt phosphorylation induced by collagen was detected 
with a concentration of 20 µg/ml and maximal phosphorylation was 
observed with 100 µg/ml stimulation [Figure 4.9]. The increase in Akt 
phosphorylation was rapid and detected within 60 seconds of collagen (100 
µg/ml) stimulation and maximal phosphorylation levels were observed at 
90 seconds [Figure 4.9]. In contrast, Akt serine473 phosphorylation induced 
by CRP-XL was observed at a concentration of 5 µg/ml and maximal 
phosphorylation was achieved with 10 µg/ml stimulation [Figure 4.10]. Akt 
phosphorylation in response to CRP-XL was similar to collagen and gAd 
with optimum phosphorylation observed at 90 seconds with CRP-XL (10 
µg/ml) stimulation [Figure 4.10]. Similar to that of gAd and collagen 
stimulated Akt phosphorylation, a rapid decrease in Akt phosphorylation at 
300 seconds time point was observed which suggests that Akt serine473 
phosphorylation is not sustained in activated platelets in response to these 
agonists [Figure 4.10]. Together, these data show that gAd displays similar 
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kinetics in Akt serine473 phosphorylation with other agonists that activate 
platelets via a tyrosine kinase mechanism.  
To further understand the differences between tyrosine kinase and non-
tyrosine kinase activation of Akt, we examined Akt phosphorylation 
induced by thrombin. Thrombin is a potent platelet activator which signals 
via G-protein coupled receptors, PAR1 and PAR4. Thrombin increased Akt 
phosphorylation in a concentration-dependent manner, with maximal Akt 
phosphorylation induced by 1 U/ml thrombin stimulation [Figure 4.11]. 
Furthermore, we found increase in maximal Akt phosphorylation by 
thrombin (1 U/ml) stimulation to be rapid and was detected at 60 second 
time point. However, a sustained Akt phosphorylation was observed 
between 90 to 300 seconds in thrombin-stimulated platelets [Figure 4.11]. 
This data suggests that Akt phosphorylation kinetics vary between tyrosine 
kinase and non-tyrosine kinase activation of Akt. 
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Figure 4.8: Globular adiponectin induces Akt phosphorylation in time and 
concentration-dependent manner. (A) Washed platelets (5x108 
platelets/ml) were stimulated with gAd in a time and concentration-
dependent manner. Platelet proteins were separated by SDS-PAGE and 
blotted for phosphoAkt-serine473, followed by re-probing for β-tubulin. (B) 
and (C) Densitometric measurement of phosphoAkt-serine473 and 
expressed as Akt phosphorylation/Total ± SEM of three independent 
experiments.   
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Figure 4.9: Collagen induces Akt phosphorylation in time and 
concentration-dependent manner. (A) Washed platelets (5x108 
platelets/ml) were stimulated with collagen in a time and concentration-
dependent manner. Platelet proteins were separated by SDS-PAGE and 
blotted for phosphoAkt-serine473, followed by re-probing for β-tubulin. (B) 
and (C) Densitometric measurement of phosphoAkt-serine473 and 
expressed as Akt phosphorylation/Total ± SEM of three independent 
experiments.   
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Figure 4.10: CRP-XL induces Akt phosphorylation in time and 
concentration-dependent manner. (A) Washed platelets (5x108 
platelets/ml) were stimulated with CRP-XL in a time and concentration-
dependent manner. Platelet proteins were separated by SDS-PAGE and 
blotted for phosphoAkt-serine473, followed by re-probing for β-tubulin. (B) 
and (C) Densitometric measurement of phosphoAkt-serine473 and 
expressed as Akt phosphorylation/Total ± SEM of three independent 
experiments.   
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Figure 4.11: Thrombin induces Akt phosphorylation in time and 
concentration-dependent manner. (A) Washed platelets (5x108 
platelets/ml) were stimulated with thrombin in a time and concentration-
dependent manner. Platelet proteins were separated by SDS-PAGE and 
blotted for phosphoAkt-serine473, followed by re-probing for β-tubulin. (B) 
and (C) Densitometric measurement of phosphoAkt-serine473 and 
expressed as Akt phosphorylation/Total ± SEM of three independent 
experiments.   
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4.4.3 Characterisation of globular adiponectin-induced Akt 
phosphorylation  
Having established that gAd induced the phosphorylation of Akt, we used 
pharmacological inhibitors to determine the downstream pathways 
involved in this event. It was important to establish if Akt serine473 
phosphorylation is dependent on upstream activation of PI3K in gAd-
stimulated platelets. This was achieved by stimulating platelets with gAd in 
the presence of the pan PI3K inhibitor, wortmannin. In these conditions we 
found that the addition of wortmannin completely inhibited gAd-induced 
Akt serine473 phosphorylation (p<0.05) [Figure 4.12]. This data confirms 
that the activation of Akt is dependent on the upstream activation of PI3K 
in gAd-stimulated platelets. Furthermore, the treatment of platelets with 
wortmannin also inhibited collagen and CRP-XL induced Akt serine473 
phosphorylation and therefore confirming that PI3K is upstream of Akt in 
GPVI-stimulated platelets [Figure 4.13 and 4.14].  
The mobilisation of intracellular Ca2+ from the platelet DTS is an important 
event in the activation of the platelet. We therefore sought to examine the 
role of intracellular calcium on Akt serine473 phosphorylation in gAd-
stimulated platelets. Platelets treated with the cell permeable high affinity 
calcium chelator, BAPTA-AM completely abolished Akt serine473 
phosphorylation [Figure 4.12]. The chelation of intracellular calcium in 
collagen or CRP-XL-stimulated platelets also completely abolished Akt 
serine473 phosphorylation [Figure 4.13 and 4.14]. Thus, phosphorylation of 
Akt under these experimental conditions requires mobilisation of 
intracellular calcium. 
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Figure 4.12: Characterisation of Akt phosphorylation in globular 
adiponectin-stimulated platelets. (A) Washed platelets (5x108 
platelets/ml) were stimulated with gAd (40 µg/ml) in the presence and 
absence of wortmannin (100 nM) and BAPTA-AM (10 µM) for 90 seconds. 
Platelet proteins were separated by SDS-PAGE and blotted for phosphoAkt-
serine473, followed by re-probing for β-tubulin. (B) Densitometric 
measurement of phosphoAkt-serine473 and expressed as %Akt 
phosphorylation ± SEM of three independent experiments, where * 
indicates p<0.05 compared with gAd alone to the inhibitors. 
.   
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Figure 4.13: Characterisation of Akt phosphorylation in CRP-XL-stimulated 
platelets. (A) Washed platelets (5x108 platelets/ml) were stimulated with 
CRP-XL (10 µg/ml) in the presence and absence of wortmannin (100 nM) 
and BAPTA-AM (10 µM) for 90 seconds. Platelet proteins were separated 
by SDS-PAGE and blotted for phosphoAkt-serine473, followed by re-probing 
for β-tubulin. (B) Densitometric measurement of phosphoAkt-serine473 and 
expressed as %Akt phosphorylation ± SEM of three independent 
experiments, where * indicates p<0.05 compared with CRP-XL alone to the 
inhibitors. 
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Figure 4.14: Characterisation of Akt phosphorylation in collagen-
stimulated platelets. (A) Washed platelets (5x108 platelets/ml) were 
stimulated with collagen (40 µg/ml) in the presence and absence of 
wortmannin (100 nM) and BAPTA-AM (10 µM) for 90 seconds. Platelet 
proteins were separated by SDS-PAGE and blotted for phosphoAkt-
serine473, followed by re-probing for β-tubulin. (B) Densitometric 
measurement of phosphoAkt-serine473 and expressed as %Akt 
phosphorylation ± SEM of three independent experiments, where * 
indicates p<0.05 compared with collagen alone to the inhibitors. 
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In the previous chapter we established that gAd-stimulated platelet 
activation was Src-kinase dependent, therefore the role of these kinases 
were examined in Akt phosphorylation. Platelets were stimulated with gAd 
(40 µg/ml) in the presence or absence of the pan Src-kinase inhibitor, PP1 
and Akt serine473 phosphorylation levels were measured. The presence of 
PP1 (20 µM) abolished Akt serine473 phosphorylation in gAd-stimulated 
platelets, therefore highlighting a key role for these kinases in Akt 
activation [Figure 4.15]. Importantly, PP3 (20 µM), the inactive analogue 
did not affect Akt phosphorylation [Figure 4.15]. Consistent with previous 
reports (Kim et al., 2009), both CRP-XL and collagen induced Akt serine473 
phosphorylation were found to be Src-kinase dependent [Figure 4.16 and 
4.17]. These data are consistent with a mechanism whereby Akt activation 
in gAd-stimulated platelets is tyrosine kinase-dependent.   
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Figure 4.15: Akt serine473 phosphorylation is Src-kinase dependent. (A) 
Washed platelets (5x108 platelets/ml) were stimulated with gAd (40 µg/ml) 
in the presence and absence of PP1 (20 µM) and PP3 (20 µM) for 90 
seconds. Platelet proteins were separated by SDS-PAGE and blotted for 
phosphoAkt-serine473, followed by re-probing for β-tubulin. (B) 
Densitometric measurement of phosphoAkt-serine473 and expressed as 
%Akt phosphorylation ± SEM of three independent experiments, where * 
indicates p<0.05 compared with gAd alone to the inhibitors. 
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Figure 4.16: Akt serine473 phosphorylation is Src-kinase dependent. (A) 
Washed platelets (5x108 platelets/ml) were stimulated with CRP-XL (10 
µg/ml) in the presence and absence of PP1 (20 µM) and PP3 (20 µM) for 90 
seconds. Platelet proteins were separated by SDS-PAGE and blotted for 
phosphoAkt-serine473, followed by re-probing for β-tubulin. (B) 
Densitometric measurement of phosphoAkt-serine473 and expressed as 
%Akt phosphorylation ± SEM of three independent experiments, where * 
indicates p<0.05 compared with CRP-XL alone to the inhibitors. 
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Figure 4.17: Akt serine473 phosphorylation is Src-kinase dependent. (A) 
Washed platelets (5x108 platelets/ml) were stimulated with collagen (10 
µg/ml) in the presence and absence of PP1 (20 µM) and PP3 (20 µM) for 90 
seconds. Platelet proteins were separated by SDS-PAGE and blotted for 
phosphoAkt-serine473, followed by re-probing for β-tubulin. (B) 
Densitometric measurement of phosphoAkt-serine473 and expressed as 
%Akt phosphorylation ± SEM of three independent experiments, where * 
indicates p<0.05 compared with collagen alone to the inhibitors. 
  
 163 
 
4.4.4 Identification of PI3K isoforms in globular adiponectin-stimulated 
Akt phosphorylation 
Selective PI3K isoform inhibitors were used to understand the roles of 
individual PI3K isoforms in gAd-stimulated Akt activation. Treatment of 
gAd-stimulated platelets with TGX-221 (500 nM) ablated Akt serine473 
phosphorylation in response to gAd (p<0.05). In contrast, the presence of 
both PIK75 (100 nM) and AS242525 (100 nM) led to more modest 
reductions in Akt serine473 phosphorylation [Figure 4.18]. These data 
suggest that the PI3Kβ isoform plays a significant role in gAd-stimulated Akt 
phosphorylation, whereas PI3Kα and PI3Kγ play a minor role.  
Since gAd-mediated activation of platelets proceeds through tyrosine 
kinase activation, we compared the roles of PI3K isoforms in CRP-XL and 
collagen-stimulated platelets. The addition of TGX-221 in CRP-XL-
stimulated platelets reduced Akt serine473 phosphorylation back to basal 
levels (p<0.05) [Figure 4.19]. In contrast, a partial but significant reduction 
in Akt serine473 phosphorylation was detected with PIK75 (p<0.05) [Figure 
4.19]. Interestingly, the inhibition of PI3Kγ only had a minor effect on Akt 
serine473 phosphorylation. Similar data was observed with collagen-
stimulated platelets [Figure 4.20]. Taken together these data highlight the 
important roles of PI3K isoforms α and β in tyrosine kinase activation of 
Akt.  
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Figure 4.18: The role of PI3K isoforms in globular adiponectin-stimulated 
Akt serine473 phosphorylation. (A) Washed platelets (5x108 platelets/ml) 
were stimulated with gAd (40 µg/ml) in the presence and absence of 
wortmannin (100 nM), PIK75 (100 nM), TGX-221 (500 nM), AS242525 (100 
nM). Platelet proteins were separated by SDS-PAGE and blotted for 
phosphoAkt-serine473, followed by re-probing for β-tubulin. (B) 
Densitometric measurement of phosphoAkt-serine473 and expressed as 
%Akt phosphorylation ± SEM of three independent experiments, where * 
indicates p<0.05 compared with gAd alone to the inhibitors. 
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Figure 4.19: The role of PI3K isoforms in CRP-XL-stimulated Akt serine473 
phosphorylation. (A) Washed platelets (5x108 platelets/ml) were 
stimulated with CRP-XL (10 µg/ml) in the presence and absence of 
wortmannin (100 nM), PIK75 (100 nM), TGX-221 (500 nM), AS242525 (100 
nM). Platelet proteins were separated by SDS-PAGE and blotted for 
phosphoAkt-serine473, followed by re-probing for β-tubulin. (B) 
Densitometric measurement of phosphoAkt-serine473 and expressed as 
%Akt phosphorylation ± SEM of three independent experiments, where * 
indicates p<0.05 compared with CRP-XL alone to the inhibitors. 
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Figure 4.20: The role of PI3K isoforms in collagen-stimulated Akt serine473 
phosphorylation. (A) Washed platelets (5x108 platelets/ml) were 
stimulated with collagen (10 µg/ml) in the presence and absence of 
wortmannin (100 nM), PIK75 (100 nM), TGX-221 (500 nM), AS242525 (100 
nM). Platelet proteins were separated by SDS-PAGE and blotted for 
phosphoAkt-serine473, followed by re-probing for β-tubulin. (B) 
Densitometric measurement of phosphoAkt-serine473 and expressed as 
%Akt phosphorylation ± SEM of three independent experiments, where * 
indicates p<0.05 compared with collagen alone to the inhibitors. 
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4.5 Is secretion required for globular adiponectin-stimulated Akt 
phosphorylation? 
To further understand the signalling events underlying Akt activation, we 
looked at the role of secondary mediators, ADP and TxA2 on Akt 
phosphorylation. To accomplish this we used selective ADP receptor 
antagonists, A3P5P (300 µM) and MRS2395 (10 µM), which inhibited Gq-
coupled P2Y1 and Gi-coupled P2Y12 ADP receptors respectively. The cyclo-
oxgenase inhibitor, indomethacin (10 µM) was used to inhibit TxA2 
synthesis.  
Inhibition of TxA2 had no effect on gAd-induced Akt phosphorylation, 
indicating a mechanism that was independent of Gq-coupled P2Y1 and 
TPα/β signalling [Figure 4.21]. In contrast, combination of ADP receptor 
antagonists reduced Akt phosphorylation back to basal levels [Figure 4.21]. 
Further exploration of this observation demonstrated that the P2Y12 
antagonist MRS2395 significantly reduced Akt serine473 phosphorylation, 
whereas inhibition of P2Y1 only had a minor effect [Figure 4.22]. These 
results suggest that Gi-coupled P2Y12 ADP receptor play an important role 
in platelet-derived ADP secretion phosphorylation of Akt. A similar 
dependency of P2Y12 stimulation of Akt phosphorylation was observed in 
both CRP-XL and collagen-stimulated platelets [Figure 4.23 and 4.24]. 
Taken together, these results suggest that platelet derived TxA2 plays a 
minor role compared to ADP which acts through P2Y12 receptor to induce 
Akt serine473 phosphorylation.       
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Figure 4.21: The role of secretion on globular adiponectin-stimulated Akt 
serine473 phosphorylation. (A) Washed platelets (5x108 platelets/ml) were 
stimulated with gAd (40 µg/ml) in the presence and absence of 
indomethacin (10 µM), A3P5P (300 µM) and MRS2395 (10 µM). Platelet 
proteins were separated by SDS-PAGE and blotted for phosphoAkt-
serine473, followed by re-probing for β-tubulin. (B) Densitometric 
measurement of phosphoAkt-serine473 and expressed as %Akt 
phosphorylation ± SEM of three independent experiments, where * 
indicates p<0.05 compared with gAd alone to the inhibitors. 
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Figure 4.22: The role of ADP secretion on globular adiponectin-stimulated 
Akt phosphorylation. (A) Washed platelets (5x108 platelets/ml) were 
stimulated with gAd (40 µg/ml) in the presence and absence of ADP 
receptor antagonists A3P5P (300 µM) and MRS2395 (10 µM). Platelet 
proteins were separated by SDS-PAGE and blotted for phosphoAkt-
serine473, followed by re-probing for β-tubulin. (B) Densitometric 
measurement of phosphoAkt-serine473 and expressed as %Akt 
phosphorylation ± SEM of three independent experiments, where * 
indicates p<0.05 compared with gAd alone to the inhibitors. 
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Figure 4.23: The role of ADP secretion on CRP-XL-stimulated Akt 
phosphorylation. (A) Washed platelets (5x108 platelets/ml) were 
stimulated with CRP-XL (10 µg/ml) in the presence and absence of ADP 
receptor antagonists, A3P5P (300 µM) and MRS2395 (10 µM). Platelet 
proteins were separated by SDS-PAGE and blotted for phosphoAkt-
serine473, followed by re-probing for β-tubulin. (B) Densitometric 
measurement of phosphoAkt-serine473 and expressed as %Akt 
phosphorylation ± SEM of three independent experiments, where * 
indicates p<0.05 compared with CRP-XL alone to the inhibitors. 
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Figure 4.24: The role of ADP secretion on collagen-stimulated Akt 
phosphorylation. (A) Washed platelets (5x108 platelets/ml) were 
stimulated with collagen (40 µg/ml) in the presence and absence of ADP 
receptor antagonists, A3P5P (300 µM) and MRS2395 (10 µM). Platelet 
proteins were separated by SDS-PAGE and blotted for phosphoAkt-
serine473, followed by re-probing for β-tubulin. (B) Densitometric 
measurement of phosphoAkt-serine473 and expressed as %Akt 
phosphorylation ± SEM of three independent experiments, where * 
indicates p<0.05 compared with collagen alone to the inhibitors. 
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4.5.1 The role of PKC on Akt phosphorylation stimulated by globular 
adiponectin 
The secretion of platelet granules is a complex process that is driven at 
least in part by the family of PKC enzymes (Harper and Poole, 2007). Since 
our previous data indicated that the secretion of ADP was required for Akt 
phosphorylation, we examined the role of PKC in this process using a pan 
PKC inhibitor, Ro 31-8220 (10 µM). Under these conditions of PKC 
blockade, the ability of gAd to stimulate the phosphorylation of Akt 
remained undiminished [Figure 4.25].  Interestingly, activation of PMA did 
lead to the phosphorylation of Akt in platelets indicating that at least one 
PKC isoform can target Akt activation [Figure 4.25]. Together, these data 
suggest that gAd-stimulated Akt serine 473 phosphorylation is independent 
of PKC. To confirm that gAd activated the PKC signalling pathway, and Ro 
31-8220 inhibited this process, the membranes were reprobed with an 
antibody that recognises substrates phosphorylation by PKC isoforms. 
Consistent with our previous data [Figure 3.14], gAd-stimulation increased 
phosphorylation of a number of PKC substrates, with prominent bands at 
50, 55, 60, 70, 110, 120 and 140 kDa [Figure 4.26]. Importantly, the PKC 
substrate phosphorylation levels of gAd and PMA treated platelets were 
blocked by the PKC inhibitor Ro 31-8220, thereby confirming the ability of 
Ro 31-8220 to inhibit PKC [Figure 4.26]. Together, these data suggest that 
gAd stimulates two distinct pathways that lead to the activation of PKC and 
phosphorylation of Akt. 
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Figure 4.25: The role of PKC on globular adiponectin-stimulated Akt 
phosphorylation. (A) Washed platelets (5x108 platelets/ml) were 
stimulated with gAd (40 µg/ml) or PMA (100 nM) in the presence and 
absence of Ro 31-8220 (10 µM). Platelet proteins were separated by SDS-
PAGE and blotted for phosphoAkt-serine473, followed by re-probing for β-
tubulin. (B) Densitometric measurement of phosphoAkt-serine473 and 
expressed as %Akt Phosphorylation ± SEM of three independent 
experiments, where * indicates p<0.05 compared with PMA alone to the 
Ro 31-8220. 
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Figure 4.26: The role of PKC on globular adiponectin-stimulated Akt 
phosphorylation. (A) Washed platelets (5x108 platelets/ml) were 
stimulated with gAd (40 µg/ml) or PMA (100 nM) in the presence and 
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absence of Ro 31-8220 (10 µM). Platelets were lysed, separated by SDS-
PAGE and blotted with anti-phospho-PKC substrate antibody. (B) 
Densitometric measurement of phospho-PKC substrate at band labelled 
“x”. (C) As in (B) except band labelled “y” was selected and expressed as 
PKC substrate phosphorylation/total ± SEM of three independent 
experiments, where * indicates p<0.05 compared with gAd alone to Ro 31-
8220 and # indicates p<0.05 compared with PMA alone to Ro 31-8220. 
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4.6 Identification of signal events underlying PKC-independent secretion 
in globular adiponectin-stimulated platelets 
4.6.1 Synergism between globular adiponectin and Gi signalling in Akt 
phosphorylation 
In chapter 3, we established that gAd can synergise with Gi/Gz mediated 
signalling to induce aggregation and secretion independently of PKC 
signalling. Furthermore, the addition of PI3K inhibitor, wortmannin 
abolished PKC independent secretion. These data suggest a role of PI3K in 
this process and therefore we measured Akt serine473 phosphorylation in 
these conditions. Platelets were stimulated with gAd in combination with 
Ro 31-8220 (10 µM), ADP (5 µM) or adrenaline (10 µM) and subjected to 
immunoblotting. GAd (40 µg/ml) alone stimulated robust Akt serine473 
phosphorylation which was maintained in the presence of Ro 31-8220 
[Figure 4.27]. Importantly, threshold levels of ADP (5 µM) in the presence 
of P2Y1 receptor antagonist and adrenaline (10 µM) failed to stimulate Akt 
serine473 phosphorylation [Figure 4.28]. However, the stimulation of P2Y12 
coupled Gi receptor by ADP potentiated Akt serine
473 phosphorylation 
compared with Ro 31-8220 alone. Furthermore, this is further evidence 
that Gi-coupled P2Y12 receptor stimulation by ADP is a major pathway 
responsible for Akt phosphorylation in gAd stimulated platelets.  
We next examined the ability of adrenaline to potentiate Akt 
phosphorylation in conditions of PKC blockade. The stimulation of Gz-
coupled α2A adrenoceptor by adrenaline potentiated gAd-mediated Akt 
serine473 phosphorylation in the presence of Ro 31-8220 [Figure 4.27]. 
Importantly, this potentiation in Akt phosphorylation occurred in the 
presence of ADP antagonists, indicating that the increased Akt serine473 
phosphorylation was induced by adrenaline signalling and not because of 
an indirect effect of secreted ADP. In conditions where platelets were 
stimulated with ADP, in the presence of A3P5P and adrenaline, we found 
Akt serine473 phosphorylation was significantly potentiated when 
compared to ADP or adrenaline alone [Figure 4.27]. Taken together, these 
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data indicate that Gi/Gz signalling can combine with gAd derived signalling 
to stimulate PI3K downstream phosphorylation of Akt, which may 
compensate for the loss of PKC activity.  
It is established that ADP can potentiate GPVI-collagen-stimulated 
aggregation and therefore indicate a synergism between tyrosine kinase-
linked and G-protein coupled receptor-linked pathways (Atkinson et al., 
2001, Dangelmaier et al., 2001). It was important to determine the role of 
PI3K in this process. Since the data suggested that gAd and Gi/Gz signalling 
can synergise to compensate for the loss of PKC signalling, we repeated 
these experiments with a GPVI specific agonist, CRP-XL. We found that 
CRP-XL induced Akt serine473 phosphorylation and was maintained in the 
presence of Ro 31-8220 [Figure 4.28]. The addition of ADP under conditions 
of PKC inhibition, acting through Gi-coupled P2Y12 receptor potentiated Akt 
serine473 phosphorylation compared to CRP-XL alone [Figure 4.28]. The 
addition of adrenaline under these same conditions of PKC blockade also 
potentiated Akt serine473 phosphorylation. Importantly, stimulation of Gi-
coupled P2Y12 receptor and Gz-coupled α2A adrenoceptor with ADP and 
adrenaline respectively even further potentiated Akt serine473 
phosphorylation. Taken together, these data suggest an important role for 
PI3K in the synergism between tyrosine kinase-linked and G-protein 
coupled receptor-linked pathways. 
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Figure 4.27: Akt serine473 phosphorylation is potentiated with Gi/Gz 
signalling in globular adiponectin-stimulated platelets. (A) Washed 
platelets (5x108 platelets/ml) were pre-incubated with Ro 31-8220 (10 µM) 
and then stimulated with gAd (40 µg/ml) alone or in combination with ADP 
(5 µM), or adrenaline (10 µM). In some cases platelets, were pretreated 
with A3P5P (300 µM) or MRS2395 (10 µM). Platelet proteins were lysed 
and separated by SDS-PAGE and blotted for phosphoAkt-serine473, followed 
by re-probing for β-tubulin. (B) Densitometric measurement of 
phosphoAkt-serine473 and expressed as %Akt phosphorylation ± SEM of 
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three independent experiments, where * indicates p<0.05 compared with 
gAd and Ro 31-8220 to the inhibitors. 
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Figure 4.28: Akt serine473 phosphorylation is potentiated with Gi/Gz 
signalling in CRP-XL-stimulated platelets. (A) Washed platelets (5x108 
platelets/ml) were pre-incubated with Ro 31-8220 (10 µM) and then 
stimulated with CRP-XL (10 µg/ml) alone or in combination with ADP (5 
µM), or adrenaline (10 µM). In some cases platelets were pre-treated with 
A3P5P (300 µM) or MRS2395 (10 µM). Platelet proteins were lysed and 
separated by SDS-PAGE and blotted for phosphoAkt-serine473, followed by 
re-probing for β-tubulin. (B) Densitometric measurement of phosphoAkt-
serine473 and expressed as %Akt phosphorylation ± SEM of three 
independent experiments, where # indicates p<0.05 compared with CRP-XL 
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alone to Ro 31-8220 and * indicates p<0.05 compared with CRP-XL and Ro 
31-8220 to the inhibitors. 
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4.6.2 The role of PI3K isoforms in synergism between globular 
adiponectin and Gi/Gz signalling in Akt phosphorylation 
Having established that Akt phosphorylation is potentiated in the synergy 
between gAd and Gi/Gz signalling, we used selective PI3K isoform inhibitors 
to determine the contribution of these isoforms in this process. This was 
achieved by measuring the combined ADP and adrenaline induced 
potentiation of Akt serine473 phosphorylation in pre-treated Ro 31-9220 (10 
µM) platelets, in absence and presence of selective PI3K isoform inhibitors.  
Under these conditions, the addition of pan PI3K inhibitor wortmannin 
abolished the potentiation of Akt phosphorylation [Figure 4.29]. This data 
confirms our previous findings that PI3K plays an integral role in this 
pathway. Selective PI3K inhibitors were then used to identify which isoform 
were involved in this process. The addition of PI3Kβ inhibitor TGX-221 
abolished Akt phosphorylation (p<0.05) [Figure 4.29]. Furthermore, the 
addition of PI3Kα inhibitor PIK75 partially reduced Akt serine473 
phosphorylation (p<0.05) [Figure 4.29]. However, inhibition of PI3Kγ by 
AS242525 failed to prevent the potentiation of Akt phosphorylation [Figure 
4.29]. Similar data was obtained with CRP-XL-stimulated platelets [Figure 
4.30]. These data implicate a key role of PI3Kβ and PI3Kα isoforms in gAd 
and Gi/Gz mediated signalling to overcome the loss of PKC activity. 
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Figure 4.29: The role of PI3K isoforms in Gi/Gz potentiation of Akt 
serine473 phosphorylation in globular adiponectin-stimulated platelets. 
(A) Washed platelets (5x108 platelets/ml) were pre-incubated with Ro 31-
8220 (10 µM) and then stimulated with gAd (40 µg/ml) in combination with 
ADP (5 µM), adrenaline (10 µM) and A3P5P (300 µM) in the presence of 
PI3K inhibitors; wortmannin (100 nM), PIK75 (100 nM), TGX-221 (500 nM) 
and AS242525 (100 nM) Platelet proteins were lysed and separated by SDS-
PAGE and blotted for phosphoAkt-serine473, followed by re-probing for β-
tubulin. (B) Densitometric measurement of phosphoAkt-serine473 and 
expressed as %Akt phosphorylation ± SEM of three independent 
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experiments, where * indicates p<0.05 compared with gAd/Ro 31-
8220/Adrenaline/ADP + A3P5P to the PI3K inhibitors. 
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Figure 4.30: The role of PI3K isoforms in Gi/Gz potentiation of Akt 
serine473 phosphorylation in CRP-XL-stimulated platelets. (A) Washed 
platelets (5x108 platelets/ml) were pre-incubated with Ro 31-8220 (10 µM) 
and then stimulated with CRP-XL (10 µg/ml) in combination with ADP (5 
µM), adrenaline (10 µM) and A3P5P (300 µM) in the presence of PI3K 
inhibitors; wortmannin (100 nM), PIK75 (100 nM), TGX-221 (500 nM) and 
AS242525 (100 nM) Platelet proteins were lysed and separated by SDS-
PAGE and blotted for phosphoAkt-serine473, followed by re-probing for β-
tubulin. (B) Densitometric measurement of phosphoAkt-serine473 and 
expressed as %Akt phosphorylation ± SEM of three independent 
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experiments, where * indicates p<0.05 compared with CRP-XL/Ro 31-
8220/Adrenaline/ADP + A3P5P to the PI3K inhibitors. 
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4.7 Discussion 
In this chapter the contribution of PI3K to gAd-stimulated platelet 
aggregation was studied. We had already determined that gAd stimulates 
platelet aggregation in two distinct phases. The first phase is mediated by 
direct activation via a tyrosine kinase-dependent signalling cascade. The 
second phase is dependent upon the release of ADP and TxA2 which 
potentiate platelet aggregation. However, the role of PI3K in gAd-
stimulated aggregation is not known. Here, we found that gAd stimulated 
aggregation through pathways requiring PI3K activation, which was 
independent of tyrosine phosphorylation levels. Further experiments with 
selective PI3K isoform inhibitors revealed that class IA PI3K isoforms α and 
β are activated downstream of gAd activation and contribute to platelet 
aggregation and secretion. Riba et al., had shown previously that platelet 
stimulation by gAd proceeds through activation of Syk, LAT and PLC2 (Riba 
et al., 2008). These data suggest that similar to GPVI signalling, PI3K 
activation may be regulated by tyrosine kinases. The exact mechanism is 
not known, but may involve the formation of a signalosome containing 
LAT, PI3K and PLC2. It is now well established that GPVI signalling involves 
the activation of PI3K and PLC2 which interact with other adapter proteins 
such as LAT to form a signalosome, leading to integrin αIIbβ3 activation 
(Songyang et al., 1994, Nieswandt and Watson, 2003). It is possible that a 
similar mechanism is used in gAd-stimulated platelets.  Furthermore, the 
assembly of a signalosome containing PI3K and PLC2 allows a direct 
association with their substrates.  For example, increased PIP2 production 
by PI3K can directly interact with PLC2 (Pasquet et al., 1999, Martin et al., 
2010). In fact, PLC2 activity can be reduced by up to 80% by the inhibition 
of PI3K in CRP-XL-stimulated platelets (Pasquet et al., 1999). This suggests 
that the inhibitory effects of wortmannin are mediated through pathways 
that are independent of tyrosine phosphorylation. 
To understand the signalling events underlying PI3K activation, we 
examined Akt serine473 phosphorylation levels as a marker of PI3K 
activation (Cantley, 2002).  Akt is a serine-threonine kinase and its activity 
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can be directly regulated by the production of phosphatidylinositol. We 
showed for the first time that gAd-stimulated Akt serine473 phosphorylation 
in a time and concentration-dependent manner. Consistent with data from 
other platelet agonists, Akt serine473 phosphorylation in response to gAd 
was completely abolished by PI3K inhibition. Further investigation of the 
potential PI3K isoforms responsible suggested that both α and β may play a 
role. However, from the current data it is predicted that PI3Kβ isoform was 
quantitatively more important since inhibition of this isoform fully blocked 
Akt serine473 phosphorylation, while inhibition of the α-isoform caused only 
a partial inhibition. Furthermore, Akt serine473 phosphorylation was 
dependent on pathways involving Src-kinase family isoforms and required 
calcium mobilisation. This is consistent with a mechanism whereby gAd-
stimulates Akt phosphorylation through PI3K and Src-kinase dependent 
signalling pathways that require calcium. Importantly, this pathway 
involving Akt phosphorylation through PI3K and Src-kinase signalling can be 
found in the literature regarding platelet activation involving collagen and 
GPVI receptor (Pasquet et al., 1999, Nieswandt and Watson, 2003).  
The release of platelet secondary mediators such as ADP and TxA2 are 
required for maximal gAd-stimulated aggregation. Inhibition of TxA2 
signalling had no effect on Akt serine473 phosphorylation. However, 
antagonism of ADP receptors was able to ablate Akt serine473 
phosphorylation levels, suggesting a key role of this agonist. Selective 
antagonism of ADP receptors revealed that Akt serine473 phosphorylation 
was dependent on Gi-coupled P2Y12 signalling. These data suggest that Gi 
signalling is required for maximal PI3K activity when platelets are 
stimulated by gAd. Since the release of ADP from platelet dense-granules is 
driven by pathways that require PKC, we examined the role of this kinase in 
Akt activation. Interestingly, the inhibition of PKC did not influence Akt 
serine473 phosphorylation levels, suggesting that Akt serine473 
phosphorylation is independent of PKC. It has been reported that Akt 
serine473 is phosphorylated by PKCβ2 isoform in mast cells (Kawakami et 
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al., 2004). However, platelets only express the PKCβ1 isoform and the role 
of this isoform in Akt phosphorylation in platelets is unclear.   
Platelets contain redundant pathways that can compensate for the loss of 
platelet signalling pathways. For example, the loss of the collagen GPVI 
receptor can be compensated by other platelet activation pathways and 
therefore only display a mild bleeding phenotype (Arai et al., 1995).   
However, some of these compensatory systems can work with existing 
systems to promote platelet activation and thrombus formation. The 
current data suggests such a system that involves the synergy between gAd 
and Gi/Gz signalling pathways to promote platelet aggregation and 
secretion independent of PKC. In chapter 3, evidence was presented to 
demonstrate the potential existence of a PKC-independent pathway for 
dense-granule secretion. Here, it was found that the addition of a PI3K 
inhibitor abolished PKC-independent secretion suggesting a role of PI3K in 
this process. Three distinct pieces of evidence are present to support this; 
1. GAd-stimulated Akt serine473 phosphorylation remained under 
conditions of PKC inhibition. 
2. The addition of either ADP or adrenaline, alone or in combination, 
with gAd potentiated Akt serine473 phosphorylation under 
conditions of PKC inhibition. An effect that was blocked by the PI3K 
inhibitor, wortmannin.  
3. The effects of wortmannin could be repeated with structurally 
distinct isoform specific inhibitors of PI3K. 
The Gi-coupled P2Y12 receptor has been reported to be linked to PI3K 
isoforms β and γ. Selective PI3K inhibitors revealed that only PI3Kβ isoform 
and to a lesser extent PI3Kα isoform are involved in the potentiation. This 
is consistent with reports that PI3Kβ isoform is major contributor to 
platelet activation downstream of P2Y12 (Jackson et al., 2005, 
Schoenwaelder et al., 2007, Canobbio et al., 2009). The exact importance 
of PI3Kβ and γ isoforms downstream of P2Y12 is controversial. The 
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activation of Gi-coupled P2Y12 by ADP is shown only to involve PI3Kβ 
activation and not PI3Kγ  (Garcia et al., 2010, Kim and Kunapuli, 2011). 
However, some studies with PI3Kγ-deficient mice show reduced responses 
to ADP, but responses to other agonists were normal (Jackson et al., 2005, 
Schoenwaelder et al., 2007). These studies suggest that PI3Kγ activation is 
not required for maximal platelet activation. However, the role of class IA 
PI3Kα isoform in gAd-stimulated platelet activation is less clear. It has been 
reported that PI3Kα along with PI3Kβ play an important role in platelet 
activation downstream of the collagen receptor GPVI in the absence of any 
secondary mediators (Watanabe et al., 2003, Kim et al., 2009). It has been 
previously suggested that gAd may activate platelets via the collagen 
receptor GPVI (Riba et al., 2008). Therefore, it is possible that PI3Kα 
isoform maybe activated downstream of GPVI activation.  
In this study we have identified PI3Kβ as a critical component in the 
potentiation of platelet responses to gAd via Gi/Gz signalling. It has been 
shown that PI3Kβ plays an important role in G-protein coupled receptors 
and GPVI activation (Rittenhouse, 1996, Canobbio et al., 2009, Kim et al., 
2009). Platelet responses to ADP downstream of P2Y12 have been shown to 
have an absolute requirement for PI3Kβ activation (Garcia et al., 2010). The 
role of PI3Kβ in the synergy between gAd and Gi/Gz signalling pathways is 
not known, but may involve downstream activation of PI3K substrates, 
which include Akt and Rap1b. Akt is a serine-threonine kinase composed of 
a centrally located catalytic domain connected to a short C-terminal tail to 
a PH domain (Kim et al., 2004). Three isoforms of Akt are expressed in 
platelets, Akt1, Akt2 and Akt3 in which Akt1 is the most abundantly 
expressed (Cho et al., 2001, Woulfe et al., 2004). Genetic deletion of Akt1 
isoform in mice have shown reduced platelet responses to thrombin and 
collagen, characterised with reduced secretion of ATP and increased tail-
bleeding time (Chen et al., 2004). Loss of Akt2 resulted in impaired platelet 
responses to PAR4 agonist but not to collagen (Woulfe et al., 2004). These 
mice showed no change in tail-bleeding time and therefore suggested Akt1 
is the major isoform involved in normal platelet function. The results of this 
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study suggest that gAd also stimulates Akt1 activation through the 
phosphorylation of serine473 residue. 
It is established that Gi signalling downstream of P2Y12 and α2A-
adrenoceptor activation leads to the activation of small GTPase Rap1 
isoforms. Platelets highly express the Rap1b isoform, which can account for 
up to 0.1% of cellular protein (Torti and Lapetina, 1994). The activation of 
Rap1b has been implicated in the stabilisation of integrin αIIbβ3 activation 
and therefore can potentiate aggregation (Lova et al., 2003). The exact role 
of Rap1b in this process is unclear but may involve class IA PI3K isoforms. In 
fact, the activation of Rap1b has been shown to be PI3K dependent (Lova 
et al., 2002, Lova et al., 2003). More recent study has identified PI3Kβ as a 
key regulator of Rap1b activation downstream of GPVI activation (Larson et 
al., 2003, Jackson et al., 2005, Canobbio et al., 2009). Jackson and 
colleagues showed that the inhibition of PI3Kβ by TGX-221 can reduce 
Rap1b activation by 70% in Gi-stimulated platelets (Jackson et al., 2005). It 
is therefore possible that a similar pathway involving PI3Kβ downstream of 
gAd and Gi/Gz signalling can potentiate platelet aggregation.        
The mechanism underlying PI3K induced granule secretion is not 
understood, but may involve the potentiation of TxA2 generation. It has 
been shown that co-stimulation of Gi and Gz pathways in the absence of Gq 
signalling can lead to enhanced platelet aggregation and TxA2 generation 
(Garcia et al., 2010). It is established that ADP-induced TxA2 generation 
occurs through the regulation of extracellular signal-regulated kinase (ERK) 
activation (Garcia et al., 2007). A recent study has shown that PI3Kβ has a 
critical role in the ADP-induced TxA2 generation through the regulation of 
ERK activation (Garcia et al., 2010). In fact, the study showed that co-
stimulation of Gi/Gz by ADP and adrenaline enhanced TxA2 generation via a 
pathway mediated by PI3Kβ (Garcia et al., 2010). We have previously 
shown that gAd and Gi/Gz signalling can synergise to enhance platelet 
dense-granule secretion independently of PKC. In conjunction to this, we 
have also shown that the release of TxA2 is required for granule secretion 
in gAd-stimulated platelets. It is therefore possible that platelet dense-
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granule secretion is potentiated via the increase in TxA2 generation 
through a pathway involving ERK and PI3Kβ activation [Figure 4.31]. This 
mechanism may suggest two waves of ADP secretion, which may 
potentiate platelet responses to gAd. The first wave of ADP secretion is 
induced by direct activation of PLA2 by primary gAd signalling which can 
drive ADP release. A second wave of ADP secretion is induced by Gi 
activation of PI3Kβ leading to increased TxA2 generation and subsequent 
ADP release, which may potentiate aggregation. This hypothesis can easily 
be tested through the measurement of TxA2 or ATP in the presence of the 
PI3K isoform inhibitors in PKC independent conditions. In conclusion, this 
study has established PI3Kβ as a major contributor to gAd-stimulated 
aggregation and secretion. Furthermore, we have identified a pathway 
involving PI3Kβ activation downstream of Gi/Gz signalling in the 
potentiation of platelet responses to gAd.           
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Figure 4.31: Proposed model for PKC independent secretion involving 
PI3Kβ. GAd signalling (Step 1) can synergise with Gi-induced activation of 
PI3Kβ to compensate for the loss of PKC signalling. TxA2 formation (Step 2) 
may be up-regulated by a pathway involving PI3Kβ (Step 5), which can 
increase ADP release from platelet-dense granules (Step 3 and 4). 
Enhanced Gi signalling leads to stable and sustained integrin activation 
(Step 6). 
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Chapter 5: Globular adiponectin: A novel collagen receptor glycoprotein 
VI agonist? 
5.1 Introduction 
In this study we have identified gAd as a novel platelet agonist that can 
stimulate platelet aggregation. However, the mechanism or receptor(s) 
involved in gAd-stimulated platelet activation is less clear. Most of our 
understanding of platelet activation by gAd stems from a study by Riba et 
al., (2008). This study used a genetic and non-genetic approach to suggest 
that gAd induced platelet activation through the collagen receptor GPVI-Fc 
chain complex. This was based on two major pieces of evidence, (i) platelet 
activation was associated with PLCγ2 activation through pathways 
involving Src-kinase isoforms, Syk and LAT in human platelets, and a lack of 
response in mice deficient in these signalling enzymes, and (ii) the 
activation of a NFAT linked signalling pathway downstream of transfected 
GPVI in Jurkat cells. Those findings suggested a new physiological GPVI 
agonist other than collagen and may represent a new group of proteins 
that can activate GPVI. However, that study failed to demonstrate a key 
role of GPVI in gAd-stimulated platelets. In this chapter we will focus on the 
role of collagen receptors, GPVI and integrin α2β1 in gAd-stimulated 
platelet aggregation and adhesion by using specific receptor blocking 
antibodies.  
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5.2 The role of collagen glycoprotein VI receptor in globular adiponectin-
stimulated aggregation  
In this study we used GPVI blocking antibody, 10B12 (kind gift from Prof. 
Richard Farndale) and integrin α2β1 blocking antibody, 6F1 (kind gift from 
Prof. Barry Coller) to assess the role of these receptors in gAd-stimulated 
aggregation. In the first instance, the antibodies were tested using 
standard aggregation experiments. The addition of 10B12 (20 µg/ml) did 
not cause inhibition of platelet aggregation. Pre-incubation of platelets 
with 10B12 (20 µg/ml) prior to the addition of gAd (20 µg/ml) did not affect 
aggregation stimulated by the adipokine [Figure 5.1A]. Interestingly, 10B12 
also failed to influence collagen (1 µg/ml)-stimulated aggregation [Figure 
5.1C]. In contrast to these data 10B12 abolished CRP-XL (5 µg/ml)-
stimulated aggregation [Figure 5.1B].  
The monoclonal antibody, 6F1 has been shown to inhibit platelet adhesion 
and aggregation induced by α2β1 specific agonists (Verkleij et al., 1998, 
Jarvis et al., 2002). However, incubation of platelets with 6F1 (10 µg/ml) 
failed to influence aggregation by any of the agonists tested [Figure 5.1]. 
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Figure 5.1: The role of glycoprotein VI in globular adiponectin-stimulated 
platelet aggregation. (A) Washed platelets (2.5x108 platelets/ml) were 
stimulated with gAd (20 µg/ml) in the absence and presence of 10B12 (20 
µg/ml) and 6F1 (10 µg/ml) and the aggregation response was monitored 
for 4 minutes under constant stirring. (B) As in (A) except platelets were 
stimulated with CRP-XL (5 µg/ml) (C) As in (A) except platelets were 
stimulated with collagen (1 µg/ml). All representative aggregation traces 
are taken from three independent experiments performed with distinct 
blood donors. 
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5.3 Immobilised globular adiponectin supports platelet adhesion  
The exposure of components of the extracellular matrix is an important 
event in the formation of a haemostatic plug. Initial experiments were 
designed to assess platelet adhesion to immobilised gAd under static 
conditions since plasma adiponectin has been found immobilised to 
collagen fibres (Okamoto et al., 2002). Here, gAd was immobilised on glass 
slides and washed platelets were allowed to adhere for 1 hour and stained 
with TRITC-conjugated phalloidin and viewed under x60 oil immersion lens 
in an inverted microscope.  
We found washed platelets adhered to immobilised gAd in a 
concentration-dependent manner [Figure 5.2]. Immobilised gAd (20 µg/ml) 
supported platelet adhesion of 604±89 platelets/0.1mm2 and optimal 
adhesion was observed with gAd (40 µg/ml) of 1087±146 
platelets/0.1mm2, although the platelets underwent a limited spreading 
response. Importantly, platelets adhered to immobilised gAd were shown 
to have undergone secretion in a concentration-dependent manner. It was 
found that adherent platelets showed extensive staining for P-selectin 
[Figure 5.2]. Taken together, these data suggest that immobilised gAd can 
support platelet adhesion, but does not induce a significant spreading 
response [Figure 5.2B]. 
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Figure 5.2: Immobilised globular adiponectin supports platelet adhesion. 
(A) Glass microscope slides were coated overnight with increasing 
concentrations of gAd and washed platelets (5x107 platelets/ml) were 
allowed to adhere for 1 hour at 37ᵒC. Adherent platelets were stained with 
TRITC-conjugated phalloidin (top panel) or p-selectin (bottom panel) and 
viewed through x60 oil immersion lens. (B) Platelets show limited 
spreading on immobilised gAd. (C) Platelets from 8 random visual fields 
with a total area of 0.1mm2 were counted and expressed as mean number 
of platelets/0.1mm2 ± SEM of three independent experiments performed 
with distinct blood donors.      
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5.3.1 Platelet adhesion induced by globular adiponectin is tyrosine 
kinase-dependent  
Since gAd-stimulated platelet activation is tyrosine kinase-dependent, a 
pan Src-kinase inhibitor, PP1 was used to assess platelet adhesion to gAd. 
In these conditions, gAd (40 µg/ml) supported similar levels of platelet 
adhesion of 1290±210 platelets/0.1mm2 found with previous experiment 
[Figure 5.3]. Incubation of platelets with PP1 significantly reduced platelet 
adhesion to 340±100 platelets/0.1mm2 (p<0.05). Importantly, the inactive 
analogue of the Src-kinase inhibitor, PP3 (20 µM) did not affect platelet 
adhesion [Figure 5.3]. Furthermore, treatment of platelets with EGTA (1 
mM) to prevent integrin dependent conditions did not ablate platelet 
adhesion [Figure 5.3]. Taken together, these data show that platelet 
adhesion to immobilised gAd occurs through a tyrosine kinase-dependent 
pathway that was independent of surface integrins.  
We next examined platelet adhesion induced by other agonists that induce 
platelet activation by tyrosine kinase-dependent manner, such as CRP-XL 
and collagen. Consistent with previous published reports (Shadle and 
Barondes, 1982, Nakamura et al., 1998), collagen (10 µg/ml) supported 
platelet adhesion of 940±130 platelets/0.1mm2 which was characterised by 
robust platelet spreading [Figure 5.4]. The addition of PP1 reduced platelet 
adhesion to 610±260 platelets/0.1mm2 and to 663±223 platelets/0.1mm2 
with the addition of EGTA [Figure 5.4]. In comparison, CRP-XL (10 µg/ml) 
stimulated platelet adhesion of 1785±455 platelets/0.1mm2 and was 
significantly reduced to 499±158 platelets/0.1mm2 by PP1 (p<0.05) [Figure 
5.5]. It is important to note that like gAd and CRP-XL induced adhesion was 
also unaffected by EGTA, whereas collagen was affected. These data 
suggest that GPVI activation alone can support platelet adhesion.  
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Figure 5.3: Platelet adhesion to immobilised globular adiponectin is 
tyrosine kinase-dependent. (A) Washed platelets (5x107 platelets/ml) were 
treated with PP1 (20 µM), PP3 (20 µM) or EGTA (1 mM) for 20 minutes at 
37°C then adhered for 1 hour at 37°C on glass microscope slides coated 
with gAd (40 µg/ml) overnight. Adherent platelets were stained with TRITC-
conjugated phalloidin and viewed through x60 oil immersion lens. (B)  
Platelets from 8 random visual fields with a total area of 0.1mm2 were 
counted and expressed as mean number of platelets/0.1mm2 ± SEM of 
three independent experiments performed with distinct blood donors, 
where * indicates p<0.05 compared with gAd alone to the inhibitors.  
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Figure 5.4: Platelet adhesion to immobilised collagen is tyrosine kinase-
dependent. (A) Washed platelets (5x107 platelets/ml) were treated with 
PP1 (20 µM), PP3 (20 µM) or EGTA (1 mM) for 20 minutes at 37°C then 
adhered for 1 hour at 37°C on glass microscope slides coated with collagen 
(10 µg/ml) overnight. Adherent platelets were stained with TRITC-
conjugated phalloidin and viewed through x60 oil immersion lens. (B)  
Platelets from 8 random visual fields with a total area of 0.1mm2 were 
counted and expressed as mean number of platelets/0.1mm2 ± SEM of 
three independent experiments performed with distinct blood donors, 
where * indicates p<0.05 compared with collagen alone to the inhibitors.   
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Figure 5.5: Platelet adhesion to immobilised CRP-XL is tyrosine kinase-
dependent. (A) Washed platelets (5x107 platelets/ml) were treated with 
PP1 (20 µM), PP3 (20 µM) or EGTA (1 mM) for 20 minutes at 37°C then 
adhered for 1 hour at 37°C on glass microscope slides coated with CRP-XL 
(10 µg/ml) overnight. Adherent platelets were stained with TRITC-
conjugated phalloidin and viewed through x60 oil immersion lens. (B)  
Platelets from 8 random visual fields with a total area of 0.1 mm2 were 
counted and expressed as mean number of platelets/0.1mm2 ± SEM of 
three independent experiments performed with distinct blood donors, 
where * indicates p<0.05 compared with CRP-XL alone to the inhibitors.   
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5.3.2 Glycoprotein VI mediates globular adiponectin-stimulated platelet 
adhesion 
While our data did not confirm a role of GPVI in gAd-stimulated 
aggregation, we examined the role of this receptor in gAd-stimulated 
adhesion since the conformation of the protein can be potentially altered 
when immobilised. Washed platelets were incubated in the presence of 
10B12 (20 µg/ml) or 6F1 (10 µg/ml) and were allowed to adhere for 1 hour 
on immobilised gAd (40 µg/ml). The presence of 10B12 (20 µg/ml) 
significantly reduced platelet adhesion from 560±110 to 170±20 
platelets/0.1mm2 (p<0.05) [Figure 5.6]. In contrast, the inhibition of 
integrin α2β1 by 6F1 (10 µg/ml) did not influence platelet adhesion [Figure 
5.6]. Importantly, platelet adhesion was reduced to 100±20 
platelets/0.1mm2 (p<0.05) in the presence of both receptor blocking 
antibodies [Figure 5.6]. These data may suggest a role of GPVI in platelet 
adhesion to immobilised gAd. 
To further understand the ability of 10B12 to block GPVI mediated platelet 
adhesion, the above experiment was repeated with collagen and CRP-XL. 
Consistent with the ability of 10B12 to abolish CRP-XL-stimulated 
aggregation, platelet adhesion was abolished with the addition of 10B12 
(20 µg/ml) from 2790±90 to 120±40 platelets/0.1mm2 (p<0.05) [Figure 5.7]. 
In contrast, the GPVI blocking antibody was found to have a minor effect 
on collagen (10 µg/ml)-stimulated platelet adhesion [Figure 5.8]. However, 
the addition of 6F1 reduced platelet adhesion from 3400±330 to 1750±60 
platelets/0.1mm2 and similar levels were found when the two blocking 
antibodies were combined [Figure 5.8]. 
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Figure 5.6: The role of glycoprotein VI in platelet adhesion to immobilised 
globular adiponectin. (A) Washed platelets (5x107 platelets/ml) were 
treated with 10B12 (20 µg/ml) or 6F1 (10 µg/ml) for 20 minutes at 37°C 
then adhered for 1 hour at 37°C on glass microscope slides coated with gAd 
(40 µg/ml) overnight. Adherent platelets were stained with TRITC-
conjugated phalloidin and viewed through x60 oil immersion lens. (B)  
Platelets from 8 random visual fields with a total area of 0.1mm2 were 
counted and expressed as mean number of platelets/0.1mm2 ± SEM of 
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three independent experiments performed with distinct blood donors, 
where * indicates p<0.05 compared with gAd alone to the inhibitors.  
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Figure 5.7: The role of glycoprotein VI in platelet adhesion to immobilised 
CRP-XL. (A) Washed platelets (5x107 platelets/ml) were treated with 10B12 
(20 µg/ml) or 6F1 (10 µg/ml) for 20 minutes at 37°C then adhered for 1 
hour at 37°C on glass microscope slides coated with CRP-XL (10 µg/ml) 
overnight. Adherent platelets were stained with TRITC-conjugated 
phalloidin and viewed through x60 oil immersion lens. (B)  Platelets from 8 
random visual fields with a total area of 0.1mm2 were counted and 
expressed as mean number of platelets/0.1mm2 ± SEM of three 
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independent experiments performed with distinct blood donors, where * 
indicates p<0.05 compared with CRP-XL alone to the inhibitors.   
  
 208 
 
 
Figure 5.8: The role of glycoprotein VI in platelet adhesion to immobilised 
collagen. (A) Washed platelets (5x107 platelets/ml) were treated with 
10B12 (20 µg/ml) or 6F1 (10 µg/ml) for 20 minutes at 37°C then adhered 
for 1 hour at 37°C on glass microscope slides coated with collagen (10 
µg/ml) overnight. Adherent platelets were stained with TRITC-conjugated 
phalloidin and viewed through x60 oil immersion lens. (B)  Platelets from 8 
random visual fields with a total area of 0.1mm2 were counted and 
expressed as mean number of platelets/0.1mm2 ± SEM of three 
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independent experiments performed with distinct blood donors, where * 
indicates p<0.05 compared with collagen alone to the inhibitors. 
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5.3.3 Immobilised globular adiponectin supports platelet adhesion under 
flow conditions 
Platelet adhesion is an important event that supports the formation of the 
haemostatic plug, therefore preliminary experiments were performed to 
examine the ability of gAd to support platelet adhesion under flow 
conditions. Whole blood was flowed over immobilised gAd (40 µg/ml) at 
two different shear rates, 100s-1 to mimic venous shear rate and at 1000s-1 
to mimic shear rate found in the arteries.  
At the lower flow rate of 100s-1, gAd supported platelet adhesion and 
thrombus formation. This was characterised by 4.78% surface coverage 
and thrombus mean height of 0.15 µm [Figure 5.9]. For comparison, 
collagen (10 µg/ml) stimulated a more robust platelet adhesion and 
thrombus formation, which corresponded to 12.75% surface coverage and 
0.26 µm mean thrombus height [Figure 5.9]. The experiments were then 
repeated at a higher flow rate of 1000s-1 to mimic arterial shear. Under 
these conditions we found platelet adhesion and thrombus formation to 
immobilised gAd was less stable [Figure 5.9]. Interestingly surface coverage 
was maintained to a similar level of 4.1%, but there was a reduction of 
mean thrombus height to 0.06 µm when compared to the lower flow rate 
of 100s-1 [Figure 5.9]. Taken together, this preliminary data suggest that 
immobilised gAd can support platelet adhesion and thrombus formation, 
but is most effective at lower shear rates. 
Adiponectin is found immobilised to components of the extracellular 
matrix (Okamoto et al., 2002). Thus it seemed reasonable to examine if gAd 
could influence platelet adhesion to other known thrombogenic matrix 
proteins. To test this, gAd (40 µg/ml) was immobilised on a combination of 
vWF type III (10 µg/ml) and the integrin α2β1 specific agonist, glycine-
phenylalanine-hydroxyproline-glycine-glutamine-arginine (GFOGER) (10 
µg/ml) (Pugh et al., 2010). Under conditions that mimic arterial shear rate 
(1000s-1), gAd alone supported weak platelet adhesion characterised by 
4.78% surface coverage and 0.06 µm mean thrombus height [Figure 5.9]. In 
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contrast, immobilised vWF-III and GFOGER supported robust platelet 
adhesion and thrombus formation at this high shear rate, which led to 
10.12% increase in surface coverage and 0.2 µm mean thrombus height. 
Interestingly, the combination of immobilised gAd with vWF-III and 
GFOGER potentiated thrombus formation [Figure 5.9]. This was associated 
with increased platelet adhesion characterised by 19.29% surface area 
coverage and a mean thrombus height of 0.36 µm [Figure 5.9]. Taken 
together, these data suggest that immobilised gAd on extracellular matrix 
proteins can support enhanced platelet adhesion and thrombus formation 
under flow conditions. These data suggest that gAd-stimulated platelet 
activation can synergise with other signalling pathways downstream of 
GPIb-V-IX and integrin α2β1 to enhance thrombus formation.  These results 
may represent a new pathological role for gAd in thrombosis. 
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Figure 5.9: Immobilised globular adiponectin enhances platelet adhesion 
and thrombus formation by sub-endothelial proteins. (A) DiOC6 (1 µM) 
labelled whole blood was perfused over immobilised gAd (40 µg/ml) alone 
or co-immobilised with vWF-III (10 µg/ml) and GFOGER (10 µg/ml) for 5 
minutes at the indicated shear rates and viewed by a fluorescent confocal 
microscope. Image J software (NIH) was used to measure percentage 
surface coverage. (B) As in (A) except data was expressed as mean 
thrombus height.  
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5.4 Discussion 
The activation of platelets at the sites of vascular damage is an essential 
step in haemostasis. These events are initiated by interaction of platelets 
with components of the extracellular matrix such as collagen with its 
receptors, GPVI and integrin α2β1 (Nieswandt and Watson, 2003, Farndale 
et al., 2004, Watson et al., 2005). In this study we have identified gAd as a 
novel platelet agonist that can activate platelets in a tyrosine kinase-
dependent manner. An important study by Riba et al., suggested that the 
GPVI-Fc receptor chain complex may be involved in gAd-stimulated platelet 
activation (Riba et al., 2008). In this chapter preliminary experiments were 
performed to examine the role of the collagen receptors, GPVI and α2β1 in 
platelet responses induced by gAd stimulation.  
Selective receptor blocking antibodies were used to establish the role of 
GPVI and integrin α2β1 in gAd-stimulated aggregation. The GPVI blocking 
antibody, 10B12 was obtained with screening of phage display libraries 
against the Ig-like domain of GPVI (Smethurst et al., 2004). The association 
between the collagen GPO repeat motif and the GPVI is disrupted upon the 
addition of 10B12. In contrast, the integrin α2β1 blocking antibody, 6F1 
disrupts the association between collagen and the integrin I domain (Coller 
et al., 1989, Nieswandt and Watson, 2003). We found that 10B12 abolished 
CRP-XL-stimulated aggregation, but did not affect gAd or collagen-
stimulated aggregation. However, 10B12 did significantly reduce platelet 
adhesion to immobilised gAd. Platelet GPVI activation by collagen involves 
the interaction of collagen to multiple binding sites found within GPVI 
receptor (Nieswandt and Watson, 2003, Smethurst et al., 2004, Smethurst 
et al., 2007). The interaction between 10B12 and GPVI has been mapped to 
the apical region of the GPVI receptor and was able to abolish CRP-XL-
stimulated aggregation. Since collagen-stimulated aggregation was not 
affected by 10B12 it may suggest that different binding sites are involved in 
GPVI activation. For example, 10B12 has been shown to be most effective 
against platelet stimulation with CRP-XL. It is thought that the 10B12 
epitope overlaps with the CRP-XL binding site (Smethurst et al., 2004). It is 
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also important to consider that the possible interaction between gAd and 
GPVI may be GPO independent and may represent a new GPVI binding site 
which allows platelet activation by gAd. Therefore, the use of GPVI blocking 
antibody was unable to confirm the role of GPVI in gAd-stimulated 
aggregation. The use of an alternative GPVI blocking antibody which can 
disrupt the activation and clustering of GPVI could have been used. 
However, with the emergence of GPVI knock-out mice, these animals 
would have provided the experimental tools needed to investigate the role 
of GPVI in gAd-stimulated activation. However, platelet activation by gAd 
was found to be independent of integrin α2β1 activation. In contrast, 
platelet adhesion to collagen is both GPVI and integrin dependent 
(Nieswandt et al., 2001, Nieswandt and Watson, 2003). Further work is 
needed to determine the exact role of GPVI in gAd-induced platelet 
activation.  
The initial step in the haemostatic process is the platelet adhesion with 
exposed elements of extracellular matrix proteins such as collagen or vWF 
at the site of vascular injury. In the latter part of this chapter, we examined 
the ability of platelets to adhere to immobilised gAd under static and flow 
conditions. We found that platelets adhered to immobilised gAd in a 
concentration-dependent manner. Furthermore, we found platelet 
adhesion to immobilised gAd was tyrosine kinase-dependent. In contrast, 
platelet adhesion to immobilised gAd was integrin-independent. 
Interestingly, the addition of 10B12 was able to ablate adhesion and 
therefore suggests that GPVI is involved in platelet adhesion to gAd. 
However, the addition of 10B12 was not able to inhibit gAd-stimulated 
platelet aggregation in suspension. The immobilisation of gAd to a glass 
surface may slightly alter the protein tertiary structure to expose new 
binding sites for GPVI interaction which can be blocked by 10B12. It is 
widely known that both fibrinogen and vWF undergo a similar 
conformation change that supports platelet adhesion (Ugarova et al., 1993, 
Siediecki et al., 1996). However, further work is needed to understand 
possible gAd interaction with GPVI in platelet adhesion.  
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It was important to understand if gAd can support platelet adhesion and 
thrombus formation under flow conditions. We found immobilised gAd 
was able to support stable platelet adhesion at low shear rate (100s-1). In 
contrast, platelet adhesion was significantly reduced at high shear rate 
(1000s-1). This data is consistent with other GPVI specific agonist such as 
CRP-XL that can only support weak platelet adhesion under flow at high 
shear (Nieswandt and Watson, 2003). Importantly, immobilisation of vWF-
III, integrin α2β1 agonist GFOGER and gAd was able to potentiate thrombus 
formation. These data suggest that platelet adhesion to gAd at high shear 
rate is weak and the stimulation of additional receptors is required to 
reinforce platelet adhesion and thrombus formation.  
These findings have established gAd as a novel platelet agonist that can 
support both platelet aggregation and adhesion. Plasma adiponectin has 
been found immobilised to components of extracellular matrix and 
therefore may support platelet adhesion with the globular domain. 
However, since full-length form of adiponectin did not stimulate platelet 
aggregation, it is unlikely if this is the case. It is more likely that the 
generation of gAd is promoted at sites of vascular inflammation such as 
atherosclerosis and can potentially become immobilised to the exposed 
components of the extracellular matrix. In this micro-environment, 
immobilised gAd in conjunction with collagen or vWF can cause unwanted 
platelet adhesion or thrombosis. However, more work is needed to 
understand these pathological roles of gAd in the vascular system. 
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Chapter 6: General discussion 
Adiponectin is the major adipokine produced by the adipose tissue and has 
complex and varied biological functions. Its primary role is as an insulin-
sensitising hormone and therefore plays a role in carbohydrate and lipid 
metabolism. However, as previously stated anti-diabetic, anti-inflammatory 
and vascular protective actions have also been described (Okamoto et al., 
2002, Ouchi and Walsh, 2007, Zhu et al., 2008). Several groups have sought 
to examine the role of adiponectin on platelet function and have proposed 
that adiponectin has anti-thrombotic properties (Kato et al., 2006, 
Restituto et al., 2010). An important study by Kato and colleagues 
proposed that adiponectin may act as an endogenous anti-thrombotic 
factor, thereby limiting thrombus formation (Kato et al., 2006). However, it 
was unclear if this anti-thrombotic property was due to the direct effect of 
adiponectin on platelet function or by increasing vascular NO production 
and thereby increasing NO bioavailability. However, this study while 
important, may have been over simplistic in its approach to the effects of 
adiponectin on platelet function, since it failed to take into account the 
multiple forms of adiponectin in circulation. In this study we addressed this 
latter issue and aimed to understand the direct effect of gAd on platelet 
function. 
The result of this investigation has established that only the globular form 
of adiponectin can stimulate platelet aggregation and adhesion, while the 
full-length form may play an inhibitory role (Restituto et al., 2010). This is 
surprising since fAd contains a collagen-like domain which can be 
recognised by the collagen receptor GPVI. It is not clear why the globular 
domain of fAd did not stimulate aggregation, although it is possible that 
binding of this collagen-like domain of fAd may create steric hindrance to 
prevent GPVI from being activated. Since these initial experiments 
established gAd as a novel platelet agonist, it was important to understand 
its mechanism of action. We found that gAd activated platelets in a 
tyrosine kinase-dependent manner. This was accompanied with the 
activation of Syk, PLCγ2, LAT and Src family kinase signalling pathways (Riba 
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et al., 2008). These data strongly suggest that gAd stimulates platelet 
activation through a similar pathway to that of collagen. It is established 
that the platelet activation by collagen involves two receptors, GPVI and 
integrin α2β1. The activation of platelets by GPVI involves the formation of 
a tyrosine kinase-dependent signalosome that leads to the mobilisation of 
intracellular Ca2+ and integrin αIIbβ3 activation. The same study by Riba et 
al., (2008) proposed that gAd-stimulated platelet activation through the 
collagen receptor GPVI. In this study we were unable to confirm the role of 
GPVI in gAd-stimulated aggregation, since the best available GPVI blocking 
antibody failed to influence aggregation. However, GPVI activation was 
implicated in platelet adhesion to immobilised gAd. Further work is needed 
to determine the exact role of gAd in GPVI activation. It is important that 
we understand the interaction between gAd and GPVI which may 
represent a novel mechanism for GPVI activation that is independent of 
GPO motif.    
Recombinant forms of adiponectin were used in this investigation and it 
was important to consider the recombinant nature of the protein. 
Importantly, no differences were found between recombinant or HEK-
derived gAd in stimulating platelet aggregation. However, during the study 
we found variation between different batches of gAd with regards to their 
ability to stimulate platelet aggregation. After much troubleshooting, it 
became apparent that the addition of BSA was vital to its stability. This is 
consistent with the physiological situation since plasma adiponectin is 
found to circulate associated with albumin or other serum proteins (Wang 
et al., 2006, Hada et al., 2007). It is possible that this association may 
enhance its stability and allow greater access to sites of vascular damage or 
inflammation. The precise origin of gAd is unclear but may involve the 
cleavage of fAd by leukocyte elastase to produce the globular fragment 
(Waki et al., 2005). These findings can suggest the generation of gAd at 
sites of inflammation (Okamoto et al., 2000). Interestingly, gAd in contrast 
to fAd can have pro-inflammatory properties since it can increase 
expression of pro-inflammatory adhesion molecules, increase angiotensin-
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II induced proliferation of cardiac fibroblasts (Hattori et al., 2006, Hattori et 
al., 2007) and stimulate THP-1 production by monocytes (Neumeier et al., 
2006).  Thus emerging evidence suggests that gAd may possess pro-
inflammatory properties in addition to its insulin-sensitising effects (Hattori 
et al., 2006, Hattori et al., 2007).  Consistent with these pathological roles, 
we have described gAd as a novel platelet agonist that can potentially 
increase unwanted platelet aggregation and thrombus formation in 
inflammatory conditions such as atherothrombosis. We have found gAd 
can support platelet adhesion and enhance thrombus formation through 
the interaction of collagen and vWF. Furthermore, platelet aggregation 
induced by gAd can be potentiated by ADP and adrenaline.  
The release of platelet derived ADP is a crucial event that enables the 
additional recruitment of platelets and stabilisation of the growing thrombi 
(Kunapuli et al., 2003, Kim and Kunapuli, 2011). The release of ADP can also 
work in conjunction with less established agonists to potentiate 
aggregation. It is widely accepted that GPVI-stimulated aggregation can be 
potentiated with other agonists such as ADP (Atkinson et al., 2003). 
Consistent with these reports, ADP-dependent potentiation of platelet 
responses to gAd was found to involve the Gi-coupled P2Y12 receptor. The 
exact mechanism involved in this Gi-dependent potentiation of platelet 
responses is not clear but may involve pathways linked to PI3K and PKC 
signalling. Therefore, it was important to understand the role of PI3K and 
PKC in gAd-stimulated aggregation. Consistent with our current 
understanding about the role of PKC on platelet aggregation, we found that 
gAd could stimulate aggregation through pathways dependent and 
independent of PKC activation. In contrast, gAd-stimulated secretion was 
found to be fully dependent on PKC signalling. Importantly, the aggregation 
response and dense-granule secretion under conditions of PKC inhibition 
could be partially restored by ADP acting through the P2Y12 coupled Gi 
receptor and by adrenaline acting through the Gz-linked α2A-adrenoceptor. 
These data have uncovered a relatively unknown pathway involved in PKC-
independent secretion of platelet dense-granules. Further examination of 
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this pathway was found to require PI3Kβ activation and to a lesser extent 
PI3Kα isoform. These results suggest that a compensatory pathway may 
exist downstream of Gi/Gz-coupled receptors that can compensate for the 
loss of PKC signalling and can potentially synergise with other pathways to 
promote platelet activation and thrombus formation.   
The activation of PI3K isoforms have been implicated in many platelet 
responses that include platelet shape change and aggregation 
(Rittenhouse, 1996, Pasquet et al., 1999). This study has identified a novel 
role for PI3Kβ isoform in ADP-dependent potentiation of platelet responses 
to gAd. In the last few years, the role of PI3Kβ in platelet function is 
becoming much clearer. The activation of PI3Kβ has been implicated in 
platelet integrin αIIbβ3 activation and adhesion (Jackson et al., 2005, 
Canobbio et al., 2009, Jackson and Schoenwaelder, 2010). This study has 
further contributed to our understanding to the role of PI3Kβ and may 
suggest a new possible target for anti-thrombotic agents. In vivo arterial 
thrombosis models have demonstrated that PI3Kβ inhibition can prevent 
occlusive thrombi from forming and had no effect on tail bleeding time 
(Jackson et al., 2005). It is possible that the inhibition of PI3Kβ may prevent 
multiple pathways involved in platelet activation and thrombus formation 
which may include the potentiation of platelet aggregation by ADP. Further 
work is needed to be done to understand the physiological significance of 
PI3Kβ activation in ADP potentiation of platelet aggregation and thrombus 
formation. 
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6.1 Conclusion  
In conclusion, this study has identified gAd as a novel platelet agonist that 
can support platelet adhesion. Furthermore, we confirmed and extended 
our understanding of how gAd stimulates platelet aggregation. These 
findings question the proposed role of adiponectin as an anti-thrombotic 
agent (Kato et al., 2006). Our evidence taken with that of Kato and 
colleagues may suggest a dual role of adiponectin on platelet function. The 
native form may inhibit platelet aggregation and in contrast, the globular 
form can stimulate platelet aggregation. Thus, it is the relative balance of 
the different forms in circulation that may determine whether a pro or 
anti-thrombotic environment exists. Furthermore, it is important to 
determine if circulating levels of gAd are elevated in certain types of 
disease, particularly in early stages of atherosclerosis. It is also important to 
consider the indirect vascular effects of adiponectin on platelet function. 
Adiponectin is a potent stimulator of NO synthesis which can inhibit 
platelet activation. However, in inflammatory conditions like those found in 
atherosclerosis, the indirect effect of adiponectin on platelet function is 
limited. Arterial thrombosis is often determined by the local environment 
at the sites of vascular rupture. In this local environment the accumulation 
of adiponectin (Okamoto et al., 2002) and the potential generation of gAd 
may promote unwanted platelet aggregation and thrombus formation. 
Here the potential of fAd to stimulate increase NO synthesis would be of 
little benefit and the ability of gAd to synergise with ADP could be critical in 
promoting platelet aggregation. 
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6.2 Future work 
In this study we have solely investigated the role of gAd on platelet 
function. However, due to time constraints not all aspects of gAd-induced 
platelet activation were investigated. Based on the experimental data 
several further aspects of study are warranted, including; 
 Clarification of the receptors involved in gAd-stimulated platelet 
activation. This study was unable to confirm the role of GPVI in gAd-
stimulated platelet activation due to the tools at our disposal. The 
role of GPVI in gAd-stimulated activation can be confirmed with the 
availability of GPVI null mice. These experiments would have 
allowed us to identify a new novel GPVI agonist. Furthermore, the 
possible interaction of gAd with GPVI would need to be closely 
examined. 
 The use of pharmacological inhibitors is a powerful tool in 
understanding signalling pathways but some inhibitors can be non-
specific. PKC and PI3K isoform specific knock-out mice would have 
allowed us to better understand the role of PI3Kβ in ADP-
dependent potentiation of platelet responses. 
 This study has proposed that platelet aggregation can be 
potentiated by ADP. It would be interesting to look at gAd ability to 
potentiate thrombus formation by an in vivo thrombosis model. 
This data would have proposed a new pathological role for gAd in 
the vascular system. 
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Abbreviations 
ACD  Acid citrate dextrose 
Acrp30  Adipose complement related protein 30 kDa 
ADP  Adensosine diphosphate 
AMPK  AMP-activated protein kinase 
APS  Ammonium persulfate 
ATP  Adenosine triphosphate 
BAPTA-AM 1,2-bis (o-Aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid 
tetra(acetoxymethyl) ester 
BSA  Bovine serum albumin 
Ca2+  Calcium 
cAMP  Cyclic adenosine monophosphate 
cGMP  Cyclic guanosine monophosphate 
COX-1  Cyclo-oxygenase-1 
CRP-XL  Cross linked-collagen related peptide 
DAG  Diacylglycerol 
DiOC6  3,3’ Dihexyloxacarbocyanine iodine 
DTS  Dense tubular system 
ECL  Enhanced chemiluminescence 
EGTA  Ethylene glycol-bis (β-aminoethyl ether)-N,N,N’,N’-
tetraacetic acid 
eNOS  Endothelial nitric oxide synthase 
ER  Endoplasmic reticulum 
ERK  Extracellular signal-regulated kinase 
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fAd  Full-length adiponectin 
FcRγ-chain Fc receptor gamma-chain 
gAd  Globular adiponectin 
Gads  Grb2 related protein downstream of Shc 
GBP-28 Gelatine binding protein 28 kDa 
GDP  Guanosine diphosphate 
GFOGER Glycine-phenylalanine-hydroxyproline-glycine-glutamine-
arginine 
GPO  Glycine-proline-hydroxyproline 
GPVI  Glycoprotein VI 
Grb2  Growth factor receptor bound protein 2 
GTP  Guanosine triphosphate 
HMW  High molecular weight isoform 
HRP  Horseradish peroxidase 
HS  Human serum 
ICAM-1 Intracellular adhesion molecule 
Ig  Immunoglobulin 
IGF-1  Insulin-like growth factor-1 
Indo  Indomethacin 
IP3  Inositol (1,4,5)-triphosphate 
ITAM  Immunoreceptor tyrosine-based activation motif 
LAT  Linker for activation of T-cells 
mAb  Monoclonal antibody 
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MAPK  p38 mitogen-activated protein kinase 
MLC  Myosin light chain 
NO  Nitric oxide 
OCS  Open canalicular system 
PAI-1  Plasminogen activator inhibitor type 1 
PAR  Protease Activated Receptor 
PBS  Phosphate buffered saline 
PDK  Phosphoinositide-dependent kinase 
PGI2  Prostacyclin 
PH  Pleckstrin homology 
PI3K  Phophoinositol 3 kinase 
PIP2  phosphatidylinositol 4,5-bisphosphate 
PKA  Protein kinase A 
PKC  Protein kinase C 
PKG  Protein kinase G 
PLA2   Phospholipase A2  
PLC  Phospholipase C 
PMA  Phorbol 12-myristate 13-acetate 
PPACK  D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone 
PPAR  Peroxisome proliferator activated receptors 
PRP  Platelet rich plasma 
PVDF  Polyvinylidene difluoride 
RBP4  Retinol binding protein 4 
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RGD  Arginine-glycine-serine 
RGDS  Arginine-glycine-aspartic acid-serine 
SDS  Sodium dodecyl sulphate 
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SEM  Standard error of the mean 
sGC  Soluble guanylyl cyclase 
SH  Src homology 
SLP76  SH2 domain containing leukocyte proteins of 76 kDa 
SNARE  Soluble NEM-sensitive attachment protein receptors 
Syk  Spleen tyrosine kinase 
TBS-T  Tris buffered saline-tween 
TEMED N,N,N’,N’-Tetramethyl ethylenediamine 
TNF-α  Tumour necrosis factor-alpha 
TxA2   Thromboxane A2  
VCAM-1 Vascular cellular adhesion molecule-1 
vWF  von Willebrand factor 
Wort  Wortmannin 
 
